

Clayton's Basic Pharmacology for Nurses 19th Edition PDF

Visit the link below to download the full version of the ebook

DOWNLOAD NOW

EDITION
19

Clayton's Basic Pharmacology for Nurses

Willihnganz Gurevitz Clayton



Evolve®

Study
Detail



Scan to Download
or Type the Link

ebook.ac/clayton19e

EDITION

19

Basic Pharmacology for Nurses

Willihnganz Gurevitz Clayton



Evolve®


Student Resources on Evolve
Access Code Inside

Evolve®

YOU'VE JUST PURCHASED MORE THAN A TEXTBOOK!

Enhance your learning with Evolve Student Resources.

These online study tools and exercises can help deepen your understanding of textbook content so you can be more prepared for class, perform better on exams, and succeed in your course.



Activate the complete learning experience that comes with each NEW textbook purchase by registering with your scratch-off access code at

<http://evolve.elsevier.com/Willihnganz/basic/>

If your school uses its own Learning Management System, your resources may be delivered on that platform. Consult with your instructor.

If you rented or purchased a used book and the scratch-off code at right has already been revealed, the code may have been used and cannot be re-used for registration. To purchase a new code to access these valuable study resources, simply follow the link above.

Place
Sticker
Here

REGISTER TODAY!



You can now purchase Elsevier products on Evolve!
Go to evolve.elsevier.com/shop to search and browse for products.

Basic Pharmacology for Nurses

This page intentionally left blank

EDITION

19

Basic Pharmacology for Nurses

Michelle J. Willihnganz, MS, RN, CNE

RCTC Nursing Instructor
Rochester Community and Technical College
Rochester, Minnesota

Samuel L. Gurevitz, PharmD

Associate Professor
College of Pharmacy and Health Sciences
Butler University
Indianapolis, Indiana

Bruce D. Clayton, BS Pharm, PharmD, RPh

Professor Emeritus of Pharmacy Practice
College of Pharmacy and Health Sciences
Butler University
Indianapolis, Indiana



ELSEVIER
3251 Riverport Lane
St. Louis, Missouri 63043

BASIC PHARMACOLOGY FOR NURSES, NINETEENTH EDITION

ISBN: 978-0-323-79630-9

Copyright © 2022 by Elsevier, Inc. All rights reserved.

Previous editions copyrighted 2020, 2017, 2013, 2010, 2007, 2004, 2001, 1997, 1993, 1989, 1985, 1981, 1977, 1973, 1969, 1965, 1961, and 1957.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by Elsevier, authors, editors or contributors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Library of Congress Control Number: 2021939099

Content Strategist: Brandi Graham
Director, Content Development: Laurie Gower
Senior Content Development Specialist: Rebecca Leenhouts
Publishing Services Manager: Deepthi Unni
Project Manager: Janish Ashwin Paul
Design Direction: Renee Duenow

Printed in India

Last digit is the print number: 9 8 7 6 5 4 3 2 1



*To Kevin, the love of my life,
and to my wonderful daughters Katie and Jennifer,
who always stand beside me.*

—MJW

*To my wonderful wife Eileen
and to our daughter Maire.*

—SLG

*To Francine,
for her unfailing support and encouragement,
and to
Sarah, Nathaniel, Evelyn, and Grace
and
Beth, Clayton, and Arden,
the lights of our lives!*

—BDC

Reviewers and Ancillary Contributors

REVIEWERS

Alice M. Hupp, BS, RN
Lead Instructor
Vocational Nursing
North Central Texas College
Gainesville, Texas

Ashley R. Williams, MSN, RN, CEN
Assistant Professor of Nursing
Capito Department of Nursing
University of Charleston
Charleston, West Virginia
Cabell Huntington Hospital
Huntington, West Virginia

Heather Clark, DNP, RN
Director
Penn State Practical Nursing Program
Penn State Lehigh Valley
Center Valley, Pennsylvania

Darla K. Shar, MSN, RN
Associate Director
Practical Nursing Education
Hannah E. Mullins School of Practical Nursing
Salem, Ohio

Joanna Cain, BSN, BA, RN
President & Founder
Global Academic Consultants
Boulder, Colorado

Lorraine Kelley, RN
Faculty
Department of Nursing and Emergency Medical Services
Pensacola State College
Pensacola, Florida

Molly M. Showalter, MSN Ed., RN
Interim Vocational Nursing Program Director
Department of Health Professions
Texas Southmost College
Brownsville, Texas

Odelia Garcia, MS, MSN, BSN, RN
Vocational Nursing Program Instructor
Nursing
Texas State Technical College
Harlingen, Texas

Grace Frankel BSc. Pharm, PharmD, BCPS
Clinical Pharmacist
Bethesda Regional Health Centre/Southern Health
Steinbach, Manitoba, Canada

James J Mizner Jr, MBA, BS, RPh
Panacea Solutions Consulting-Principal
Reston, VA

ANCILLARY CONTRIBUTOR

Laura Bevlock Kanavy, MSN, BSN, RN
Director, Practical Nursing Program
Career Technology Center of Lackawanna County
Scranton, Pennsylvania
Test Bank, NCLEX Review Questions

LPN/LVN Advisory Board

Nancy Bohnczyk, MA
Adjunct Instructor
College of Mount St. Vincent
New York, New York

Sharyn P. Boyle, MSN, RN-BC
Instructor, Associate Degree Nursing
Passaic County Technical Institute
Wayne, New Jersey

Nicola Contreras, BN, RN
Faculty
Galen College
San Antonio, Texas

Dolores Cotton, MSN, RN
Practical Nursing Coordinator
Meridian Technology Center
Stillwater, Oklahoma

Patricia Donovan, MSN, RN
Director of Practical Nursing and Curriculum Chair
Porter and Chester Institute
Rocky Hill, Connecticut

Nancy Haughton, MSN, RN
Practical Nursing Program Faculty
Chester County Intermediate Unit
Downingtown, Pennsylvania

Dawn Johnson, DNP, RN, Ed
Practical Nurse Program Director
Great Lakes Institute of Technology
Erie, Pennsylvania

Mary E. Johnson, MSN, RN
Director of Nursing
Dorsey Schools
Roseville, Michigan

Bonnie Kehm, PhD, RN
Faculty Program Director
Excelsior College
Albany, New York

Tawnya S. Lawson, MS, RN
Dean, Practical Nursing Program
Hondros College
Westerville, Ohio

Kristin Madigan, MS, RN
Nursing Faculty
Pine Technical and Community College
Pine City, Minnesota

Hana Malik, DNP, FNP-BC
Academic Director
Illinois College of Nursing
Lombard, Illinois

Mary Lee Pollard, PhD, RN, CNE
Dean, School of Nursing
Excelsior College
Albany, New York

Barbara Ratliff, MSN, RN
Program Director, Practical Nursing
Cincinnati State
Cincinnati, Ohio

Mary Ruiz-Nuve, MSN, RN
Director of Practical Nursing Program
St. Louis College of Health Careers
St. Louis, Missouri

Renee Sheehan, MSN/Ed, RN
Director of Nursing, Vocational Nursing
Nursing Assistant Programs
Summit College
Colton, California

Faye Silverman, MSN/ED, RN, WOCN, PHN
Nursing Education Consultant
Online Nursing Instructor
Lancaster, California

Fleur de Liza S. Tobias-Cuyco, BSc, CPhT
Dean, Director of Student Affairs, and Instructor
Preferred College of Nursing
Los Angeles, California

Preface

The 19th edition of *Basic Pharmacology for Nurses*, in the tradition of the book's standards first established in 1957, advocates the administration of medication with safety and precision while focusing on medication safety through medication monitoring and patient education. In the practice setting, the nurse not only must demonstrate knowledge of the underlying disease process but also must be able to perform an accurate assessment. The nurse must also plan and implement care in a manner that involves the patient as an active participant in decisions affecting care. Therefore a primary concern throughout this book is the integration of patient teaching about drug therapy to enable the patient to reach therapeutic goals and attain an optimum level of health. The nurse must also validate patient understanding to ensure that the individual has the ability to provide safe self-care and monitoring of the prescribed treatment plan. User friendly in content, structure, and layout, the text is concise and easy to read. With its emphasis on the seven Rights of Drug Administration (right drug, right time, right indication, right dosage, right patient, right route, and right documentation), *Basic Pharmacology for Nurses* provides students with the information needed to provide safe, effective nursing care for patients receiving drug therapy.

ORGANIZATION AND SPECIAL FEATURES

CONTENT THREADS

Basic Pharmacology for Nurses, 19th edition, shares some features and design elements with other Elsevier books that you may be using. The purpose of these Content Threads is to make it easier for students and instructors to use the variety of books required by a fast-paced and demanding curriculum.

The shared features in *Basic Pharmacology for Nurses*, 19th edition, include the following:

- Cover and internal design similarities; the colorful, student-friendly design encourages reading and learning of this core content
 - Numbered lists of Objectives that begin each chapter
 - Key Terms with pronunciations at the beginning of each chapter; the Key Terms are in color when they are defined in the chapter
 - Bulleted lists of Key Points at the end of each chapter
- Next Generation (NG) NCLEX style questions are at the end of each chapter. These questions use single-episode and unfolding cases. They include the six

NCSBN Clinical Judgment Measurement Model cognitive processes and skills; answers are provided on the Evolve student website.

In addition to content and design threads, these textbooks benefit from the advice and input of the Elsevier Advisory Board.

CONTENTS

Unit I explores pharmacology foundations, principles, life span considerations, the nursing process with pharmacology, and patient education. Unit II contains the unique Illustrated Atlas of Medication Administration that provides extensive step-by-step instructions and illustrations that show primary routes of administration and proper administration techniques for all forms of medications.

Units III through X provide an overview of each drug class, followed by narrative discussions of the most common individual drugs. The units and chapters are organized by body system.

CHAPTER ORGANIZATION

- Each drug chapter in Units III through X begins with an overview of a clinical problem and its management.
- The general nursing implications section includes clearly identified headings for Assessment, Implementation, and Patient Education. The Patient Education section helps the nurse incorporate patient education designed to promote health into the overall treatment plan.
- Drug monographs are provided for each major drug class. These monographs describe Actions, Uses, and Therapeutic Outcomes for each class.
- A drug class-specific nursing implications section for each drug monograph highlights Premedication Assessment, Product Availability, Dosing Instructions, Common Adverse Effects, Serious Adverse Effects, and Drug Interactions.

SPECIAL FEATURES

Basic Pharmacology for Nurses includes special features designed to foster effective learning and comprehension.

- Chapter-opening features include lists of Objectives and Key Terms with pronunciations.

- Clinical Pitfall and Medication Safety Alert boxes highlight critically important clinical considerations to help students practice safety and reduce medication errors.
- Clinical Goldmine boxes put a spotlight on tips and best practices for clinical procedures.
- Life Span Considerations boxes focus on the implications of drug therapy for children, pregnant and breastfeeding women, and older adults.
- Herbal Interactions boxes discuss well-documented interactions among drugs, herbal therapies, and dietary supplements.
- A handy bulleted list of Key Points at the end of most chapters facilitates review of essential chapter content.

NEW TO THIS EDITION

- This edition includes the latest US Food and Drug Administration (FDA) approvals, including up-to-date clinical drug indications, guidelines for use, and recently released new drugs.
- Increased emphasis on medication safety that stresses imperative information for patient protection.
- Additional information on genetics, pharmacogenomics, and racial/gender factors in drug actions is included to highlight current research.
- New figures have been added to illustrate proper medication administration.
- End-of-chapter NCLEX-style questions that include NG types such as Cloze, Grid/Matrix, Drag and Drop, and Extended Multiple Response. These types cover the six cognitive skills: Recognize Cues, Analyze Cues, Prioritize Hypotheses, Generate Solutions, Take Action, and Evaluate Outcomes.

TEACHING AND LEARNING PACKAGE

FOR STUDENTS

- The Evolve Website provides free student resources, including answers and rationales for in-text Review Questions for the NCLEX® Examination, a math

review, animations, video clips, a collection of Patient Teaching handouts, fully customizable Patient Self-Assessment Forms provided as “completable” PDF documents, and a collection of 500 NCLEX-style Review Questions.

- The revised Study Guide provides additional learning resources that complement those in the textbook. Questions for each chapter follow the objectives in the book for additional focus on these key concepts. Matching starts each chapter, and patient scenarios are included with the chapters that detail the medications. NG NCLEX-style questions are included, as are typical NCLEX questions. Each question includes the correct answer, rationale, NCLEX style used, and cognitive skill measured. Each question has a page number identified to help the student find the answer in the textbook. Answers to the Study Guide questions are available from instructors.

FOR INSTRUCTORS

The comprehensive *Evolve Resources with TEACH Instructor Resource* provides a rich array of resources that include the following:

- Updated TEACH Lesson Plans, based on textbook learning objectives, provide ready-to-use lesson plans that tie together all of the text and ancillary components provided for *Basic Pharmacology for Nurses*.
- The collection of PowerPoint Lecture Slides is specific to the text.
- A Test Bank, delivered in ExamView, now provides an expanded collection of approximately 900 multiple-choice and alternate-format NCLEX-style questions. Each question includes the Correct Answer, Rationale, and corresponding text page numbers.
- The Image Collection contains every reproducible image from the text. Images are suitable for incorporation into classroom lectures, PowerPoint presentations, or distance-learning applications.
- Answer keys are provided for the Study Guide.

Special Features

Basic Pharmacology for Nurses focuses on medication safety through medication monitoring and patient education. Full-color art and design features accompany detailed, understandable discussions of drugs organized by body system.

5 Patient Education to Promote Health

https://www.elsevier.com/bspharm

Objectives

1. Differentiate among the cognitive, affective, and psychomotor learning domains.
2. Identify the main principles of learning that are applied when teaching a patient, family, or group.
3. Describe the essential elements of patient education in relation to prescribed medications.

Key Terms

cognitive domain (KOG-ni-tiv; ps-MAN) (p. 50)	psychomotor domain (si-kō-MO-tōr) (p. 51)	health teaching (p. 52)
affective domain (i-FEK-tiv) (p. 50)	objectives (ōb-ĪK-tiv) (p. 51)	ethnocentrism (ēth-nō-SEN-tri-sim) (p. 55)
	teach-back (p. 52)	

4. Describe the nurse's role in fostering patient responsibility for maintaining well-being and for adhering to the teaching regimen.
5. Identify the types of information that should be discussed with the patient or significant others.

An important nursing responsibility is making certain that patients receive correct healthcare information. Because patient education is a key component of what nurses do, understanding the principles of how people learn is important. Nurses need to learn how to instruct patients correctly, making information specific to the individual, and also determine whether the information is understood by the patient.

THREE DOMAINS OF LEARNING

The three domains of learning that all adults use when acquiring new knowledge are the cognitive domain, the affective domain, and the psychomotor domain (Fig. 51).

COGNITIVE DOMAIN

The cognitive domain is the level at which basic knowledge is learned and stored. It is the thinking portion of the learning process, and it incorporates a person's previous experiences and perceptions. Previous experiences with health and wellness influence the learning of new materials. Prior knowledge and experience are the foundation of the addition of new concepts. Thus the learning process begins by identifying what experiences the person has had with the subject.

However, learning involves more than the delivery of new information or concepts. A person must build relationships between prior experiences and new concepts to formulate new meanings. At a higher level

of the learning process, the new information is used to question something that is uncertain, to recognize when to seek additional information, and to make decisions using real-life situations.

AFFECTIVE DOMAIN

The affective domain is the most intangible portion of the learning process. It refers to the feelings and beliefs a patient has about what they understand. The affective domain includes opinions and values that the patient brings to their understanding of the world. When a patient says, "I don't know what I'm on. I let my spouse deal with that," they are expressing the value that learning about medications is not important to them.

It is well known that individuals view events from different perspectives. People often choose to internalize feelings rather than to express them. The nurse must be willing to approach patients in a non-judgmental fashion, listen to their concerns, to recognize the nonverbal messages being given, and to assess patient needs with an open mind.

Clinical Goldmine

The development of a sense of trust and confidence in healthcare providers can have a powerful effect on the attitude of the patient and their family members. This can influence the patient's response to the new information that is being taught. The nurse should be positive and accepting, and involve the patient in a discussion to draw out their views regarding solutions to problems.

Chapters open with **Objectives and Key Terms** with pronunciations and page references.

Clinical Goldmine boxes focus on best practices in the clinical setting.

312 UNIT 8 Drugs Affecting the Autonomic and Central Nervous System

5. Review the medicines that have been prescribed that may require dose adjustments. Plan to perform focused assessments to detect responses to therapy that would need to be reported to the healthcare provider.

Availability. PO: Sinemet is a combination product that contains both carbidopa and levodopa. The combination product is available in ratios of 10/100, 25/100, and 25/250 mg of carbidopa and levodopa, respectively. There is also a sustained-release tablet that contains either 25/100 or 50/200 mg of carbidopa and levodopa, respectively.

Rytray is an oral extended-release combination product that contains both carbidopa and levodopa. It is available in capsules in ratios of 23.75/195, 36.25/145, 48.75/195, and 61.25/245 mg of carbidopa and levodopa, respectively.

Daupra is an oral suspension of carbidopa 4.63 mg and levodopa 20 mg/mL in 100-mL containers.

Dosage and administration. Adult: PO: For patients who are not receiving levodopa initially, give Sinemet 10/100 or 25/100 mg three times daily, increasing by 1 tablet every other day, until a dosage of 6 tablets daily is attained. As therapy progresses and patients show indications of needing more levodopa, substitute Sinemet 25/250 mg, 1 tablet three or four times daily. Increase by 1 tablet every other day to a maximum of 8 tablets daily. See the manufacturer's guidelines for converting a patient from the immediate-release to the sustained-release formulation of Sinemet.

Administer this medication with food or milk to reduce gastric irritation. Therapy for at least 6 months may be necessary to determine this medication's full therapeutic benefits.

Extended-Release Formulations: Sinemet Extended-Release Tablets: For patients not currently receiving levodopa initially, start with sustained-release tablet 50 mg/200 mg twice daily at intervals of 6 hours or more. Following an interval of at least 3 days between dosage adjustments, increase or decrease dosage based on response. Most patients are adequately treated with a dose that provides 400 to 1400 mg of levodopa per day in divided doses at intervals of 4 to 8 hours while awake. If an interval of less than 4 hours is used and/or if the divided doses are not equal, give the smaller doses at the end of the day.

Rytray Extended-Release Capsules: For patients not currently receiving levodopa initially, start with Rytray 23.75/195 mg three times daily for 3 days; on day 4, increase to 36.25/145 mg three times daily. The dose may be increased up to 50.5/390 mg three times daily, and the frequency of dosing may be increased to a maximum of five times daily if needed and tolerated (maximum 612.5/2450 mg per day).

See the manufacturer's guidelines for converting a patient from immediate-release formulations to extended-release capsules.

Oral Formulation: Daupra:

- See the manufacturer's guidelines for calculation and titration of morning dose and continuous infusion doses.
- Before initiation of therapy, convert patient from all forms of levodopa to oral immediate-release carbidopa-levodopa tablets (1:4 ratio). Total daily dose of levodopa consists of the morning dose, a continuous dose and any extra doses.
- See manufacturer's recommendations on frozen storage, thawing in a refrigerator for 96 hours, protection from light, administration by nasogastric tube or PEG-J tube and type of pump to be used.
- Following discontinuation of the daily infusion, patients should receive their routine nighttime dosage or oral immediate release carbidopa-levodopa.

Common adverse effects: Levodopa causes many adverse effects, but most are dose related and reversible. Adverse effects vary greatly depending on the stage of the disease.

Gastrointestinal

Nausea, vomiting, anorexia. These effects can be reduced by slowly increasing the dose, dividing the total daily dosage into four to six doses, and administering the medication with food or antacids. See manufacturer's precautions pertaining to potential GI complications associated with enteral infusions.

Cardiovascular

Orthostatic hypotension. Although the effects are generally mild, levodopa may cause some degree of orthostatic hypotension; this is manifested by dizziness and weakness, particularly when therapy is initiated. Tolerance usually develops after a few weeks of therapy. Monitor the patient's blood pressure daily in both the supine and standing positions. Anticipate the development of postural hypotension and take measures to prevent such an occurrence. Teach patients to rise slowly from a supine or sitting position, and encourage them to sit or lie down if feeling faint.

Neurologic

Chewing motions, bobbing, facial grimacing, rocking movements. These involuntary movements occur in about half of the patients who take levodopa for more than 6 months. A reduction in dosage may be beneficial.

Psychological

Nightmares, depression, confusion, hallucinations. Perform a baseline assessment of the patient's degree of alertness and orientation to name, place, and time before initiating therapy. Make regularly scheduled subsequent evaluations of mental status, and compare findings. Report alterations in mood. Provide for patient safety during these episodes. Reducing the daily dosage may control these adverse effects.

Cardiovascular

Tachycardia, palpitations. Take the patient's pulse at regularly scheduled intervals. Report any changes for further evaluation.




Fig. 11.13 (A) Apply a tourniquet using a strip that is placed 2 to 6 inches above the chosen (shaded) vein. (B) Allow the vein to distill. (C) Prepare the vein to feel its depth and direction. (D) Cleanse the skin surface with an antiseptic alcohol swab, starting at the anticipated site of entry and working outward in a circular motion to the periphery. (E) For an over-the-needle catheter, hold the backbar chamber with the thumb and forefinger and rest the catheter with the needle at a 10- to 30-degree angle to or at the angle as specified in manufacturer's directions, with the level up. (F) Withdraw the needle from the catheter. (G) Apply gentle pressure over the catheter tip to prevent the excessive backflow of blood while the needle is removed and the intravenous line is attached. (H) Secure the connection of the intravenous tubing to the hub of the catheter.

12. Allow the area to air-dry.
13. Hold the catheter or butterfly needle to be inserted in the dominant hand, and remove the protective cover while maintaining the sterility of the needle. Approach the vein directly from above or from slightly to one side of the vein. Provide tension on the skin surface to stretch the skin and stabilize the vein.

Step-by-step full color art shows proper medication administration techniques.

236 UNIT III Drugs Affecting the Autonomic and Central Nervous Systems

Sensory
Blurred vision. Caution the patient that blurred vision may occur and make appropriate suggestions for personal safety.

Gastrointestinal
Constipation, dryness of the mucosa of the mouth, throat, and nose. Mucosal dryness may be relieved by sucking hard candy or ice chips or by chewing gum. The use of stool softeners (e.g., docusate) may be required for constipation.

Neurologic
Sedation, slurred speech, dizziness. People who work around machinery, drive, administer medication, or perform other duties for which they must remain mentally alert should not take these medications while working. Slurred speech and dizziness are signs of excessive dosing. Report to the healthcare provider for further evaluation. Provide patient safety during these episodes.

Drug interactions
Anticholinergics, alcohol, analgesics, anesthetics, tranquillisers, epinephrine, other sympathomimetics. These all are agents that can increase toxic effects. Monitor the patient for excessive sedation, and reduce the dosage of butyrophenone if necessary.

Clinical Judgment and Next-Generation NCLEX® Examination-Style Questions

Key Points

- Anxiety is an unpleasant feeling of apprehension or nervousness that is caused by the perception of danger threatening the patient's security. In most cases, it is a normal human emotion.
- When a patient's response to anxiety is irrational and impairs their daily functioning, they are said to have an anxiety disorder. Some 10% of the general population will experience an anxiety disorder during their lifetime.
- The most common types of anxiety disorders are generalized anxiety disorder, panic disorder, social phobia, simple phobias, and obsessive-compulsive disorder.
- Anxiety is a component of many medical illnesses that involve the cardiovascular, pulmonary, digestive, and endocrine systems. It is also a primary symptom of many psychiatric disorders. Therefore the evaluation of the anxious patient requires a thorough history and physical and psychiatric examination to determine whether the anxiety is the primary condition or secondary to another illness. Persistent irrational anxiety or episodic anxiety usually requires medical and psychiatric treatment.
- The treatment of anxiety disorders usually requires a combination of pharmacologic and nonpharmacologic therapies.
- It is the responsibility of the nurse to educate patients about their therapy, to monitor for therapeutic benefits and common and serious adverse effects, and to intervene whenever possible to optimize therapeutic outcomes.

Additional Learning Resources

SG Go to your Study Guide for additional Review Questions for the NCLEX® Examination, Critical Thinking Clinical Scenarios, and other learning activities to help you master this chapter content.

OL Go to your Evolve website (<https://evolve.elsevier.com/Waltingard>) for additional online resources.

Clinical Judgment and Next-Generation NCLEX® Examination-Style Questions

Scenario

A patient, admitted to the mental health unit following a panic attack that lasted longer than 10 minutes was advised to come in for medication adjustment.

1. Identify the type of behavior the patient may be exhibiting with each cue. Indicate with an X in the box that gives an example of the behavior.

	Counts the number of steps that it takes to walk to the car	Excessive and unrealistic worry about grades as a student	Declines getting into the left machine, feeling too confused	Suddenly feeling lightheaded and seeing spots, then fainting during a course examination
Panic disorder				
Generalized anxiety disorder				
Obsessive-compulsive and related disorder				
Panic disorder				

Get Ready for the NCLEX® Examination! sections include Key Points, Additional Learning Resources, and Review Questions for the NCLEX® Examination.

- Patient Education and Health Promotion** is emphasized in the overall treatment plan.
- Life Span Considerations** boxes focus on implications of drug therapy for children, pregnant and breastfeeding women, and older adults.
- Clinical Pitfall and Medication Safety Alert** boxes highlight critically important clinical considerations.
- Herbal Interactions** boxes describe possible adverse effects of alternative therapies.
- Chapters open with **Objectives** and **Key Terms** with pronunciations and page references.

STUDY GUIDE

Includes *Practice Questions for the NCLEX® Examination* for each textbook chapter. Answers to the revised study guide are available from your instructor.

Contents

UNIT I Applying Pharmacology to Nursing Practice, 1

- 1 Drug Definitions, Standards, and Information Sources, 1
- 2 Basic Principles of Drug Action and Drug Interactions, 13
- 3 Drug Action Across the Life Span, 22
- 4 The Nursing Process and Pharmacology, 38
- 5 Patient Education to Promote Health, 50

UNIT II Illustrated Atlas of Medication Administration, 60

- 6 Principles of Medication Administration and Medication Safety, 60
- 7 Percutaneous Administration, 83
- 8 Enteral Administration, 103
- 9 Parenteral Administration: Safe Preparation of Parenteral Medications, 119
- 10 Parenteral Administration: Intradermal, Subcutaneous, and Intramuscular Routes, 137
- 11 Parenteral Administration: Intravenous Route, 149

UNIT III Drugs Affecting the Autonomic and Central Nervous Systems, 180

- 12 Drugs Affecting the Autonomic Nervous System, 180
- 13 Drugs Used for Sedation and Sleep, 192
- 14 Drugs Used to Treat Neurodegenerative Disorders, 204
- 15 Drugs Used for Anxiety Disorders, 228
- 16 Drugs Used for Depressive and Bipolar Disorders, 238
- 17 Drugs Used for Psychoses, 262
- 18 Drugs Used for Seizure Disorders, 276
- 19 Drugs Used for Pain Management, 300

UNIT IV Drugs Affecting the Cardiovascular System, 330

- 20 Introduction to Cardiovascular Disease and Metabolic Syndrome, 330
- 21 Drugs Used to Treat Dyslipidemias, 338
- 22 Drugs Used to Treat Hypertension, 353
- 23 Drugs Used to Treat Dysrhythmias, 382
- 24 Drugs Used to Treat Angina Pectoris, 397
- 25 Drugs Used to Treat Peripheral Vascular Disease, 409
- 26 Drugs Used to Treat Thromboembolic Disorders, 417

- 27 Drugs Used to Treat Heart Failure, 438
- 28 Drugs Used for Diuresis, 454

UNIT V Drugs Affecting the Respiratory System, 469

- 29 Drugs Used to Treat Upper Respiratory Disease, 469
- 30 Drugs Used to Treat Lower Respiratory Disease, 482

UNIT VI Drugs Affecting the Digestive System, 507

- 31 Drugs Used to Treat Oral Disorders, 507
- 32 Drugs Used to Treat Gastroesophageal Reflux and Peptic Ulcer Disease, 516
- 33 Drugs Used to Treat Nausea and Vomiting, 530
- 34 Drugs Used to Treat Constipation and Diarrhea, 550

UNIT VII Drugs That Affect the Endocrine System, 561

- 35 Drugs Used to Treat Diabetes Mellitus, 561
- 36 Drugs Used to Treat Thyroid Disease, 596
- 37 Corticosteroids, 606
- 38 Gonadal Hormones, 615

UNIT VIII Drugs Affecting the Reproductive System, 624

- 39 Drugs Used in Obstetrics, 624
- 40 Drugs Used in Men's and Women's Health, 644

UNIT IX Drugs Affecting Other Body Systems, 670

- 41 Drugs Used to Treat Disorders of the Urinary System, 670
- 42 Drugs Used to Treat Glaucoma and Other Eye Disorders, 682
- 43 Drugs Used to Treat Cancer, 699
- 44 Drugs Used to Treat Musculoskeletal Disorders, 711
- 45 Drugs Used to Treat Infections, 724

UNIT X Drugs Affecting the General Health of the Body, 771

- 46 Nutrition, 771
- 47 Herbal and Dietary Supplement Therapy, 792
- 48 Substance Abuse, 809

Drug Definitions, Standards, and Information Sources

<https://evolve.elsevier.com/Willihnganz>

Objectives

1. Differentiate between the chemical, generic, and brand names of drugs.
2. Identify the various methods used to classify drugs.
3. Identify sources of drug information available for healthcare providers.
4. Discuss the difference between prescription and nonprescription drugs.
5. Describe the process of developing and bringing new drugs to market.
6. Differentiate between the Canadian chemical names and the proper name of a drug.

Key Terms

pharmacology (fār-mă-KŌL-ō-jē) (p. 1)

therapeutic methods (thēr-ă-PYŪ-tīk MĒTH-ēdz) (p. 1)

drugs (p. 1)

biologic therapies (p. 1)

chemical name (KĒM-ī-kŭl) (p. 2)

generic name (jē-NĀR-īk) (p. 2)

brand name (p. 2)

prescription drugs (p. 2)

nonprescription drugs (p. 2)

over-the-counter (OTC) drugs (p. 2)

illegal drugs (īl-LĒ-gŭl) (p. 2)

biosimilars (p. 2)

schedules (SKĒD-jŭlz) (p. 5)

black box warnings (p. 8)

orphan drugs (ŌR-fān) (p. 8)

Food and Drugs Act and

Regulations (p. 9)

Controlled Drugs and Substances

Act (p. 10)

Pharmacology (from the Greek *pharmakon*, meaning “drugs,” and *logos*, meaning “science”) deals with the study of drugs and their actions on living organisms. Diseases that cause illness may be treated in several different ways, which are referred to as *therapies*. The various approaches to therapy are called **therapeutic methods**. Examples of therapeutic methods include the following:

- **Drug therapy:** Treatment with drugs
- **Diet therapy:** Treatment with diet (e.g., a low-salt diet for patients with cardiovascular disease)
- **Physiotherapy:** Treatment with natural physical forces (e.g., water, light, heat)
- **Psychological therapy:** The identification of stressors and methods that can be used to reduce or eliminate stress

Most illnesses caused by diseases require a combination of therapeutic methods for successful treatment.

Drugs (from the Dutch *droog*, meaning “dry”) are chemical substances that have an effect on living organisms. Therapeutic drugs, which are often called *medicines*, are those drugs that are used for the prevention or treatment of diseases. Up until the early to mid-20th century, dried plants were the most abundant source of medicines, thus the word *drug* was applied to them.

Whereas most drugs are individual chemicals that cause a response in living tissues, a new class known as **biologic therapies** have been discovered that have transformed treatment of patients with disorders that attack the body’s own organs, tissues, and cells (auto-immune disorders), blood (hematologic disorders), and cancers. Biologic agents are large, complex proteins manufactured in a living system such as a micro-organism, or within plant or animal cells. Biologics have added major therapeutic choices for the treatment of many diseases for which no effective therapies were available or previously existing therapies were clearly inadequate.

DRUG NAMES, STANDARDS, LEGISLATION, AND DEVELOPMENT IN THE UNITED STATES

DRUG NAMES

All drugs have several names, which may cause confusion. When administering the prescribed drug, the spelling on the drug package must correspond exactly with the spelling of the drug ordered to ensure that the proper medicine is administered.

Each drug has three names: (1) a *chemical* name, (2) a *generic* name, and (3) a *brand* name. The **chemical name** is most meaningful to the chemist. By means of the chemical name, the chemist understands the exact chemical constitution of the drug and the exact placement of its atoms or molecular groupings.

Before a drug becomes official, it is given a **generic name** or common name. The generic name is simpler than the chemical name. It may be used in any country and by any manufacturer. The first letter of the generic name is not capitalized. Students are strongly encouraged to learn and refer to drugs by their generic names because formularies (i.e., lists of medicines available through a pharmacy) are maintained by generic names. When a therapeutically equivalent drug becomes available in generic form, the generic medicine is routinely substituted for the brand-name medicine.

Generic names are provided by the United States Adopted Names Council, which is an organization sponsored by the United States Pharmacopeial Convention, the American Medical Association, and the American Pharmacists Association. The official name, which is virtually always the generic name in the United States, is the name under which the drug is listed by the US Food and Drug Administration (FDA). The FDA is empowered by federal law to generically name the drugs for human use in the United States.

A trademark or **brand name** is followed by the symbol ®. This symbol indicates that the name is registered and that the use of the name is restricted to the owner of the drug, which is usually the manufacturer. Most drug companies place their products on the market under brand names rather than generic names. The brand names are deliberately made easier to pronounce, spell, and remember. The first letter of the brand name is capitalized.

Example of Chemical, Generic, and Brand Names for Drugs

Chemical name: [2-[4-[(4-Chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride (Fig. 1.1)

Generic name: cetirizine

Brand name: Zyrtec Allergy

DRUG CLASSIFICATIONS

Drugs may be classified by a variety of methods according to the *body system* that they affect (e.g., the central nervous system, the cardiovascular system, the




Fig. 1.1 Cetirizine, an antihistamine.

gastrointestinal system); their *therapeutic use* or *clinical indications* (e.g., antacids, antibiotics, antihypertensives, diuretics, laxatives); and their *physiologic* or *chemical action* (e.g., anticholinergics, beta-adrenergic blockers, calcium channel blockers, cholinergics).

Drugs may be further classified as prescription or nonprescription. **Prescription drugs** require an order by a health professional who is licensed to prescribe drugs, such as a primary healthcare provider, a nurse practitioner, a physician assistant, a pharmacist, or a dentist. **Nonprescription drugs**, or **over-the-counter (OTC) drugs**, are sold without a prescription in a pharmacy or in the health section of department or grocery stores. **Illegal drugs**, sometimes referred to as *recreational drugs*, are drugs or chemical substances used for nontherapeutic purposes. These substances either are obtained illegally or have not received approval for use by the FDA. See **Chapter 48** for further information about substance abuse.

A **biosimilar** is a biologic product that is close in structure and function to an existing approved biologic product, known as a *reference product*. For example, infliximab-dyyb (Inflectra) and infliximab-abda (Renflexis) are biosimilars for the reference product infliximab (Remicade) used to treat rheumatoid arthritis. With many patents for biologics expiring, biosimilar agents will become available. In 2010 legislation created an abbreviated licensure pathway for biologic products that are demonstrated to be biosimilar. Biosimilars offer an opportunity to increase access to biologics while lowering the cost of therapy. However, unlike generic medicines in which the active ingredients are identical to the reference small-molecule drugs, biosimilars will not be identical to the reference biologics. This is due to the inherent complexity of biologic proteins. Biosimilars made by different manufacturers will differ from the reference product and from each other, making each biosimilar a unique therapeutic option for patients (Table 1.1). Biosimilars are not generics and are not interchangeable. These agents cannot be substituted for the original reference molecule.

SOURCES OF DRUG STANDARDS AND DRUG INFORMATION

Drug products made by different manufacturers or in different batches by the same manufacturer must be uniformly pure and potent. The United States Pharmacopeial Convention is a nongovernment organization that promotes public health by establishing state-of-the-art standards to ensure the quality of medicines and other healthcare technologies. These standards are developed by a unique process of public involvement, and they are accepted worldwide. The Convention publishes a single-volume text, the *United States Pharmacopeia (USP)/National Formulary (NF)*, which is revised annually. The primary purpose of this volume is to provide standards for the identity, quality, strength, and purity of substances used in the practice of healthcare. The standards described in the *USP/NF* are enforced by the FDA as the

Table 1.1 Comparing and Contrasting Biosimilar and Generic Products

PROPERTIES	BIOSIMILAR DRUGS (BIOLOGICS)	GENERIC (SMALL-MOLECULE DRUGS)
Size	Large	Small
Structure	Complex with potential structural variations	Simple and well defined
Manufacturing	Unique bank of living cells Unlikely to achieve identical copy	Predictable chemical reaction Identical copy can be made
Complexity	Difficult to fully characterize	Easy to fully characterize
Stability	More sensitive to storage and handling conditions	Less sensitive to storage and handling conditions
Immunogenicity (promotes immune response; potential for allergy)	Higher potential	Lower potential
Approval requirements	Large clinical trials in patients	Small clinical trials for safety in healthy volunteers

official standards for the manufacture and quality control of medicines and nutritional supplements produced in the United States. The *USP/NF* is also recognized by the Canadian Food and Drugs Act as an authoritative source of drug standards in Canada.

Table 1.2 lists and describes the common sources of drug information available for the professional health-care provider; additional resources are described in the following sections.

PACKAGE INSERTS

Manufacturers of drugs are required to develop a comprehensive but concise description of the drug, indications and precautions for clinical use, recommendations for dosage, known adverse reactions, contraindications, and other pharmacologic information relating to the drug. Federal law mandates that this material be approved by the FDA before the product is released for marketing and that it be presented on an insert that accompanies each package of the product.

The FDA adopted a format for package inserts to help reduce medication errors and to improve patient education. The labeling reduces practitioners' time looking for information, decreases the number of preventable medication errors, and improves treatment effectiveness and patient education. Because this labeling represents considerable effort and is most critical for newer and less familiar drugs, the formatting applies only to relatively new prescription drug products, developed since 2006.



Clinical Goldmine

DailyMed (see Online Resources), which is sponsored by the US National Library of Medicine, provides a database for new package inserts that is searchable by product name, indications, dosage and administration, warnings, description of drug product, active and inactive ingredients, and how the drug is supplied. See the section Electronic Databases.

NURSING JOURNALS

Many specialty journals have articles about drug therapy as it relates to a specific field of interest (e.g.,

Geriatric Nursing, *American Journal of Critical Care*). Nursing journals such as *RN* and *American Journal of Nursing* provide drug updates and articles that discuss nursing considerations related to drug therapy and drugs. Nurses must keep in mind that the purpose of using resources such as journals is to obtain professional knowledge of current evidence-based practice changes and they should not be used as a primary source for drug information. Nurses must be mindful of the accuracy of the information contained and should check the dates on articles to validate the currency of the information.

ELECTRONIC DATABASES

With the exponential growth of information about medicines and health, it is almost impossible to make the information available without the use of electronic databases. The National Library of Medicine (NLM) provides Medline and other searchable databases at no cost. Databases incorporated into the NLM include information on drugs and other chemicals that breastfeeding mothers may be exposed to and the levels in breast milk and infant blood with the possible adverse effects in the nursing infant. They also provide suggested therapeutic alternatives to the drugs. Information regarding the development and reproductive toxicology of drugs covering teratology is included. Most of the drug information sources listed in Table 1.2 are also available via electronic retrieval from libraries. Many college libraries subscribe to the Cumulative Index to Nursing and Allied Health Literature (CINAHL). These databases give nurses access to a wealth of information from sources published in the United States and other countries.

Databases for practitioners are also available by subscription. UpToDate, Lexicomp, and ePocrates are three vendors with several different packages of regularly updated information (see Online Resources). Lexicomp has a particularly strong database because the American Hospital Formulary Service is available through its portal.

Table 1.2 Sources of Drug Information for Healthcare Providers

SOURCES OF DRUG INFORMATION	DESCRIPTION
<i>AHFS Drug Information</i>	Contains monographs about virtually every single-entity drug available in the United States Describes therapeutic uses of drugs, including approved and unapproved uses Online version available
<i>Drug Facts and Comparisons</i>	Contains drug monographs that describe all drugs in a therapeutic class Monographs are formatted as tables to allow comparison of similar products, brand names, manufacturers, cost indices, and available dosage forms Online version available
<i>ASHP's Handbook on Injectable Drugs</i>	Collection of monographs about 360 injectable drugs with sections on available concentrations, compatibility with other drugs, dosage and rate of administration, stability, pH, and other useful information Interactive version available
<i>Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care</i>	Most comprehensive text available about over-the-counter medications that can be purchased in the United States Online version available
<i>Martindale: The Complete Drug Reference</i>	Considered one of the most comprehensive texts available for information about drugs in current use throughout the world Contains extensive referenced monographs about the international names, pharmacologic activity, and side effects of more than 6400 drugs Online subscription available
<i>Natural Medicines Comprehensive Database</i>	Scientific gold standard for evidence-based information about herbal medicines and combination products involving herbal medicines Only available in an online database by subscription or at libraries
CANADIAN DRUG STANDARDS	
<i>European Pharmacopoeia</i> <i>Pharmacopée Française</i> <i>The International Pharmacopoeia (Ph. Int.)</i> <i>British Pharmacopoeia</i> <i>Canadian Formulary</i> <i>The National Formulary</i> <i>Pharmaceutical Codex</i> <i>United States Pharmacopeia-National Formulary</i>	All recognized by the Canadian Food and Drugs Act as authoritative sources of drug standards
CANADIAN DRUG INFORMATION	
<i>Compendium of Pharmaceuticals and Specialties (CPS)</i>	Published annually by the Canadian Pharmacists Association Comprehensive list of the pharmaceutical products distributed in Canada, as well as other practical information e-CPS available
<i>Patient Self-Care: Helping Patients Make Therapeutic Choices</i>	Published by the Canadian Pharmacists Association Provides comprehensive information for health professionals and consumers about nonprescription drug products available in Canada e-Therapeutics available
<i>Compendium of Self-Care Products (CSCP)</i>	Nonprescription companion to <i>CPS</i> and <i>Patient Self-Care</i> Offers at-a-glance comparative tables for thousands of products and monographs about hundreds of commonly used nonprescription products

AHFS, American Hospital Formulary Service; ASHP, American Society of Health-System Pharmacists; USP, United States Pharmacopeia.

The DailyMed system (see Online Resources) was developed in collaboration with federal agencies—including the FDA, the NLM, the Agency for Healthcare Research and Quality, the National Cancer Institute in the US Department of Health and Human Services, and the US Department of Veterans Affairs—to provide high-quality information about marketed drugs. DailyMed makes available to healthcare providers

and the public a standard, comprehensive, up-to-date resource about medicines.

UNITED STATES DRUG LEGISLATION

Drug legislation approved by Congress provides the legal basis (Table 1.3) for drug manufacturing and protects the consumer from false claims made by a drug

Table 1.3 Selected Major US Legislation Pertaining to Safety of Medicines

LEGISLATION (LAW)	PURPOSE AND EFFECT
Food, Drug, and Cosmetic Act of 1938	Requires that new drugs be safe, as well as pure (but did not require proof of efficacy). Enforcement by FDA.
Durham-Humphrey Amendment (1951) to the Food, Drug, and Cosmetic Act	Gives the FDA the power to determine which products may be sold with and without a prescription.
Kefauver-Harris Amendment (1962) to the Food, Drug, and Cosmetic Act	Requires proof of efficacy as well as safety for medicines released since 1938; establishes guidelines for reporting of information about adverse reactions, clinical testing, and advertising of new drugs.
Comprehensive Drug Abuse Prevention and Control Act (1970) (Controlled Substances Act, 1970)	Outlines strict controls in the manufacture, distribution, and prescribing of habit-forming drugs; establishes drug schedules and programs to prevent and treat drug addiction. Established the Drug Enforcement Administration (DEA).
Dietary Supplement Health and Education Act (1994) (DSHEA Act–1994)	Under this act, almost all herbal medicines, vitamins, minerals, amino acids, and chemicals used for health are reclassified as dietary supplements , a food category. The legislation allows the label to include information about how these products affect the human body. Labels must contain a statement that the product has not been evaluated by the FDA for treating, curing, or preventing any disease. The law does not prevent nonlicensed personnel from making founded or unfounded claims about the therapeutic effects of supplement ingredients. The result is that dietary supplements are not required to be safe and effective, and unfounded claims of therapeutic benefit abound. See Chapter 47 .

manufacturer. The FDA is the administrative body that oversees the drug evaluation process in the United States and grants approval for or removal of drug products from the market.

CONTROLLED SUBSTANCES ACT

The Comprehensive Drug Abuse Prevention and Control Act, which is commonly referred to as the *Controlled Substances Act*, is designed to improve the administration and regulation of the manufacturing, distribution, and dispensing of drugs that require tighter control by the government because of their higher incidence of abuse and potential for addiction. The basic structure of the Controlled Substances Act consists of five classifications, or **schedules**, of controlled substances. The degree of control, the conditions of record keeping, the particular order forms required, and other regulations depend on which schedule the individual drug is assigned ([Box 1.1](#)).

Drugs that are listed as Schedule I are not available for other than highly controlled research purposes because of their very high potential for abuse and addiction. Drugs in Schedule II have a high potential for abuse and addiction, but are available by prescription only, in limited quantities, usually with no more than a 7- to 30-day supply. The prescription cannot be refilled; a new prescription must be issued for continued use. Drugs categorized as Schedule III, IV, or V have a lower potential for abuse and addiction and may be ordered by prescription with a

Box 1.1 Examples of Medicines in the Controlled Substances Drug Schedules

SCHEDULE I DRUGS

Examples: lysergic acid diethylamide (LSD), peyote, heroin, hashish

SCHEDULE II DRUGS

Examples: amphetamines, morphine, hydrocodone/acetaminophen (Vicodin), hydrocodone/acetaminophen (Lortab), hydrocodone/acetaminophen (Norco), methadone, oxycodone/aspirin (Percodan), methylphenidate (Ritalin), amphetamine/dextroamphetamine (Adderall)

SCHEDULE III DRUGS

Examples: aspirin/codeine (Empirin with codeine), aspirin/butalbital/caffeine (Fiorinal), acetaminophen/codeine (Tylenol with codeine)

SCHEDULE IV DRUGS

Examples: phenobarbital, chlordiazepoxide, diazepam, flurazepam, temazepam

SCHEDULE V DRUGS

Example: atropine/diphenoxylate (Lomotil, Virtussin AC)

maximum supply of 30 days of medicine. If so written by the prescriber, the prescription may be refilled up to five times but outdates at 6 months, at which time a new prescription is required if the medicine is to be continued. Prescription medicines that are not classified as controlled substances may be refilled for up to a period of time defined by individual state law, if

approved by the prescriber. Most state laws mandate that a prescription outdates in 1 year and must be rewritten if therapy is to be continued.

Drug Enforcement Administration

The US Drug Enforcement Administration (DEA) was organized to enforce the Controlled Substances Act, to gather intelligence, to train its officers, and to conduct research in the area of dangerous drugs and drug abuse.

Every manufacturer, primary healthcare provider, nurse practitioner, physician assistant, dentist, pharmacy, and hospital that manufactures, prescribes, or dispenses any of the drugs listed in the five schedules must register biannually with the DEA. A healthcare provider's prescription for substances named in this law must contain the healthcare provider's name, address, DEA registration number, and signature; the patient's name and address; and the date of issue. The pharmacist cannot fill such a prescription for a controlled substance without this information on the prescription.

Possession of Controlled Substances by Individuals

Federal and state laws make the possession of controlled substances without a valid prescription a crime, except in specifically exempted cases. The law makes no distinction between professional and practical nurses with regard to the possession of controlled drugs. Nurses may give controlled substances only under the direction of a healthcare provider who has been licensed to prescribe or dispense these agents. Nurses may not have controlled substances in their possession unless the following conditions are met: (1) the nurse is giving them to a patient under an order from a healthcare provider, (2) the nurse is a patient for whom a healthcare provider has prescribed scheduled drugs, or (3) the nurse is the official custodian of a limited supply of controlled substances on a unit or for a department of the hospital. Controlled substances that are ordered for patients but not used must be returned to the source from which they were obtained (i.e., the primary healthcare provider or pharmacy). Violation of or failure to comply with the Controlled Substances Act is punishable by fine, imprisonment, or both and by the possible loss of professional licensing.

EFFECTIVENESS OF DRUG LEGISLATION

The effectiveness of drug legislation depends on the interest and determination used to enforce these laws, the appropriation by government of adequate funds for enforcement, and the vigor used by proper authorities in enforcement. The interest and cooperation of healthcare professionals and the public with regard to the benefits of appropriate drug use and the possible consequences of indiscriminate use of drugs can be very beneficial. Many individuals assist in this

education through support of national and state professional organizations, consumer advocacy groups, and local, state, and county health departments.

NEW DRUG DEVELOPMENT

It currently takes an average of 8 to 15 years and more than \$2 billion in research and development costs to bring a single new drug to market; healthcare professionals and consumers alike often have a lack of understanding about this process. The Pharmaceutical Research and Manufacturers of America estimates that only 1 of 10,000 chemicals investigated is actually found to be "safe and effective" and ultimately brought to the pharmacist's shelf.

The Food, Drug, and Cosmetic Act of 1938 charged the FDA with the responsibility of regulating new drugs. Rules and regulations evolved by the FDA divide new drug development into four stages: (1) preclinical research and development; (2) clinical research and development; (3) New Drug Application (NDA) review; and (4) postmarketing surveillance (Fig. 1.2).

PRECLINICAL RESEARCH AND DEVELOPMENT STAGE

The preclinical research phase of new drug development begins with the discovery, synthesis, and purification of the drug. The goal at this stage is to use laboratory studies to determine whether the experimental drug has therapeutic value and whether the drug appears to be safe in animals. Enough data must be gained to justify testing the experimental drug in humans.

The preclinical phase of data collection may require 1 to 3 years, although the average length of time is 18 months. Near the end of this phase, the investigator (often a pharmaceutical manufacturer) submits an Investigational New Drug (IND) application to the FDA; this application describes all of the studies completed to date, discusses the expected safety of the drug, and explains the testing that is planned for human subjects. Within 30 days, the FDA must make a decision on the basis of safety considerations about whether to allow the human study to proceed. Only about 20% of the chemicals tested in the preclinical phase advance to the clinical testing phase.

CLINICAL RESEARCH AND DEVELOPMENT STAGE

The stage in which humans are first tested (i.e., the clinical research or IND stage) is usually subdivided into three phases. Phase 1 studies determine an experimental drug's pharmacologic properties, such as its pharmacokinetics, metabolism, safe dosage range, potential for toxicity at a certain dosage, and safe routes of administration. The study population is composed of normal volunteers or the intended treatment population, such as those patients for whom the standard




Fig. 1.2 The new drug review process. FDA, US Food and Drug Administration; NDA, New Drug Application.

treatments of certain cancers or dysrhythmias have been ineffective. Phase 1 studies usually require 20 to 100 subjects who are treated for 4 to 6 weeks.

If phase 1 trials are successful, the drug is moved to phase 2 trials, which involve a smaller population of patients who have the condition that the drug is designed to treat. Studies at various dosages are conducted to determine the success rate and safety of a drug for its intended use. If successful, the drug is advanced to phase 3 trials, in which larger patient populations are used to ensure the statistical significance of the results. Phase 3 studies also provide additional information about proper dosing and safety.

The entire clinical research phase may require 2 to 10 years, with the average experimental drug requiring 5 years. Each study completed is reviewed by the FDA to help ensure patient safety and efficacy. Only one of five drugs that enter clinical trials makes it to the marketplace. The others are eliminated because of efficacy or safety problems or a lack of commercial interest.

Fast Tracking

To expedite the development and approval of drugs for the treatment of life-threatening illnesses (e.g., acquired immunodeficiency syndrome), the FDA has drafted rules that allow certain INDs to receive the highest priority for review within the agency.

This procedure is sometimes known as *fast tracking*. Additional rules allow INDs to be used for the treatment of a life-threatening disease in a particular patient—even if the patient does not fit the study protocol for the drug—when there is no alternative therapy. These cases are known as *treatment INDs*. A potentially lifesaving drug may be allowed for treatment IND status during late phase 2 studies, during phase 3 studies, or after all clinical studies have been completed but before marketing approval.

Parallel Tracking

Another mechanism to make INDs available to patients with life-threatening illnesses is known as *parallel tracking*. With this procedure, an IND may be used for patients who cannot participate in controlled clinical trials and when there is no satisfactory standard therapeutic alternative. Parallel track studies are conducted along with the principal controlled clinical trials; however, unlike a controlled study, the parallel track study does not involve a concurrent control group.

Investigators and patients must realize that there may be greater uncertainty regarding the risks and benefits of therapy with agents that are in relatively early stages of testing and development. Parallel tracking is similar to the treatment IND process but allows for access to investigational agents when there is less accumulated evidence of efficacy than required for a treatment

IND. A drug may be released through the parallel track mechanism when phase 2 trials have been given approval to proceed but have not necessarily been started.

NEW DRUG APPLICATION REVIEW

When sufficient data have been collected to demonstrate that the experimental drug is both safe and effective, the investigator submits an NDA to the FDA to formally request approval to market a new drug for human use. Thousands of pages of NDA data are reviewed by a team of pharmacologists, toxicologists, chemists, primary healthcare providers, and others (as appropriate), who then make a recommendation to the FDA about whether the drug should be approved for use. The average NDA review takes 24 months. After a drug is approved by the FDA, it is the manufacturer's decision as to when to bring a product to the marketplace.

POSTMARKETING SURVEILLANCE STAGE

If the manufacturer decides to market the medicine, the postmarketing surveillance stage begins; this is the fourth stage of drug product development. This process consists of an ongoing review of adverse effects of the new drug and periodic inspections of the manufacturing facilities and the resulting products. Other studies completed during the fourth stage include identifying other patient populations for whom the drug may be useful, refining dosing recommendations, and exploring potential drug interactions.



Clinical Goldmine

Healthcare providers make a significant contribution to the knowledge of drug safety by reporting adverse effects to the FDA using the MedWatch program for the voluntary reporting of adverse events and product problems (see Online Resources).

BLACK BOX WARNING

Although the FDA's drug approval process is one of the most stringent in the world, the value of ongoing safety review of medicines has been demonstrated through the use of the MedWatch program. If safety concerns are identified after a drug is approved for marketing, the FDA can issue **black box warnings** to the package insert of the product. When a medication's risks and known dangers outweigh its benefits, the FDA and/or the manufacturer may decide that the product should be withdrawn from the market.

The probability of a drug acquiring a new black box warning or being withdrawn from the market within 25 years of being released is estimated at 20%. Consequently, it is the responsibility of all healthcare professionals to constantly monitor their patients for adverse effects of drugs and to complete a MedWatch form when adverse effects are suspected. More than 200,000 MedWatch forms are filed with the FDA annually. Health Canada has a program for reporting adverse effects (Canada

Vigilance Program: <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/canada-vigilance-program.html>).

From a safety standpoint, prescribers and patients should be aware that recently marketed medicines carry a risk of causing unsuspected serious adverse effects. Even with the high probability that there will be no serious complications, the devastating—and sometimes fatal—consequences cannot be ignored. When choosing medicines for treatment, it becomes important to consider whether an equally effective alternative drug is already available. At a minimum, this reduces the risk of an undiscovered adverse drug reaction, and it is often less expensive. At a maximum, the patient, the family, and the prescriber are saved the anguish of an avoidable adverse drug reaction.

RARE DISEASES AND THE DEVELOPMENT OF ORPHAN DRUGS

The National Organization for Rare Disorders, which is a coalition of 140 rare-disease groups, estimates that more than 6000 rare health conditions exist in about 20 million Americans. Examples of these rare diseases are cystic fibrosis, Hansen disease (leprosy), sickle cell anemia, blepharospasm, infant botulism, and *Pneumocystis jiroveci* pneumonia (see Online Resources). Historically, pharmaceutical manufacturers have been reluctant to develop products that could be used to treat these illnesses. The medicines that are developed for these conditions are known as **orphan drugs** because the manufacturers have been unable to recover the costs of the research on account of the very limited use of the final product. Because no companies were willing to “adopt” the diseases to complete extensive research to develop products for treatment, the diseases became known as *health orphans*.

In 1983 Congress passed the Orphan Drug Act to stimulate the development and market availability of products that are used for the treatment of rare diseases. The act defines the term *rare disease* as a condition that affects fewer than 200,000 people in the United States. The FDA's Office of Orphan Products Development (OOPD) promotes the development of products that demonstrate promise for the diagnosis or treatment of rare diseases or conditions. The OOPD interacts with medical and research communities, professional organizations, academia, and the pharmaceutical industry, as well as with rare-disease groups. The OOPD administers the major provisions of the Orphan Drug Act, which provide incentives for sponsors to develop products for rare diseases.

The law provides research grants, protocol development assistance by the FDA, special tax credits for the cost of clinical trials, and 7 years of exclusive marketing rights after the product has been approved. On average, an orphan drug receives FDA approval 10 to 11 months sooner than a nonorphan drug. The act has been quite successful: more than 200 new drugs have been approved by the FDA for rare diseases, benefiting several million people. Examples include

pentamidine and atovaquone for *Pneumocystis jiroveci* pneumonia, thalidomide for Hansen disease, zidovudine for the human immunodeficiency virus, dornase alfa (Pulmozyme) for cystic fibrosis, and cladribine (Leustatin) for hairy cell leukemia.

DRUG NAMES, STANDARDS, AND LEGISLATION IN CANADA

CANADIAN DRUG NAMES

OFFICIAL DRUG

The term *official drug* pertains to any drug for which a standard is described specifically in the Food and Drug Regulations or in any publication named in the Food and Drugs Act as being satisfactory for officially meeting the standards for drugs in Canada.

CHEMICAL NAME

The *chemical name* is most meaningful to the chemist. By means of the chemical name the chemist understands the exact chemical constitution of the drug and exact placing of its atoms or molecular groupings. The chemical name is the same in both Canada and the United States.

PROPER NAME OR GENERIC NAME

The *proper name* is the nonproprietary (generic) name, which is used to identify an official drug in Canada. The *generic name* is the same in both Canada and the United States.

BRAND NAME

The *brand name* (or proprietary name) is the name assigned to the drug by its manufacturer to distinguish the drug for advertisement and sale. Brand names for the same generic drug product are frequently different between Canada and the United States. The following example and Fig. 1.3 depict the application of terminology to drug nomenclature.

Example of Canadian Drug Names

Chemical name: 4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene carboxamide (see Fig. 1.3)

Proper name: tetracycline

Official name: Tetracycline, USP

Brand names: Apo-Tetra; Nu-Tetra




Fig. 1.3 Tetracycline, an antibiotic.

SOURCES OF CANADIAN DRUG STANDARDS

The Food and Drugs Act recognizes the standards described by international authoritative books as being acceptable for official drugs in Canada (see Table 1.2).

CANADIAN DRUG LEGISLATION

FOOD AND DRUGS ACT AND REGULATIONS

The **Food and Drugs Act** (1927) and **Regulations** (1953, 1954, 1979) empower Health Canada to protect the public from foreseeable risks related to the manufacture and sale of drugs, cosmetics, food, and therapeutic devices. The legislation provides for a review of the safety and efficacy of drugs before their clearance for marketing in Canada and determines whether the medicine is *prescription* or *nonprescription*. Also included in this legislation are requirements for good manufacturing practices, adequate labeling, and fair advertising.

In Canada (as in the United States), an effort has been made to align the provincial drug schedules so that the conditions for the sale of medicines are consistent across Canada. The National Association of Pharmacy Regulatory Authorities (NAPRA) governs national drug schedules but each province's regulatory body can regulate how a particular drug can be sold/sold/dispensed. The National Association of Pharmacy Regulatory Authorities (NAPRA) proposed a new national drug scheduling model. This model is in various stages of implementation across the provinces and territories of Canada. With the use of this model, all medicines in Canada are assigned to one of four categories: **Schedule I:** All prescription drugs, including narcotics **Schedule II:** Restricted-access nonprescription drugs **Schedule III:** Pharmacy-only nonprescription drugs **Unscheduled:** Drugs that are not assigned to the previous categories

Schedule II drugs are available for sale directly from the pharmacist and are kept "behind the counter." Examples include insulin, pseudoephedrine, glucagon, loperamide (for children younger than age 12 years), and nitroglycerin sublingual spray and tablets (other dosage forms are Schedule I). These medications are in two categories: (1) those that patients may require urgently and cannot delay taking until after an appointment with a prescriber (e.g., insulin, nitroglycerin, glucagon); and (2) those that require appropriate counseling to avoid improper use (e.g., loperamide, pseudoephedrine). Placement with a pharmacist does not allow for patient self-selection and allows for pharmacist intervention for these medications. This restriction is meant to ensure the following: (1) that patients are not self-diagnosing medically serious diseases (e.g., diabetes mellitus, angina); and (2) that patients are educated about the proper use of these drugs through appropriate counseling from the pharmacist.

Schedule III drugs are pharmacy-only nonprescription drugs. These medicines can be sold only

through pharmacies and include levonorgestrel emergency contraception, diphenhydramine, child preparations of antihistamines, and the low-dose histamine-2 antagonists. It is expected that if patients have questions, they could easily consult with a pharmacist.

Medicines that are not categorized in Schedule I, II, or III are considered to be “unscheduled” (e.g., nicotine gum and patches, acetylsalicylic acid, lower-dose ibuprofen, some lower-dosage “cough and cold” preparations) and can be sold at any retail outlet. Adequate information is available for the patient to make a safe and effective choice, and labeling is sufficient to ensure the appropriate use of the drug without professional supervision.

Drugs requiring a prescription—except for controlled drugs—are listed on Schedule F of the Food and Drug Regulations. Schedule F drugs may be prescribed only by qualified healthcare providers because they would normally be used most safely under supervision. Most antibiotics, antineoplastics, corticosteroids, cardiovascular drugs, and antipsychotics are Schedule F drugs.

CONTROLLED DRUGS AND SUBSTANCES ACT

The **Controlled Drugs and Substances Act** (1997) established the requirements for the import, production, export, distribution, and possession of substances classified as narcotics and substances of abuse in Canada. The Controlled Drugs and Substances Act describes eight schedules of controlled substances. Assignment to a schedule is based on the potential for abuse and the ease with which illicit substances can be manufactured in illegal laboratories. The degree of control; the conditions of record keeping; assignment of penalties for possession, trafficking, and manufacturing; and other regulations depend on these classifications. (Note that Schedules I, II, and III under the US Food and Drugs Act as described earlier are different from Schedules I through VIII of the Canadian Controlled Drugs and Substances Act). Examples of controlled substances schedule assignment are as follows:

Schedule I: Opium poppy and its derivatives (e.g., heroin, morphine); coca and its derivatives (e.g., cocaine), pethidine (meperidine), methadone, fentanyl

Schedule II: Cannabis

Schedule III: Amphetamines, methylphenidate, lysergic acid diethylamide (LSD), methaqualone, psilocybin, mescaline

Schedule IV: Sedative-hypnotic agents (e.g., barbiturates, benzodiazepines); butorphanol, anabolic steroids

Schedule V: Propylhexedrine, phenylpropanolamine, pyrovalerone

Schedule VI: Part I class A precursors (e.g., ephedrine, pseudoephedrine, norephedrine [phenylpropanolamine], ergotamine) and part II precursors (e.g., acetone, ethyl ether, hydrochloric acid, sulfuric acid, toluene)

Schedule VII: Cannabis resin (3 kg); cannabis (marijuana) (3 kg) (must be read in conjunction with Schedule II)

Schedule VIII: Cannabis resin (1 g); cannabis (marijuana) (30 g) (must be read in conjunction with Schedule II)

The Controlled Drugs and Substances Act and accompanying regulations provide for the non-prescription sale of certain codeine preparations (e.g., Tylenol No. 1 with codeine, Benlyn with codeine). The content must not exceed the equivalent of 8 mg of codeine phosphate per solid dosage unit or 20 mg per 30 mL of a liquid preparation, and the preparation must also contain two additional nonnarcotic medicinal ingredients. These preparations may not be advertised or displayed, and they may be sold only by pharmacists (see previous discussion of Schedule II drugs). In hospitals, the pharmacy usually requires strict inventory control of these products and other narcotics.

Requirements for the legitimate administration of drugs to patients by nurses are generally similar in Canada and the United States. Individual hospital policy determines specific record-keeping requirements on the basis of federal and provincial laws. Violations of these laws will result in fines or imprisonment in addition to the loss of professional licensing.

NONPRESCRIPTION DRUGS

The NAPRA drug schedules list three categories of nonprescription drugs: Schedule II, Schedule III, and unscheduled drugs (see discussion under Food and Drugs Act and Regulations).


Clinical Judgment and Next-Generation NCLEX® Examination-Style Questions

Key Points

- In the classification system used in the United States, each drug has three names: a *chemical* name, a *generic* name, and a *brand* name. The chemical name is most meaningful to the chemist. The generic name is simpler than the chemical name. The first letter of the generic name is not capitalized. The brand names are selected by the manufacturer and deliberately made easier to pronounce, spell, and remember. A brand name is followed by the symbol ®. The first letter of the brand name is capitalized.
- Drugs may be classified by a variety of methods according to the *body system* that they affect (e.g., the central nervous system, the cardiovascular system, the gastrointestinal system); their *therapeutic use* or *clinical indications* (e.g., antacids, antibiotics, antihypertensives, diuretics, laxatives); and their *physiologic* or *chemical action* (e.g., anticholinergic agents, beta-adrenergic blockers, calcium channel blockers, cholinergic agents).
- Table 1.2 lists and describes the common sources of drug information available for the healthcare provider.
- Prescription drugs require an order by a healthcare provider who is licensed to prescribe drugs, such as a primary healthcare provider, a nurse practitioner, a physician assistant, a pharmacist, or a dentist. Nonprescription or over-the-counter (OTC) drugs are sold without a prescription in a pharmacy or in the health section of department or grocery stores.
- Rules and regulations evolved by the FDA divide new drug development into four stages: (1) preclinical research and development; (2) clinical research and development; (3) new drug application review; and (4) postmarketing surveillance (see Fig. 1.2).
- In Canada, the *proper name* is the nonproprietary (generic) name, which is used to identify an official drug. The *generic name* is the same in both Canada and the United States.

Additional Learning Resources

SG Go to your Study Guide for additional Review Questions for the NCLEX® Examination, Critical Thinking Clinical Situations, and other learning activities to help you master this chapter content.

 Go to your Evolve website (<https://evolve.elsevier.com/Cla/ytton>) for additional online resources.

Online Resources

- DailyMed: <https://dailymed.nlm.nih.gov/dailymed/index.cfm>
- ePocrates: <http://www.epocrates.com/>
- iPharmacy: <https://itunes.apple.com/us/app/ipharmacy-drug-guide-pubmed-direct/id378721295>
- Lexicomp: <http://www.wolterskluwercli.com/lexicomp-online/>
- MedicinesComplete: <https://about.medicinescomplete.com/#/>

- MedWatch: <https://www.fda.gov/Safety/MedWatch/default.htm>
- National Organization for Rare Disorders (NORD): <https://rarediseases.org/>
- UpToDate: <https://www.uptodate.com/home>
- US National Library of Medicine: <https://www.nlm.nih.gov/>

Online Resources for Canadian Practitioners

- Controlled Substances and Drugs Act (Justice Laws Website): <http://laws-lois.justice.gc.ca/eng/acts/c-38.8/>
- Drug Product Database: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>
- National Association of Pharmacy Regulatory Authorities (NAPRA) proposal for drug schedule outlines: <http://napra.ca/national-drug-schedules>

Clinical Judgment and Next-Generation NCLEX® Examination-Style Questions

The National Council of State Boards of Nursing (NCSBN) is the body that develops and administers the NCLEX (National Council Licensure Exam). Recent studies indicate that graduates need to develop the skill of clinical decision making, so the NCLEX examination is changing with different types of questions that are designed to develop clinical judgment in patient situations. These type of questions are referred to as Next Generation NCLEX or NGN. The following questions are typical of the NCLEX examination and include both NGN (Next Generation) and traditional questions. Within each chapter the NCLEX section will identify the objective associated with it, the type of NCLEX question that will be used, and the cognitive skill associated with the item type. Six essential cognitive skills of clinical judgment are being tested: recognize cues; analyze cues; prioritize hypotheses; generate solutions; take action; and evaluate outcomes. These six clinical judgment skills build on and expand the nursing process (NCSBN, 2019).

TRADITIONAL NCLEX-TYPE QUESTIONS	NGN-TYPE QUESTIONS
Multiple Choice Test Item	• Enhanced Hot Spot Test Item
Multiple Response Test Item	• Cloze Test Item
Ordering Test Item	• Extended Multiple Response Test Item
	• Extended Drag and Drop Test Item
	• Matrix Text Item

- A patient has received a prescription from his primary care provider for the drug metoprolol (Lopressor). He asks the nurse why there are two names for the same drug. The nurse responds with which statement(s)? (Select all that apply.)
 - “One of the names is the brand name of the drug, and the other is the generic name.”

2. "When drugs are discovered, all drugs are given a detailed chemical name and a simple generic name. If the company that discovered the drug brings it to the marketplace for sale, the manufacturer will give it a distinctive brand name."
3. "Lopressor is the generic name, and metoprolol is the brand name."
4. "The two names are used to determine whether the drug is a Schedule III or a Schedule IV drug."
5. "Generally, the generic product of the drug is less expensive than the brand name product."

Objective: Differentiate between the chemical, generic, and brand names of drugs.

NCLEX test item: Multiple response

Cognitive skill: Application

2. Drugs can be classified using various methods; identify the different classification and examples as indicated.

Choose the most likely option for the information missing from the statements below by selecting from the list of options provided.

Medications such as _____ 1 _____ are classified by the _____ 2 _____ method, whereas medications such as _____ 1 _____ are classified by the _____ 2 _____ method.

OPTIONS FOR 1	OPTIONS FOR 2
antacids antibiotics calcium channel blockers Diuretics Cholinergics	body systems chemical action clinical indication

Objective: Identify the various methods used to classify drugs.

NGN test item: Cloze

Cognitive skill: Analyze cues

3. A young mother with a 2-month-old infant tells the nurse that she is concerned about the use of any medications because she is breastfeeding her baby. The nurse reviews the possible information sources to discuss with the mother.

Indicate with an X in the "recommended by the nurse" column the source of drug information listed in the left column the nurse can recommend for the mother to use. Note that not all drug information sources will be used.

DRUG INFORMATION SOURCE	RECOMMENDED BY THE NURSE
Nursing journals Electronic databases Package inserts Natural medicines database	

Objective: Identify sources of drug information available for healthcare providers.

NGN test item: Extended drag and drop

Cognitive skill: Take action

4. The nurse knows which of these factors are the differences between prescription and nonprescription drugs? (Select all that apply.)

1. Nonprescription drugs are available over-the-counter.
2. Prescription drugs are those drugs that may be prescribed by dentists, pharmacists, nurse practitioners, and primary healthcare providers.
3. Recreational drugs are available by prescription only.
4. Over-the-counter drugs are available at a pharmacy or health section of grocery stores.
5. Prescription drugs have been approved for use by the FDA.

Objective: Discuss the difference between prescription and nonprescription drugs.

NCLEX test item: Multiple response

Cognitive skill: Application

5. During which stage of the process of new drug development does testing on humans start?

1. The preclinical research and development stage
2. The postmarketing surveillance stage
3. The postclinical research and development stage
4. The clinical research and development stage

Objective: Describe the process of developing and bringing new drugs to market.

NCLEX test item: Multiple choice

Cognitive skill: Knowledge

6. A nurse is teaching a patient from Canada the names of her medications and reviews the differences between Canadian names. Which statement indicates that the patient understands the instructions?

1. "The proper name of the medication is the same as the brand name in Canada."
2. "The proper name of the medication is the same as the generic name in Canada."
3. "The chemical name is the one used the most when buying medications in Canada."
4. "The chemical names and the brand names are the only names used in Canada."

Objective: Differentiate between the Canadian *chemical* name and the *proper* name of a drug.

NCLEX test item: Multiple choice

Cognitive skill: Evaluation

Basic Principles of Drug Action and Drug Interactions

2

<https://evolve.elsevier.com/Willihnganz>

Objectives

1. Identify common drug administration routes.
2. Identify the meaning and significance of the term *half-life* when used in relation to drug therapy.
3. Describe the process of how a drug is metabolized in the body.
4. Compare and contrast the following terms that are used in relationship to medications: *desired action*, *common adverse effects*, *serious adverse effects*, *allergic reactions*, and *idiosyncratic reactions*.
5. Identify what is meant by a drug interaction.
6. Differentiate among the terms *additive effect*, *synergistic effect*, *antagonistic effect*, *displacement*, *interference*, and *incompatibility*.
7. Identify one way in which alternatives in metabolism create drug interactions.

Key Terms

receptors (rê-SĒP-tĕrz) (p. 13)	drug blood level (p. 15)	allergic reactions (ă-LŪR-jĭk) (p. 18)
pharmacodynamics (făr-mă-kô-dĭ-NĂM-ĭks) (p. 13)	metabolism (mĕ-TĂB-ô-lĭz-ĕm) (p. 15)	drug interaction (p. 18)
agonists (ĂG-ô-nĭsts) (p. 13)	excretion (ĕks-KRĒ-shŭn) (p. 15)	unbound drug (ŭn-BŌWND) (p. 18)
antagonists (ăn-TĂG-ô-nĭsts) (p. 13)	half-life (p. 16)	additive effect (ĂD-ĭ-tĭv) (p. 19)
partial agonists (PĂR-shŭl ĂG-ô-nĭsts) (p. 13)	onset of action (p. 17)	synergistic effect (sĭn-ĕr-JĪS-tĭk) (p. 19)
enteral (ĔN-tĕr-ăl) (p. 14)	peak action (p. 17)	antagonistic effect (ăn-tăg-ô-NĪST-ĭk) (p. 19)
parenteral (pă-RĔN-tĕr-ăl) (p. 14)	duration of action (p. 17)	displacement (dĭs-PLĂS-mĕnt) (p. 19)
percutaneous (pĕr-kŭ-TĂ-nĕ-ŭs) (p. 14)	desired action (p. 17)	interference (ĭn-tŭr-FĒR-ĕns) (p. 19)
pharmacokinetics (făr-mă-kô-kĭ-NĔT-ĭks) (p. 14)	side effects (p. 17)	incompatibility (ĭn-kôm-păt-ĭ-BĪL-ĭ-tĕ) (p. 19)
absorption (ăb-SŌRP-shŭn) (p. 14)	common adverse effects (ĂD-vŭrs ĕ-FĔKTS) (p. 17)	
distribution (dĭs-trĭ-BŪ-shŭn) (p. 15)	serious adverse effects (p. 17)	
	idiosyncratic reaction (ĭd-ĕ-ô-sĭn-KRĂT-ĭk rê-ĂK-shŭn) (p. 18)	

BASIC PRINCIPLES RELATED TO DRUG THERAPY

DRUG RESPONSES IN THE BODY

When administered to the body, drugs do not create new responses but rather alter existing physiologic activity in several different ways. Usually the drug forms chemical bonds with specific sites, called **receptors**, within the body. This bond forms only if the drug and its receptor have similar shapes and if the drug has a chemical affinity for the receptor. The relationship between a drug and a receptor is similar to that seen between a key and lock (Fig. 2.1A). The study of the interactions between drugs and their receptors and the series of events that result in a pharmacologic response is called **pharmacodynamics**. Most drugs have several different atoms within each molecule that interlock into various locations on a receptor. The better the fit between the receptor and the drug molecule, the better

the response from the drug. The intensity of a drug response is related to how well the drug molecule fits into the receptor and to the number of receptor sites that are occupied. Drugs that interact with a receptor to stimulate a response are known as **agonists** (Fig. 2.1B). Drugs that attach to a receptor but do not stimulate a response are called **antagonists** (Fig. 2.1C). Drugs that interact with a receptor to stimulate a response but inhibit other responses are called **partial agonists** (Fig. 2.1D).

Drug response must be stated in relation to the physiologic activity expected in response to the drug therapy (e.g., an antihypertensive agent is successful if the patient's blood pressure is lower after receiving the drug than it was before the drug was started). Therefore it is important to perform a thorough nursing assessment to identify the baseline data. After that is done, results from regular assessments can be compared




Fig. 2.1 (A) Drugs act by forming chemical bonds with specific receptor sites, similar to a key and lock. The better the fit, the better the response. (B) Drugs with complete attachment and response are called *agonists*. (C) Drugs that attach but do not elicit a response are called *antagonists*. (D) Drugs that attach and elicit a small response but also block other responses are called *partial agonists*.

Table 2.1 Drug Therapy Used in Disease Management^a

DISEASES/ILLNESSES	CLASSIFICATION OF THE DRUGS USED
Cancer	Chemotherapy, immunotherapy
Mental illness	Antidepressants and antipsychotic agents
Hypertension	Antihypertensive agents
Diabetes	Antidiabetic agents
Infections	Antimicrobial agents
Inflammatory diseases	Antiinflammatory agents
Nausea and vomiting	Antiemetic agents
Constipation	Laxatives
Diarrhea	Antidiarrheal agents
GERD	Antacids

^aList is not inclusive.
GERD, Gastroesophageal reflux disease.

with the baseline data by the primary healthcare provider, the nurse, and the pharmacist to evaluate the effectiveness of the drug therapy. Table 2.1 lists examples of drug therapies and their related diseases.

ROUTES OF DRUG ADMINISTRATION

The most common routes of drug administration are the enteral, parenteral, and percutaneous routes. When using the **enteral** route, the drug is administered directly into the gastrointestinal (GI) tract by the oral, rectal, or nasogastric route. The **parenteral** route bypasses the GI tract with the use of subcutaneous (subcut), intramuscular (IM), or intravenous (IV) injection. The **percutaneous** route involves drugs being absorbed through the skin and mucous membranes. Methods of the percutaneous route include inhalation, sublingual (under the tongue), and topical (on the skin) administration.

LIBERATION, ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

After they have been administered, all drugs go through five stages: *liberation*, *absorption*, *distribution*, *metabolism*, and *excretion* (LADME). After liberation from the dosage form, each drug has its own unique ADME

characteristics. The study of the mathematical relationships among the ADME features of individual medicines over time is called **pharmacokinetics**.

Liberation

Regardless of the route of administration, a drug must be released from the dosage form (i.e., liberated) and dissolved in body fluids before it can be absorbed into body tissues. For example, before a solid drug that is taken orally can be absorbed into the bloodstream for transport to the site of action, the dosage form (usually a capsule or tablet) must disintegrate and the active drug must dissolve in the GI fluids so that it can be transported across the stomach or intestinal lining into the blood. The process of converting the drug into a form that will activate a response can be partially controlled by the pharmaceutical dosage form used (e.g., solution, suspension, capsule, tablet [with various coatings]). This conversion process can also be influenced by administering the drug with or without water or food in the patient's stomach.

Absorption

Absorption is the process whereby a drug is transferred from its site of entry into the body to the circulating fluids of the body (i.e., blood and lymph) for distribution around the body. The rate at which this occurs depends on the route of administration, the blood flow through the tissue where the drug is administered, and the solubility of the drug. It is therefore important to do the following: (1) administer oral drugs with an adequate amount of fluid (usually a large [8-ounce] glass of water); (2) give parenteral forms properly so that they are deposited in the correct tissue for enhanced absorption; and (3) reconstitute and dilute drugs only with the diluent recommended by the manufacturer in the package literature so that drug solubility is not impaired. Equally important are nursing assessments that reveal poor absorption (e.g., if insulin is administered subcutaneously and a lump remains at the site of injection 2 to 3 hours later, absorption from that site may be impaired).

The rate of absorption when a drug is administered by a parenteral route depends on the rate of blood flow through the tissues. Circulation or blood flow must be determined before the administration of drugs by the parenteral route to identify any circulatory insufficiency. If any such insufficiency is noted, injections will not be absorbed properly, and the drug will not be effective. Subcut injections have the slowest absorption rate, especially if peripheral circulation is impaired. IM injections are more rapidly absorbed because of greater blood flow per unit weight of muscle compared with subcut tissue. Cooling the area of injection slows the rate of absorption, whereas heat or massage hastens the rate of absorption. Drugs are dispersed throughout the body most rapidly when they are administered by IV injection. The nurse must be thoroughly educated

regarding the responsibilities and techniques associated with administering IV medications. It is important to remember that after a drug enters the patient's bloodstream, it cannot be retrieved.

The absorption of topical drugs that have been applied to the skin can be influenced by the drug concentration, the length of contact time, the size of the affected area, the thickness of the skin surface, the hydration of the tissue, and the degree of skin disruption. Percutaneous (i.e., across-the-skin) absorption is greatly increased in newborns and young infants, who have thin, well-hydrated skin. When drugs are inhaled, their absorption can be influenced by the depth of the patient's respirations, the fineness of the droplet particles, the available surface area of the patient's mucous membranes, the contact time, the hydration state, the blood supply to the area, and the concentration of the drug itself.

Distribution

The term **distribution** refers to the ways in which a drug is transported throughout the body by the circulating body fluids to the sites of action or to the receptors that the drug affects. *Drug distribution* refers to the transport of the drug throughout the entire body by the blood and lymphatic systems and the transport from the circulating fluids into and out of the fluids that bathe the receptor sites. Organs with the most extensive blood supplies (e.g., heart, liver, kidneys, brain) receive the distributed drug most rapidly. Areas with less extensive blood supplies (e.g., muscle, skin, fat) receive the drug more slowly.

After a drug has been dissolved and absorbed into the circulating blood, its distribution is determined by the chemical properties of the drug and how it is affected by the blood and tissues that it contacts. Two factors that influence drug distribution are protein binding and lipid (fat) solubility. Most drugs are transported in combination with plasma proteins (especially albumin), which act as carriers for relatively insoluble drugs. Drugs that are bound to plasma proteins are pharmacologically inactive because the large size of the complex keeps them in the bloodstream and prevents them from reaching the sites of action, metabolism, and excretion. Only the free, or *unbound*, portion of a drug is able to diffuse into tissues, interact with receptors, and produce physiologic effects; it is also only this portion that can be metabolized and excreted. The same proportions of bound and free drug are maintained in the blood at all times. Thus as the free drug acts on receptor sites or is metabolized, the decrease in the serum drug level causes some of the bound drug to be released from protein to maintain the ratio between bound and free drug.

When a drug leaves the bloodstream, it may become bound to tissues other than those with active receptor sites. The more lipid-soluble drugs have a high affinity for adipose tissue, which serves as a

repository site for these agents. Because there is a relatively low level of blood circulation to fat tissues, the more lipid-soluble drugs tend to stay in the body much longer. Equilibrium is established between the repository site (i.e., lipid tissue) and the circulation so that as the **drug blood level** drops as a result of binding at the sites of physiologic activity, metabolism, or excretion, more drug is released from the lipid tissue. By contrast, if more drug is given, a new equilibrium is established among the blood, the receptor sites, the lipid tissue repository sites, and the metabolic and excretory sites.

Distribution may be general or selective. Some drugs cannot pass through certain types of cell membranes, such as the blood-brain barrier (i.e., the central nervous system) or the placental barrier (i.e., the placenta), whereas other types of drugs readily pass into these tissues. The distribution process is very important because the amount of drug that actually gets to the receptor sites determines the extent of pharmacologic activity. If little of the drug actually reaches and binds to the receptor sites, the response will be minimal.

Metabolism

Metabolism is the process whereby the body inactivates drugs. The enzyme systems of the liver are the primary sites for the metabolism of drugs, but other tissues and organs (e.g., white blood cells, GI tract, lungs) metabolize certain drugs to a minor extent. Genetic, environmental, and physiologic factors are involved in the regulation of drug metabolism reactions. The most important factors for the conversion of drugs to their metabolites are genetic variations of enzyme systems, the concurrent use of other drugs, exposure to environmental pollutants, concurrent illnesses, and age. (For more information, see [Chapter 3](#).)

Excretion

The elimination of drug metabolites and, in some cases, of the active drug itself from the body is called **excretion**. The two primary routes of excretion are through the GI tract into the feces and through the renal tubules into the urine. Other routes of excretion include evaporation through the skin, exhalation from the lungs, and secretion into saliva and breast milk.

Because the kidneys are major organs of drug excretion, the nurse should review the patient's chart for the results of urinalysis and renal function tests. A patient with renal failure often has an increase in the action and duration of a drug if the dosage and frequency of administration are not adjusted to allow for the patient's reduced renal function.

[Fig. 2.2](#) shows a schematic review of the ADME process of an oral medication. It is important to note how little of the active ingredient actually reaches the receptor sites for action.




Fig. 2.2 Factors that modify the quantity of drug that reaches a site of action after a single oral dose. GI, Gastrointestinal.

HALF-LIFE

Drugs are eliminated from the body by means of metabolism and excretion. A measure of the time required for elimination is the half-life. The **half-life** is defined as the amount of time required for 50% of the drug to be eliminated from the body. For example, if a patient is given 100 mg of a drug that has a half-life of 12 hours, the following would be observed:

TIME (HOURS)	HALF-LIFE	DRUG REMAINING IN BODY (%)
0	—	100mg (100)
12	1	50mg (50)
24	2	25mg (25)
36	3	12.5 mg (12.5)
48	4	6.25 mg (6.25)
60	5	3.12 mg (3.12)

Note that as each 12-hour period (i.e., one half-life) passes, the amount remaining is 50% of what was there 12 hours earlier. After six half-lives, more than 98% of the drug has been eliminated from the body.

The half-life is determined by an individual's ability to metabolize and excrete a particular drug. Because most patients metabolize and excrete a particular drug at approximately the same rate, the approximate half-lives of most drugs are now known. When the half-life of a drug is known, dosages and frequency of administration can be calculated. Drugs with long half-lives (e.g., digoxin, with a half-life of 36 hours) need to be administered only once daily, whereas drugs with short half-lives (e.g., aspirin, with a half-life of 5 hours) need to be administered every 4 to 6 hours to maintain therapeutic activity. For patients who have impaired hepatic or renal function, the half-life may become considerably longer because of their reduced ability to metabolize or excrete the drug. For example, digoxin has a half-life of about 36 hours in a patient with normal renal function; however, it has a half-life of about 105 hours in a patient with complete renal failure. Monitoring diagnostic tests that measure renal or hepatic function is important. Whenever laboratory data reflect impairment of




Fig. 2.3 A time-response curve, which is also known as a *drug concentration–time profile*, demonstrates the relationship between the administration of a drug and the patient’s response. If the drug level does not reach the minimum effective concentration (*MEC*), there will be no pharmacologic effect. If the peak level exceeds the toxicity threshold, toxic effects will result. The optimal drug concentration is in the middle of the therapeutic range. *MDR*, Maximum drug response (peak effect).

either function, the nurse should notify the healthcare provider.

DRUG ACTIONS

All drug actions have an onset, peak, and duration of action. The **onset of action** is when the concentration of a drug at the site of action is sufficient to start a physiologic (pharmacologic) response. Many factors—such as the route of administration and the rates of absorption, distribution, and binding to receptor sites—affect the onset of action. In general, increasing the dose of the drug hastens the onset of action by shortening the time required to achieve the necessary concentration of drug at the target site. **Peak action** is the time at which the drug reaches the highest concentrations on the target receptor sites, thereby inducing the maximal pharmacologic response for the dose given. The **duration of action** is how long the drug has a pharmacologic effect. The onset, peak, and duration of action of a drug are often illustrated by a time-response curve, which is also known as a drug concentration–time profile (Fig. 2.3). A time-response curve demonstrates the relationship between the administration of a drug and the associated response. If the drug level does not reach the minimum effective concentration, there will be no pharmacologic effect. If the peak level exceeds the toxicity threshold, toxic effects will result. Generally, the drug concentration is targeted to be in the middle of this range, between the minimum effective response and the toxic response; this is referred to as the *therapeutic range*.

DRUG BLOOD LEVEL

When a drug is circulating in the blood, a blood sample may be drawn and assayed to determine the amount of

drug present. This is known as a *drug blood level*. It is important for certain drugs (e.g., anticonvulsants, aminoglycoside antibiotics) to be measured to ensure that the drug blood level is within the therapeutic range. If the drug blood level is low, the dosage must be increased, or the medicine must be administered more frequently. If the drug blood level is too high, the patient may develop signs of toxicity; in this case, the dosage must be reduced or the medicine administered less frequently.

ADVERSE EFFECTS OF DRUGS

No drug has a single action. When a drug enters a patient and is then absorbed and distributed, the **desired action** (i.e., the expected response) usually occurs. However, all drugs have the potential to affect more than one body system simultaneously, thereby producing responses that are known as **side effects** or **common adverse effects**, which are mild, or **serious adverse effects**, which can lead to toxicity. The World Health Organization’s definition of an adverse drug reaction (ADR) is “any noxious, unintended, and undesired effect of a drug, which occurs at dosages used in humans for prophylaxis, diagnosis, or therapy.” A more common definition is as follows: “Right drug, right dose, right patient, bad effect.” ADRs should not be confused with medication errors or adverse drug events (ADEs), which are defined as “an injury resulting from medical intervention related to a drug.” (For more information, see Chapter 6.)

Recent studies have indicated the following:

- ADRs may be responsible for more than 100,000 deaths among hospitalized patients per year, which makes them one of the top six leading causes of death in the United States.
- An average of 6% of hospitalized patients experience a significant ADR at some point during their hospitalizations.
- Between 5% and 9% of hospitalization costs are attributable to ADRs.
- The most commonly seen ADRs are rash, nausea, itching, thrombocytopenia, vomiting, hyperglycemia, and diarrhea.
- The classes of medicines that account for the largest number of ADRs are antibiotics, cardiovascular medicines, cancer chemotherapy agents, analgesics, and antiinflammatory agents.

Most ADEs are predictable because of the pharmacologic effects of a drug, and patients should be monitored so that dosages can be adjusted to allow for the maximum therapeutic benefits with a minimum of adverse effects. As described in Units III through X of this text, each drug has a series of parameters (e.g., therapeutic actions to expect, adverse effects, probable drug interactions) that should be monitored by the nurse, primary healthcare provider, pharmacist, and patient to optimize therapy while reducing the possibility of serious adverse effects.

Accurate and appropriate drug-drug interaction information must be available to prescribers, and continual attention is currently focused on this issue. Further

population-based studies still need to be conducted to meet federal initiatives to promote the meaningful use of information technologies and to integrate knowledge databases with clinical decision systems. Ideally, clinical decision systems and the databases of drug interactions that interface with them help the prescriber to identify and avoid potential medication interactions.

All hospitals have internal mechanisms for reporting suspected ADRs, and healthcare providers should not hesitate to report possible reactions. By monitoring and tracking the occurrences of ADRs, clinical protocols and improved patient screening will reduce the frequency of recurrence. The US Food and Drug Administration's MedWatch program is also available for the voluntary reporting of adverse events. (For more information, see MedWatch on Evolve.)

Idiosyncratic Reaction

Two other types of drug actions are much more unpredictable: idiosyncratic reactions and allergic reactions. An **idiosyncratic reaction** occurs when something unusual or abnormal happens when a drug is first administered. The patient usually demonstrates an unexpectedly strong response to the action of the drug. This type of reaction is generally the result of a patient's inability to metabolize a drug because of a genetic deficiency of certain enzymes. Fortunately, this type of reaction is rare.

Allergic Reaction

Allergic reactions, which are also known as *hypersensitivity reactions*, occur in about 6% to 10% of patients who are taking medications. Allergic reactions occur among patients who have previously been exposed to a drug and whose immune systems have developed antibodies to the drug. On reexposure to the drug, the antibodies cause a reaction; this reaction is most commonly seen as raised, irregularly shaped patches on the skin known as *hives*, which cause severe itching, known as *urticaria*.

Occasionally, a patient has a severe, life-threatening reaction that causes respiratory distress and cardiovascular collapse; this is known as an *anaphylactic reaction*. This condition is a medical emergency, and it must be treated immediately. Fortunately, anaphylactic reactions occur much less often than the more mild urticarial reactions.

If a patient has a mild reaction, it should be understood as a warning to not take the medication again. The patient is much more likely to have an anaphylactic reaction during their next exposure to the drug. Patients should receive information about the drug name and be instructed to tell healthcare providers that they have had such reactions and that they must not receive the drug again. In addition, patients should wear a medical alert bracelet or necklace that explains the allergy.

DRUG INTERACTIONS

A **drug interaction** is said to occur when the action of one drug is altered or changed by the action of another drug.

Drug interactions are elicited in two ways: (1) by agents that, when combined, *increase* the actions of one or both drugs; and (2) by agents that, when combined, *decrease* the effectiveness of one or both drugs. Some drug interactions are beneficial, such as the use of caffeine, a central nervous system stimulant, with an antihistamine, a central nervous system depressant. The stimulatory effects of the caffeine counteract the drowsiness caused by the antihistamine without eliminating the antihistaminic effects. The mechanisms of drug interactions can be categorized as those that change the absorption, distribution, metabolism, or excretion of a drug and those that enhance the pharmacologic effect of a drug.

CHANGES IN ABSORPTION

Most drug interactions that change absorption take place in the GI tract, usually the stomach. Examples of this type of interaction include the following:

- Antacids inhibit the dissolution of ketoconazole tablets by increasing the gastric pH. The interaction is managed by giving the antacid at least 2 hours after ketoconazole administration.
- Aluminum-containing antacids inhibit the absorption of tetracycline. Aluminum salts form an insoluble chemical complex with tetracycline. The interaction is managed by separating the administration of tetracycline and antacids by 3 to 4 hours.

CHANGES IN DISTRIBUTION

Drug interactions that cause a change in distribution usually affect the binding of a drug to an inactive site (e.g., circulating plasma albumin, muscle protein). When a drug is absorbed into the blood, it is usually transported throughout the body bound to plasma proteins. It often binds to other proteins, such as those in muscle. A drug that is highly bound (e.g., >90% bound) to a protein-binding site may be displaced by another drug that has a higher affinity for that binding site. Significant interactions can take place this way because little displacement is required to have a major impact. Remember, only the **unbound drug** is pharmacologically active. If a drug is 90% bound to a protein, then 10% of the drug is providing the physiologic effect. If another drug is administered with a stronger affinity for the protein-binding site and it displaces just 5% of the bound drug, there is now 15% unbound for physiologic activity; this is the equivalent of a 50% increase in dosage (i.e., from 10% to 15% active drug). For example, the anticoagulant action of warfarin is increased by administration with furosemide, which is a loop diuretic. Furosemide displaces warfarin from albumin-binding sites, thereby increasing the amount of unbound anticoagulant. This interaction is managed by decreasing the warfarin dosage.

CHANGES IN METABOLISM

Drug interactions usually result from a change in metabolism that involves inhibiting or inducing (stimulating)

the enzymes that metabolize a drug. Medicines known to bind to enzymes and to slow the metabolism of other drugs include verapamil, ketoconazole, amiodarone, cimetidine, and erythromycin. Serum drug levels usually increase as a result of inhibited metabolism when these drugs are given concurrently, and the dosages of the inhibited drugs usually must be reduced to prevent toxicity. For example, erythromycin inhibits the metabolism of theophylline; therefore the dose of theophylline must be reduced on the basis of theophylline serum levels and signs of toxicity. Because erythromycin (an antibiotic) is usually administered only in short courses, the theophylline dosage usually needs to be increased when the erythromycin is discontinued.

Common drugs that bind to enzymes and increase the metabolism of other drugs (enzyme inducers) are phenobarbital, carbamazepine, rifampin, and phenytoin. Rapidly metabolized drugs include doxycycline, warfarin, metronidazole, theophylline, and verapamil. When administered with enzyme inducers, the dosages of the more rapidly metabolized drugs should generally be increased to provide therapeutic activity. The patient must be monitored closely for adverse effects. For example, if a woman who is taking oral contraceptives (see Chapter 40) requires a course of rifampin antimicrobial therapy, the rifampin will induce the enzymes that metabolize both the progesterone and estrogen components of the contraceptive, thereby causing an increased incidence of menstrual abnormalities and reduced effectiveness of conception control. This interaction is managed by advising the patient to use an additional form of contraception while she is receiving rifampin therapy. Adverse effects may also occur if an enzyme inducer is discontinued. The metabolism of the induced drug then decelerates, leading to accumulation and toxicity if the dosage is not reduced.

CHANGES IN EXCRETION

Drug interactions that cause a change in excretion usually act in the kidney tubules by changing the pH to enhance or inhibit excretion. The classic example of altered urine pH is the combination of acetazolamide (which elevates urine pH) and quinidine. The alkaline urine produced by acetazolamide causes quinidine to be reabsorbed in the renal tubules, which potentially increases the physiologic and toxic effects of quinidine. The frequent monitoring of quinidine serum levels and assessments for signs of quinidine toxicity are used as guides for reducing quinidine dosage.

DRUGS THAT ENHANCE THE PHARMACOLOGIC EFFECTS OF OTHER DRUGS

Major drug interactions also occur between drugs. This may occur when one drug enhances the physiologic effects of another drug. Alcohol and sedative-hypnotic agents both cause sedation, but when used together can cause significant central nervous system depression. Another drug interaction that can have serious consequences is the interaction between aminoglycoside antibiotics (gentamicin, tobramycin) and a neuromuscular blocking agent such as pancuronium. When used together, the antibiotic increases the neuromuscular blockade, prolonging return to normal respirations and recovery time. Table 2.2 defines the terminology related to drug-drug interactions.

Because it is impossible to memorize all possible drug interactions, the nurse must check for drug interactions when they are suspected. The nurse must take the time to consult drug resource books and pharmacists to ensure that a patient who is receiving multiple medications does not experience unanticipated drug interactions.

Table 2.2 Terminology Related to Drug-Drug Interactions

TERM	DEFINITION	EXAMPLE
Additive effect	Two drugs with similar actions are taken for an increased effect.	hydrocodone + acetaminophen = added analgesic effect
Synergistic effect	The combined effect of two drugs is greater than the sum of the effect of each drug given together.	aspirin + codeine = much greater analgesic effect
Antagonistic effect	One drug interferes with the action of another.	tetracycline + antacid = decreased absorption of the tetracycline
Displacement	The displacement of the first drug from protein-binding sites (i.e., bound drugs are inactive) by a second drug increases the activity of the first drug because more unbound drug is available.	warfarin + valproic acid = increased anticoagulant effect
Interference	The first drug inhibits the metabolism or excretion of the second drug, thereby causing increased activity of the second drug.	probenecid + ampicillin = prolonged antibacterial activity of ampicillin because probenecid blocks the renal excretion of ampicillin
Incompatibility	The first drug is chemically incompatible with the second drug, thereby causing deterioration when the drugs are mixed in the same syringe or solution or are administered together at the same site. Signs include haziness, formation of a precipitate, or a change in the color of the solution when the drugs are mixed.	ampicillin + gentamicin = ampicillin inactivates gentamicin


Clinical Judgment and Next-Generation NCLEX® Examination-Style Questions

Key Points

- The most common routes of drug administration are the enteral, parenteral, and percutaneous routes.
- The half-life of a drug is defined as the amount of time required for 50% of the drug to be eliminated from the body.
- After administration, all drugs go through five stages: liberation, absorption, distribution, metabolism, and excretion (LADME). The enzyme systems of the liver are the primary sites for the metabolism of drugs, but other tissues and organs (e.g., white blood cells, GI tract, lungs) metabolize certain drugs to a minor extent.
- When a drug enters a patient and is absorbed and distributed, the desired action usually occurs. However, all drugs have the potential to affect more than one body system simultaneously, causing common adverse effects, which are generally mild, or serious adverse effects, which can be more severe and lead to toxicity.
- Drug interactions are elicited in two ways: (1) by agents that, when combined, *increase* the actions of one or both drugs; and (2) by agents that, when combined, *decrease* the effectiveness of one or both of the drugs.
- The mechanisms of drug interactions can be categorized as those that change the absorption, distribution, metabolism, or excretion of a drug and those that enhance the pharmacologic effect of a drug.

Additional Learning Resources

SG Go to your Study Guide for additional Review Questions for the NCLEX® Examination, Critical Thinking Clinical Situations, and other learning activities to help you master this chapter content.

 Go to your Evolve website (<https://evolve.elsevier.com/Willihnganz>) for additional online resources.

Clinical Judgment and Next-Generation NCLEX® Examination-Style Questions

The following questions are typical of the NCLEX exam and include both NGN (Next Generation) and traditional questions. See [Chapter 1](#) for further information regarding question types and formats.

1. A nurse is reviewing the drug route for an order written to be given via nasogastric tube and understands that this means that the drug will be administered by which route?
 1. Enteral
 2. Parenteral
 3. Percutaneous
 4. Intramuscular

Objective: Identify common drug administration routes.
NCLEX test item: Multiple choice
Cognitive skill: Knowledge
2. A patient takes 50 mg of a drug that has a half-life of 12 hours. What percentage of the dose remains in the body 36 hours after the drug is administered?
 1. 50 mg (100%)

2. 25 mg (50%)
3. 12.5 mg (25%)
4. 6.25 mg (12.5%)

Objective: Identify the meaning and significance of the term half-life when used in relation to drug therapy.

NCLEX test item: Multiple choice

Cognitive skill: Comprehension

3. The nurse reviews the patient's charts for laboratory tests that relate to how well the patient's organ systems are working because drug metabolism is influenced by certain body systems.

Choose the most likely options for the information missing from the sentence below by selecting from the lists of options provided.

Metabolism is the process that deactivates drugs; sites for metabolism of drugs are _____ 1 _____ and _____ 1 _____, and factors that influence these drug metabolism reactions are _____ 2 _____ and _____ 2 _____.

OPTIONS FOR 1	OPTIONS FOR 2
kidneys	exercise tolerance
white blood cells	environmental pollutants
GI tract	repository sites
liver	concurrent use of other drugs
heart	receptor sites

Objective: Describe the process of how a drug is metabolized in the body.

NGN test item: Cloze

Cognitive skill: Recognize cues

4. When an antihypertensive drug causes a drop in blood pressure to the normal range, what is this effect called?
 1. Antagonistic effect
 2. Desired therapeutic effect
 3. Side effect
 4. Additive effect

Objective: Compare and contrast the following terms that are used in relationship to medications: desired action, common adverse effects, serious adverse effects, allergic reactions, and idiosyncratic reactions.

NCLEX test item: Multiple choice

Cognitive skill: Understanding

5. The nurse noticed that, after administering an antibiotic ampicillin in the patient's IV line, the solution in the tubing started to turn milky and hazy after injecting another drug in the same tubing. The precipitate that was created meant the nurse needed to do what next? (*Select all that apply.*)
 1. Recognize that the two drugs are incompatible and notify the healthcare providers.
 2. Flush the line still connected to the patient until the precipitate is gone.
 3. Stop the infusion, disconnect the IV line, flush the precipitate out, and reconnect the line.
 4. Request that the drugs be placed on different schedules so that they are not administered at the same time.
 5. Recognize that the two drugs are having a synergistic effect and notify the healthcare providers.

Objective: Differentiate among the terms: additive effect, synergistic effect, antagonistic effect, displacement, interference, and incompatibility.

NCLEX test item: Multiple response

Cognitive skill: Application

6. A patient is experiencing a rash over their torso and legs accompanied by severe itching after receiving an antibiotic for an ear infection. What does the nurse suspect is happening? *Select all that apply.*

1. The patient is having an idiosyncratic reaction.
2. The patient is having an antagonistic effect.
3. The patient is having an allergic reaction.
4. The patient is having a common adverse effect.
5. The patient is having the desired effect.
6. The patient is having a serious adverse effect.
7. The patient is having an anaphylactic reaction.

Objective: Compare and contrast the following terms that are used in relationship to medications: desired actions, common adverse effects, serious adverse effects, allergic reactions, and idiosyncratic reactions.

NGN test item: Extended multiple response

Cognitive skill: Recognize cues

7. When a patient who was prescribed warfarin and valproic acid begins experiencing an increased effect of warfarin (bruising on arms, bleeding gums), what is this known as?

1. Synergistic effect
2. Antagonistic effect
3. Idiosyncratic effect
4. Displacement effect

Objective: Compare and contrast the following terms that are used in relationship to medications: desired action, common adverse effects, serious adverse effects, allergic reactions, and idiosyncratic reactions.

NCLEX test item: Multiple choice

Cognitive skill: Knowledge

8. The nurse is aware that a patient who has an increased metabolic rate (e.g., hyperthyroidism) generally requires what type of dosage?

1. Normal dosage
2. Lower-than-normal dosage
3. Higher-than-normal dosage
4. A dosage that is based on the patient's thyroid function levels

Objective: Identify one way in which alternatives in metabolism create drug interactions.

NCLEX test item: Multiple choice

Cognitive skill: Comprehension

9. The nurse studied the terms for drug interactions and recognized that there are medications that will create an antagonistic effect when given together.

Choose the most likely option for the information missing from the statements below by selecting from the list of options provided.

An example of the drug interaction that causes an antagonistic effect is between _____ 1 _____ and _____ 2 _____ in which there is a decrease in the absorption of the second drug.

OPTIONS FOR 1	OPTIONS FOR 2
antacid	codeine
warfarin	ampicillin
probenecid	tetracycline
aspirin	valproic acid

Objective: Differentiate among the following terms: additive effect, synergistic effect, antagonistic effect, displacement, interference, and incompatibility.

NGN test item: Cloze

Cognitive skill: Analysis cues

10. The nurse is aware of enzymes that affect metabolism and therefore affect drug actions that are caused by alterations in enzyme activity.

Indicate with an arrow (up or down) whether the reaction by the enzyme activity will increase or decrease metabolism of a drug.

ENZYME ACTIVITY	CHANGE IN DRUG ACTION CAUSED BY ALTERED METABOLISM
Enzyme inhibitors	
Enzyme inducers	
Enzyme enhancers	
Enzyme metabolizers	

Objective: Identify one way in which alternatives in metabolism create drug interactions.

NGN test item: Extended Drag and Drop

Cognitive skill: Recognize cues

11. The nurse reviews terms used to describe the therapeutic effects of drugs and knows they include the additive effect and the synergistic effect.

Choose the most likely option for the information missing from the statements below by selecting from the list of options provided.

An example of a synergistic effect is one that is caused by the combination of _____ 1 _____ and _____ 2 _____, which increases the therapeutic analgesic effect of the drugs.

OPTIONS FOR 1	OPTIONS FOR 2
antacid	codeine
warfarin	ampicillin
probenecid	tetracycline
aspirin	valproic acid

Objective: Differentiate among the following terms: additive effect, synergistic effect, antagonistic effect, displacement, interference, and incompatibility.

NGN test item: Cloze

Cognitive skill: Analysis cues

- Junctional dysrhythmias, 382–383
 Junel 1/20 (norethindrone-ethinyl estradiol), 649t
- K**
- Kadian (morphine), 312t–314t
 Kardex records, 66
 Kefauver-Harris Drug Amendment, 5t
 Keflex (cephalexin), 733t
 Kelnor (ethynodiol-ethinyl estradiol), 649t
 Kenalog (triamcinolone), 611t
 Keppra (levetiracetam), as antiepileptic drug, 278, 289–290
 ketoconazole (Nizoral)
 as antifungal agent, 757t–758t
 drug interactions of, 18, 201, 667
 enzyme interactions of, 18–19
 Ketones, urinary, in diabetes mellitus, 572–573
 ketoprofen (Nu-Ketoprofen), 323t–325t
 ketorolac (Apo-Ketorolac), 323t–325t
 ketotifen (Zaditor), as ophthalmic antihistamine, 696t
- Kidney
 role in drug excretion, 27
 tubules, 454
- Kilocalories, 775b, 776–777
- Klonopin (clonazepam), as antiepileptic drug, 281, 282t
- Kussmaul's respiration, 490
- Kwashiorkor, 781
- Kwashiorkor-marasmus, 781
- L**
- Labels, for drugs, 3
 new FDA system for, 33–34
- labetalol (Trandate), as beta-adrenergic agent, 186t
- Labile mood, 239–240
- Labor and delivery
 assessment during, 626–627
 augmentation of, with uterine stimulants, 636
 dysfunctional, 636
 normal, 632–633
 postpartum care and, 626–627, 633–634
 precipitous, 635–636
 preterm, 627f, 639
- Laboratory tests record, 62
- lacosamide (Vimpat), as antiepileptic drug, 297t–298t
- Lacrimal canaliculi, 683
- Lactation and breastfeeding
 benzodiazepine precautions in, 198
 drug therapy monitoring, 34, 34t
 nutrition during, 776
- Lactic acidosis, metformin-related, 580b
- Lactitol, 556
- LactMed, 33–34
- Lactobacillus acidophilus* (Lactinex), 558t
- lactulose (Constulose), 554t
- LADME (liberation, absorption, distribution, metabolism, excretion), of drugs, 14
- Lamictal (lamotrigine)
 as antiepileptic drug, 278, 288
 carbamazepine and, 287
- Lamisil AT (topical terbinafine), 757t–758t
- lamotrigine (Lamictal)
 as antiepileptic drug, 278, 288
 carbamazepine and, 287
- Lanoxin (digoxin), 448
 for heart failure, 448–450
- lansoprazole (Prevacid; Teva-Lansoprazole), 524t
- Lasix (furosemide), 458, 458t
- Lastacaft (alcaftadine), as ophthalmic antihistamine, 696t
- latanoprost (Xalatan), 691t
- Latuda (lurasidone), as antipsychotic agent, 263–264, 265t–267t, 269–270
- Laxatives, 550, 553–556
 actions of, 553–556
 bulk-forming, 554
 excessive use of, 551
 lubricant, 555
 nursing implications for, 555–556, 555b
 osmotic, 553
 saline, 553, 554t
 stimulant, 553
 therapeutic outcomes of, 555
 uses of, 555
- Lazanda (fentanyl), 309, 312t–314t
- Learning
 domains of, 50–51
 affective, 50, 50b, 51f
 cognitive, 50, 51f
 psychomotor, 51, 51f
 motivation for, 52
 readiness for, 52–54
 repetition in, 54–55
 styles of, 51
- Lefamulin, 742
- Legal considerations
 drug legislation (Canada), 9–10
 drug legislation (U.S.), 4–6
 in medication administration, 60–61
 of substance abuse and dependence, 815
- Lemborexant, 199t–200t
- Lens, of eye, 682, 683f
- Lescol XL (fluvastatin), as antilipemic agent, 343t
- lesinuradlecovorin, as chemoprotective agent, 704t
- Leukine (sargramostim), as bone marrow stimulant, 704t
- Leukorrhea, 644
- levalbuterol (Xopenex), 496t
- Levamlodipine, 374t–375t
- levarterenol (norepinephrine), as vasoconstrictor, 184t–185t
- levetiracetam (Keppra), as antiepileptic drug, 278, 289–290
- Levitra (vardenafil), for erectile dysfunction, 666t
- levobunolol hydrochloride (Betagan), 690t
- levocetirizine (Xyzal Allergy 24), 476t
- levodopa. *See also* carbidopa-levodopa (Sinemet; Rytary), for Parkinson's disease.
 drug interactions of, 807b
 for Parkinson's disease, 211
- levofloxacin, 695t, 743, 744t
- levomilnacipran (Fetzima), for depressive disorders, 246t–247t, 250
- Levophed (norepinephrine), as vasoconstrictor, 184t–185t
- Levorphanol, 312t–314t
- levothyroxine (Synthroid), 600, 601t
- Lexicomp, 3, 33–34
- Liberation, of drugs, 14
- Licensed practical nurses/licensed vocational nurses, role in intravenous drug administration, 150
- lidocaine (Xylocaine)
 as antidysrhythmic agents, 387, 387b
 drug interactions of, 187
 as oral analgesic, 510
- Life span considerations. *See also* Adolescents; Children; Geriatric patients; Infants; Neonates.
 for analgesics, 305b
 in androgen use, 622b
 in antacid use, 520b
 in antiepileptic therapy, 279b
 in decongestants, 472b
 in depressive disorder, 239b
 in diabetes mellitus, 616b
 in digoxin dosage, 449b
 in digoxin toxicity, 449b
 in diminished visual acuity, 686b
 in diuretic therapy for, 455b
 in drug actions, 22–37
 in hypothyroid state, 597b
 in inhaled medication administration, 98b
 in insulins, 578b
 in intravenous therapy, 167b
 for pain, in older adult patient, 308b
 for Parkinson's disease, 205b
 in patient education, 52b
 in pregnancy, 626b
 salivary flow, 509b
 in urinary tract infections, 671b
- Life-threatening illnesses, new drug development procedures for, 7
- Lifestyle, antiepileptic therapy in, 280
- Limb pain, peripheral vascular disease-related, 411–412
- linagliptin (Tradjenta), 591, 591t
- linezolid (Zyvox), 738
- Linoleic acid, 778
- Lioresal (baclofen), as muscle relaxants, 716, 716b
- liothyronine (Cytomel), 600, 601t
- liotrix (Thyrolar), 600, 601t
- Lipids, 777–778
 as intravenous solutions component, 156b
- Lipid-soluble drugs
 administration of, 161
 distribution in body, 15
- Lipitor (atorvastatin), for hyperlipidemia, 343t
- Lipodystrophies, diabetes mellitus and, 578
- Lipoproteins, types of, 338–339
- liraglutide (Victoza), 590t
- lisinopril (Prinivil; Zestril), as antihypertension agent, 365t
- Lithium
 for depressive disorders, 258
 for psychoses, 263

- Lithium carbonate, 602
- Livalo (pitavastatin), for hyperlipidemia, 343t
- Livedo reticularis, from amantadine, 214
- Liver, drug metabolism in, 27
- lixisenatide (Adlyxin), 590t
- Lo Loestrin FE (norethindrone-ethinyl estradiol), 650t
- Localized seizures, 277
- Iodoxamide (Alomide), 695–696
- Lomotil (diphenoxylate with atropine), 558t
- Long-acting beta-adrenergic bronchodilators, 496t
- Long-acting beta-2 agonists (LABAs), 486–488
- Loop of Henle, 458
- loperamide (Imodium A-D), 558t
- Lopressor (metoprolol), as beta-adrenergic blocking agent, 186t
- Loprox (ciclopirox), as antifungal agent, 757t–758t
- loratadine (Claritin), 476t
- lorazepam (Ativan; Apo-Lorazepam), 197t
 - as alcohol withdrawal treatment, 818
 - as antiemetic agent, 534, 539, 540t–545t
 - as antiepileptic drug, 281, 282t
 - for anxiety disorders, 232, 233t
- Lorzone (chlorzoxazone), as muscle relaxant, 715t
- losartan (Cozaar), as antihypertension agent, 368t
- Lotensin (benazepril), as antihypertension agent, 365t
- loteprednol (Lotemax), 695t
- Lotions, 83
 - administration of, 84–85
- Lotrimin AF (clotrimazole), 757t–758t
- Lotrimin Ultra (butenafine), as topical antifungal agent, 757t–758t
- lovastatin (Altoprev; Apo-Lovastatin), 373
 - for hyperlipidemia, 343t
- Lovaza (omega-3 fatty acids), 351
- Lovenox (enoxaparin), for thromboembolism, 431, 431b
- Low-density lipoproteins (LDLs), 332–334, 339f, 778
- Lower respiratory disease, 482–506
 - common, 483–486
 - drug therapy for, 489–493
 - nursing implications for, 489–493
 - treatment of, 486–489
- Lower respiratory tract, anatomy and physiology of, 482–483, 483f
- loxapine (Xylac), for psychoses, 263–264, 265t–267t
- Lozenges, 104
- lubiprostone (Amitiza), 554t, 556
- Luer adapter, 153, 153f
- Luer-Lok
 - blunt-access cannula attached by, 166f
 - male, 171f
- Luer-Slip, 121f
- luliconazole (Luzu), 757t–758t
- Lumateperone, 265t–267t
- Lumigan (bimatoprost), 691t
- Lunesta (eszopiclone), as antidepressant, 199t–200t
- Lungs, anatomy and physiology of, 482, 483f
- lurasidone (Latuda), as antipsychotic agent, 263–264, 265t–267t, 269–270
- Luxiq (betamethasone), 611t
- Luzu (luliconazole), 757t–758t
- Lycopene, 804
- Lyrica (pregabalin), as antiepileptic drug, 279, 292–293, 293b
- Lysergic acid diethylamide (LSD), 823
- M**
- Maalox, 520, 521t
- Macrochantin (nitrofurantoin), for urinary tract infection, 674, 675b
- Macrodrup chambers, 150, 151f
- Macrolide antibiotics, 737–738, 738t
- Macronutrients, 771, 776–778
- Magnesium
 - actions and sources of, 780t
 - dietary intake of, 773
- magnesium citrate (Citrate of Magnesia), 554t
- magnesium hydroxide (Milk of Magnesia), 510, 519–520, 521t, 554t
- magnesium salicylate (Doan's), 323t–325t
- magnesium sulfate, 639, 639b
 - toxicity of, 640b
- Major depressive disorder (MDD), 238
- Malaise
 - metformin-related, 580
 - from oxcarbazepine, 291
- Malnutrition, 781
 - drug distribution in, 23
 - therapy for, 781–784
- Manganese, actions and sources of, 780t
- Mania, 239
- Manic depression, 239
- Mannitol, for glaucoma, 685
- Marasmus, 781
- Marijuana, 823 *See also* Cannabinoids, as antiemetic agents.
- Marinol (dronabinol), as antiemetic agent, 540t–545t
- Maslow's hierarchy of human needs, 43b, 48
- Maxidex (dexamethasone), as corticosteroid, 611t
- Maxipime (cefepime), 733t
- Maxzide (triamterene with hydrochlorothiazide), 466t
- McGill-Melzack Pain Questionnaire, 304, 306f
- Mean arterial pressure (MAP), 353
- Measurable goal and outcome statements, 42–44
- Measurement systems
 - household and metric measurement equivalents in, 106t
 - measuring devices for, 76
 - medicine cups, 105–106, 106f
 - medicine dropper, 106, 106f
 - oral syringe, 106, 106f
 - teaspoon, 106, 106f, 106t
- meclizine, as antiemetic agent, 538, 540t–545t
- Meclofenamate, 323t–325t
- Medical diagnosis, 41
- Medical nutrition therapy (MNT), 564, 569
- Medical record
 - unscheduled, 64
 - electronic, 61, 66f
- Medication administration record, 63–64, 65f
 - in pain management, 308–309
- Medication errors
 - definition of, 72
 - example of, 72b
 - in floor or ward stock system, 67
 - prevention of, 3
 - for high-alert medications, 73
 - with medication reconciliation, 73
 - nurse's responsibilities for, 74
 - for sound-alike medications, 74
 - with technology, 72–73
 - reporting, 74
- Medication orders, 71–72
 - electronic transmission of, 72
 - types of, 72
- Medication profile, 63–64
- Medication reconciliation, 73
- Medication safety, 72–74
 - with high-alert medications, 73
 - medication reconciliation for, 73
 - nurse's responsibilities for, 74
 - with sound-alike medications, 74
 - technology-based, 72–73
- Medication worklist, 63–64
- Medicine cups, 105–106, 106f
 - measuring with, 109, 109f
 - reading the meniscus on, 109f
- Medicine dropper, 106, 106f
- Medicines, US legislation pertaining to safety of, 5t
- Mediterranean diets, 332–334
- Medline, 3
- Medlock, 153, 166f
- Medrol (methylprednisolone), 611t
- medroxyprogesterone (Provera), 620t
- MedWatch program, 8, 8b
- mefenamic acid (PMS-Mefenamic acid), 323t–325t
- Meglitinide oral hypoglycemic agents, 565, 582–583, 583t, 583b
- melatonin, 805, 805b
 - for sleep disorders, 199t–200t, 200
- Melatonin receptor, 199t–200t, 200
- meloxicam (Mobic), 323t–325t
- memantine (Namenda), for Alzheimer's disease, 225
- Menostar (estradiol), 618t–619t
- Mental status
 - angina pectoris and, 398
 - in anxiety disorder, 230
 - in depressive and bipolar disorders, 242
 - in dysrhythmias, 385
 - in substance abuse, 824
- Mentax (butenafine), as antifungal agent, 757t–758t
- meperidine (Demerol), 311, 312t–314t
- Meperidine-like derivatives, 312t–314t
- mepolizumab (Nucala), as immunomodulator, 503, 503t
- mercaptopurine, drug interactions of, 722
- meropenem (Merrem IV), 732t

- mesna (Mesnex), 704t
 Mesnex (mesna), 704t
 Mestinon (pyridostigmine), 188t
 Metabolic rate, effect on drug metabolism, 23
 Metabolic risk factors, 335t
 Metabolic syndrome, 330–337, 339
 definitions and characteristics of, 331t
 resulting conditions in, 331
 risk factors for, 331–332
 treatment of, 334b, 335
 drug therapy for, 335
 Metabolism, of drugs, 15
 definition of, 26
 drug interaction-related changes in, 18–19
 effect of illness on, 23
 effect of metabolic rate on, 23
 effect on half-life, 16–17
 factors influencing, 26–27
 genetics and, 29t, 34–35
 Metabolites, 27
 Metallic taste, from lithium, 259
 Metamucil (psyllium hydrophilic mucilloid), 554t, 556
 metaproterenol, 184t–185t
 herbal interactions of, 800b
 Metastases, 699
 metaxalone (Skelaxin), as muscle relaxant, 715t
 Metered-dose inhaler, 96f
 aerosolized, 97
 with extenders or spacers, 96–97, 97f
 metformin (Glucophage), 565, 579
 Meth mouth, 822
 Methadone, 819–820
 methadone (Methadone; Dolophine), 312t–314t
 Methadone-like derivatives, 312t–314t
 Methamphetamine, 822
 methazolamide (Neptazane), as carbonic anhydrase inhibitor, 688t
 methimazole, 602
 methocarbamol (Robaxin), as muscle relaxant, 715t
 methotrexate, drug interactions of, 720
 methsuximide (Celontin), as antiepileptic drug, 282t, 285
 methyl dopa, as antihypertension agent, 376–378, 377t
 methylergonovine maleate, as uterine stimulants, 638, 638b
 methyl naltrexone (Relistor), 554t, 556
 methylprednisolone (Solu-Medrol; Depo-Medrol; Medrol), 539, 611t
 metipranolol, 690t
 metoclopramide (Reglan), 32t–33t, 526, 527b, 534, 537, 540t–545t
 metolazone (Zaroxolyn), 462t
 metoprolol (Betaloc; Toprol-XL; Lopressor), as beta-adrenergic blocking agent, 186t, 389–390
 Metoprolol, drug interactions with, 677
 Metric system
 equivalent measurements of, 106t
 use on tuberculin syringes, 122b
 metronidazole (Flagyl), 646t, 754
 drug interactions, 828
 Micardis (telmisartan), as antihypertension agent, 368t
 Micatin (miconazole), as antifungal agent, 757t–758t
 miconazole
 as antifungal agent cream, powder, spray, ointment (Micatin), 757t–758t
 vaginal cream, suppositories (Monistat 3; Monistat 7), 646t, 757t–758t
 Microdrip chambers, 150, 151f
 Midamor (amiloride), 463
 midazolam, 197t, 539
 Midbrain modulator, 234
 Mifeprex (mifepristone), 631t
 mifepristone (Mifeprex), 631t
 miglitol (Glyset), 585, 586t
 Mild anxiety, 228
 Mild depression, 239
 Milk of Magnesia. *See* magnesium hydroxide (Milk of Magnesia)
 Milliliter (mL) scale, on syringe, 120, 121f
 milrinone, for heart failure, 441, 450–451
 Mineral oil, 554t, 556
 Mineralocorticoids, 606, 610
 Minerals, 771, 778
 essential, 780t
 Minipress (prazosin), as antihypertension agent, 373–376, 376t
 Minocin (minocycline), 748t
 minocycline (Minocin), 748t
 Miosis, 682
 mirabegron (Myrbetriq), 184t–185t
 for overactive bladder syndrome, 677
 MiraLAX (polyethylene glycol), 554t
 Mircette (desogestrel-ethinyl estradiol), 650t
 mirtazapine (Remeron)
 for depressive disorders, 254–255
 for sleep disorder, 194
 misoprostol (Cytotec), 523, 523b, 631t
 Mitotic inhibitors, 701
 Mix-O-Vials, 128, 128f
 preparation of drugs from, 131, 131f
 Mobic (meloxicam), 323t–325t
 Moisturizing agents, 83
 Molybdenum, actions and sources of, 780t
 mometasone (Elocon; Nasonex), 478t, 611t
 mometasone furoate (Arnuity Ellipta; Asmanex), 500t
 mometasone/formoterol (Dulera), 500t
 Monistat (miconazole), 646t, 757t–758t
 Monoamine oxidase inhibitors, 245–249, 246t–247t
 actions of, 245–249
 adverse effects of, 258
 dosage and administration of, 258
 drug interactions with, 259
 nursing implications for, 245–249
 premedication assessment in, 245
 therapeutic outcomes of, 257
 type B, 209–211
 actions of, 209
 adverse effects of, 224
 availability, dosage, and administration in, 210, 210t
 drug interactions with, 211
 nursing implications for, 210–211
 premedication assessment in, 210
 therapeutic outcomes of, 220
 uses of, 209
 Monoclonal antibodies, as targeted anticancer agents, 35, 703
 Monosaccharides, 777
 montelukast (Singulair), 472, 501
 Monurol (fosfomycin), for urinary tract infection, 674
 Mood, 238
 alterations, in Parkinson's disease, 209
 assessment of, 242–243
 labile, 239–240
 Mood disorder, 238. *See also* Depressive disorders.
 assessment of, 242–243
 Morning sickness, during pregnancy, 34, 534
 morphine
 abuse of, 819–820
 administration errors with, 73
 for pain management (Morphine sulfate; Morphine sulfate CR; MS-Contin; Kadian), 312t–314t
 Morphine-like derivatives, 312t–314t
 morphine sulfate/naltrexone (Embeda), 312t–314t
 Motion sickness, 531, 533
 Motofen (difenoxyin with atropine), 558t
 Motrin (ibuprofen), 323t–325t
 Mouth disorders, 507–509
 Mouthwashes, 513
 MoviPrep (polyethylene glycol-electrolyte solution), 554t
 Moxeza (moxifloxacin), 695t
 moxifloxacin
 ophthalmic eyedrops (Moxeza; Vigamox), 695t
 tablets, injection (Avelox), 743, 744t
 MS-Contin (morphine), 312t–314t
 Mucolytic agents, 489, 495–496
 Mucositis, 507, 509t
 Mucous cells, gastric, 516
 Mucous glands, pulmonary, 483
 Mucous membranes, administration of medications to, 90
 eardrops, 92–93, 93f
 eyedrops and ointment, 91–92, 91f
 inhaled medications, 95–96
 nasal spray, 94–95, 95f
 nose drops, 93–94, 94f
 sublingual and buccal tablets, 90–91, 90f
 vaginal medications, 98–99, 99f
 Multidisciplinary plans, 42, 66
 Multiple sclerosis, 711
 Muscle relaxants, 711–714
 Muscle spasms, 714
 Musculoskeletal system, 711–723
 disorders, drug therapy for, 714–722
 Myalgias, metformin-related, 580
 Myasthenia gravis, 729
 Mydraciyl (tropicamide), 694t
 Mydriasis, 682
 Myocardial cell sodium channel blocker, for angina pectoris, 398, 406–407, 406b
 Myocardial infarction, 330
 dalteparin prophylaxis for, 430
 hypertension treatment in, 357–359
 Myoclonic seizures, 277

- Myrbetriq (mirabegron), for overactive bladder syndrome, 677
- Myxedema, 596
- N**
- nabumetone, 323t–325t
- nadolol (Corgard), as beta-adrenergic blocking agent, 186t
- nafcillin, 741t
- naftifine (Naftin), as antifungal agent, 757t–758t
- Naftin (naftifine), as antifungal agent, 757t–758t
- nalbuphine, 315–316, 317t
- naldemedine, 556
- Nalfon (fenoprofen), 323t–325t
- naloxegol, 556
- naloxone (Evezio), 318
- naltrexone (Revia; Vivitrol), 319, 819
- naphazoline hydrochloride (Clear eyes), 689t
- Naprosyn (naproxen), 323t–325t
- naproxen (Naprosyn; Aleve; Anaprox DS), 323t–325t
- Narcotics, 310, 824
 - control systems for, 69–71, 70f
 - drug interactions of, 198, 201
- Nardil (phenelzine), for depressive disorders, 246t–247t, 248
- Nasacort (triamcinolone), 478t, 611t
- Nasal sprays, administration of, 94–95, 95f
- NasalCrom (cromolyn sodium), 478
- Nasoduodenal/nasojejunal intubation, **110–112**, 111f
- Nasogastric intubation, blocked, irrigation of, 533
- Nasogastric tube administration, 110–112
- Nasonex (mometasone), 478t
- Natacyn (natamycin), 693
- natamycin (Natacyn), 693
- Natazia (estradiol valerate), 651t
- nateglinide (Starlix), 583t
- National Association of Pharmacy Regulatory Authorities (NAPRA), 9
- National Center for Health Statistics, 820
- National Center for Human Genome Research, 35
- National Library of Medicine, 3
- National Organization for Rare Disorders, 8
- National Patient Safety Goals, 47
- National Survey on Drug Use and Health, 810
- Nausea and vomiting, 530–549
 - adrenergic agent-related, 183
 - amantadine-related, 214
 - anatomic areas involved in, 530, 531f
 - anticipatory, 530, 534
 - antihypoglycemic agents inducing, 593
 - antimicrobial therapy-related, 726
 - cancer and, 707–708
 - causes of, 531–533, 531b
 - chemotherapy-induced, 532–533, 532t
 - diuretic therapy-related, 463
 - DPP-4 inhibitor-related, 591
 - drug therapy for, 533–536
 - glucagon-like peptide-1 agonists-related, 589
- Nausea and vomiting (*Continued*)
 - metformin-related, 580
 - motion sickness, 531, 533
 - nursing implications of, 535–536
 - oral medications and, 76
 - postoperative, 530–533
 - in pregnancy, 532
 - psychogenic, 532, 534
 - radiation-induced, 533
 - sulfonylurea-related, 584
 - thiazolidinedione-related, 581
- nebivolol (Bystolic)
 - as beta-adrenergic blocking agent, 186t
 - drug interactions, 677
- Nebulizer, 96f
- Necon (norethindrone-ethinyl estradiol), 650t
- Needle-free access devices, 126f
- Needle puncture site infections, 119–120
- Needles, 122–124
 - butterfly, 163
 - insertion, 165
 - disposal of, 128f
 - gauge of, 124, 124f, 140f, 142
 - for intramuscular drug administration, 140
 - Huber, 175b
 - for intradermal drug administration, 138–139
 - for intravenous therapy, 153
 - length of, 124, 124f, 141
 - packaging of, 124–125
 - parts of, 122, 124f
 - selection criteria of, 124t
 - winged (butterfly or scalp), 153, 153f
- Needlestick injuries, 126
- Needlestick Safety and Prevention Act, 125
- Negative symptoms, in psychoses, 263
- Neo-Polycyn ophthalmic (neomycin-polymyxin B-bacitracin), 695t
- Neo-Synephrine (phenylephrine), as nasal decongestant, 474t
- neomycin, 730t
- neomycin-polymyxin B-bacitracin (Neo-Polycyn ophthalmic), 695t
- neomycin-polymyxin B-gramicidin (Neosporin ophthalmic), 695t
- Neonates
 - assessment of, 627
 - care, immediate, 633
 - drug absorption in, 24–25
 - maturity rating, 628f–629f
 - phenytoin absorption rate in, 25
- Neoplastic disease, 699
- Neosporin
 - for cold sores, 509
 - ophthalmic (neomycin-polymyxin B-gramicidin), 695t
- neostigmine (Prostigmin), 188t
- Nephrotic syndrome, drug distribution in, 23
- Nephrotoxic drugs, drug interactions of, 660
- Nephrotoxicity, of antimicrobial agents, 764
- Neptazane (methazolamide), as carbonic anhydrase inhibitor, 688t
- Nesina (alogliptin), 591t
- nesiritide (Natrecor), for heart failure, 441
- netupitant (Akyzreo), as antiemetic agent, 540t–545t
- Neulasta (pegfilgrastim), as bone marrow stimulant, 704t
- Neupro (rotigotine), for Parkinson's disease, 218, 219b
- Neurodegenerative disorders, drugs for, 204–227
- Neurokinin-1 receptor inhibitor antagonists, 540t–545t, 546–547
- Neuroleptic malignant syndrome (NMS), from antipsychotic drug therapy, 269
- Neuroleptic medications, for psychoses, 263–264
- Neurologic assessment, in substance abuse, 824
- Neuromuscular blocking agents, 711–714, 717–719
 - interaction with sedative hypnotics, 19
- Neurons, 180–181
- Neurontin (gabapentin), as antiepileptic drug, 279, 287
- Neuropathic pain, 301
- Neuropathies, diabetes mellitus and, 563–564, 574
- Neurotransmitters, 238–239
 - definition and types of, 180–181
- Neutropenia, cancer and, 708
- New drug development, 6–9, 7f
 - application review process in, 8
 - clinical research and development phase of, 6–8
 - fast tracking in, 7
 - gender-specific medicine in, 23
 - of orphan drugs, 8–9
 - postmarketing surveillance stage of, 8
 - preclinical research and development phase of, 6
- Niacin (nicotinic acid; Vitamin B₃)
 - actions and sources of, 779t
 - for hyperlipidemia, 340–342, 348–350
- nicardipine (Cardene), 374t–375t, 405t
- Nickel, 780t
- Nicotine replacement, bupropion and, 254
- Nicotinic acid. *See* Niacin (nicotinic acid; Vitamin B₃)
- nifedipine (Procardia; Adalat CC), as antihypertension agent, 374t–375t, 405t
- Nipple, for oral medication administration, 106, 107f
- nisoldipine (Sular), as antihypertension agent, 374t–375t
- Nitrates, for angina pectoris, 398, 400–403, 401b, 402t
- Nitro-Bid (nitroglycerin), for angina pectoris, 402t
- Nitro-Dur (nitroglycerin), for angina pectoris, 402t
- nitrofurantoin (Furadantin; Macrochantin; Macrobid), for urinary tract infection, 673–674, 675b
- nitroglycerin
 - for angina pectoris, 400–401, 402t
 - intravenous, 441

- nitroglycerin (*Continued*)
 ointment (Nitro-Bid), 87–88, 87f, 88b, 89f, 667
 patches, drug interactions of, 667
 for Raynaud's disease, 410
 sublingual, 87
 transdermal delivery of, 89
- Nitrolingual Pumpspray (nitroglycerin), for angina pectoris, 402t
- Nitroprusside, 441
- Nitrostat (nitroglycerin), for angina pectoris, 402t
- nizatidine (Apo-Nizatidine), 521, 522t
- Nizoral (ketoconazole), as antifungal agent, 757t–758t
- NMDA receptor inhibitor, for Alzheimer's disease, 225
- Nocebo effect, 23–24
- Nociception, 300
- Nociceptive pain, 301, 302f
- Nociceptors, 301
- Nocturia, 675
- Non-rapid eye movement sleep (NREM) sleep, 192
- Noncompliance, 46
- Nonconvulsive seizures, generalized, 277
- Nonphenothiazines, for psychoses, 265t–267t
- Nonprescription drugs, 2
 in Canada, 10
 during pregnancy, 33
- Nonsteroidal antiinflammatory drugs (NSAIDs), 259
 drug interactions of, 187, 660, 797b
 for pain management, 301, 322, 323t–325t, 326b
 peptic ulcer disease and, 517
- norelgestromin-ethinyl estradiol transdermal system (Xulane), 653–654
- norepinephrine
 neurotransmitter functions of, 181
 as vasoconstrictor (levarterenol; Levophed), 184t–185t
- norethindrone, in contraceptives, 620t
- North American Diagnosis Association International (NANDA-I), 40–41
- nortriptyline (Pamelor), for depressive disorder, 246t–247t
- Norvasc (amlodipine), 374t–375t, 405t
- Nose drops
 administration of, 93–94, 94f
 saline, 494
- Novo-Lorazepam (lorazepam), as antiepileptic drug, 281, 282t
- Novo-Temazepam (temazepam), for sedation and hypnosis, 197t
- Nucala (mepolizumab), as immunomodulator, 503, 503t
- Nu-Cefaclor (cefaclor), 733t
- Nucynta ER (tapentadol), 311, 312t–314t
- Nucynta (tapentadol), 311, 312t–314t
- Nu-Ketoprofen (ketoprofen), 323t–325t
- Nuplazid (pimavanserin), for psychoses, 263–264, 265t–267t
- Nurse practice act, 39, 60–61
- Nurses' notes, 62
- Nursing actions
 dependent, 46, 48
 independent, 47–48
- Nursing actions (*Continued*)
 interdependent, 46–48
 statements, 44
- Nursing assessment, 45
 data collection during, 40
 definition of, 39
 focused, 41
 Gordon's Functional Health Patterns Model of, 40, 41b
 nurses' notes on, 62
 relating to pharmacology, 39–40
- Nursing care plans, 41–42, 65
 risk for infection, 78b–79b
- Nursing diagnosis, 40–41
 actual, 41
 defining characteristics of patient-related problems, 41
 definition of, 40–41
 focused assessment for, 41
 medical diagnosis *vs.*, 41
 on medication-related problems, 45
 nurse practice act on, 39
 priority setting of, 42, 43b
 relating to pharmacology, 45–46
- Nursing journals, 3
- Nursing orders, 44
- Nursing process, 38–49
 assessment in. *See* Nursing assessment
 conceptual frameworks/models of, 38, 40b
 diagnosis in. *See* Nursing diagnosis
 evaluation in, 47
 relating to pharmacology, 44
 function of, 38
 as holistic care, 39, 39f
 implementation in, 46–47
 relating to pharmacology, 44
 ongoing cyclic nature of, 39
 planning in, 46
 evidence-based practice, 42
 related to pharmacology, 41–44
 relating to pharmacology, 45–47
- Nutrition, 208t, 771–791, 771b
 Adequate Intake (AI) in, 776
 assessment of, 772–782
 caloric intake, 774–775
 in cancer, 707
 in corticosteroid therapy, 609
 cultural considerations in, 774b
 Dietary Reference Intakes (DRIs) in, 775–776
 in diuretic therapy, 457
 Estimated Average Requirement (EAR) in, 776
 Estimated Energy Requirement (EER) in, 777, 777t
 governmental guidelines for, 772–773
 Healthy Eating Plate guide on, 774, 775f
 in hyperlipidemia, 342
 in hypertension, 361–362
 macronutrients in, 771, 776–778
 malnutrition and, 781
 medical nutrition therapy (MNT), 564, 569
 minerals, 778, 780t
 MyPlate Food Guide for, 773f, 774
 in pain management, 309–310
 in Parkinson's disease, 208
 in peripheral vascular disease, 413
- Nutrition (*Continued*)
 physical activity and, 780–781
 during pregnancy, 34, 624, 635
 principles of, 771–781
 Recommended Dietary Allowances (RDAs) in, 776
 in sleep disorders, 194
 in stomach disorders, 519
 in substance abuse, 826
 in thromboembolism, 420
 in thyroid diseases, 599
 Tolerable Upper Intake Level (UL) in, 776
 vitamins in, 772, 778
 water in, 778–780
- NuvaRing (etonogestrel-ethinyl estradiol vaginal ring), 656
- Nystagmus, from hydantoins, 284
- nystatin
 for candidiasis, 757t–758t
 for mucositis, 510
- Near point, 682
- O**
- Obesity
 body mass index and, 332t
 hyperlipidemia and, 341
 as hypertension risk factor, 360
 in metabolic syndrome, 331–332
 in peripheral vascular disease patients, 411
 prevalence of, 332, 333f–334f
- Objective data, of information, 45
- Obsessions, 229, 231
- Obsessive-compulsive and related disorders (OCRDs), 229
- Obsessive-compulsive disorder, 229
- Obstetrics, 624–635. *See also* Labor and delivery.
 drugs used in, 624–643
 nursing implications for, 624–635
- Obstructive airway diseases, 483–484. *See also* Chronic obstructive pulmonary disease (COPD).
- Obtundation, from oxcarbazepine, 291
- Occupational Safety and Health Administration (OSHA), 120
- Ocuflox (ofloxacin), 695t
- Off-label use, of drugs, for children, 30
- Official drug, 9
- ofloxacin, 744t
 for *Chlamydia trachomatis*, 646t
 ophthalmic (Ocuflox), 695t
- Ointments, 84
 administration of, 84–85
 nitroglycerin (Nitro-Bid), 88f, 89
 ophthalmic, 91, 91f
- olanzapine (Zyprexa)
 as antipsychotic agent, 263–264, 265t–267t, 269
 for sleep disorder, 194
- Older adults. *See* Geriatric patients
- olmesartan (Benicar), as antihypertension agent, 368t
- olodaterol (Striverdi Respimat), 496t, 497
- olopatadine
 as nasal spray (Patanase), 476t
 as ophthalmic antihistamine (Pataday; Patanol; Pazeo), 696t

- Omadacycline, 747
omalizumab (Xolair), as immunomodulator, 503, 503t
Omega-3 fatty acids, 774f, 806
 for hyperlipidemia, 340–342, 351
 recommended daily intake of, 806t
omeprazole (Prilosec; Losec), 524t
Omnaris (ciclesonide), 478t
Onbrez Breezhaler (indacaterol), 184t–185t
ondansetron (Zofran; Zofran ODT), as antiemetic agent, 534, 538, 540t–545t
Onfi (clobazam), as antiepileptic drug, 282t
Onglyza (saxagliptin), 591t
Onset of action, of drugs, 17
Opana ER (oxymorphone), 312t–314t
Opana (oxymorphone), 312t–314t
Open-angle glaucoma, 684, 684f
Operating room, drugs used in, 133, 134f
Ophthalmic antiinflammatory agents, 695
Ophthalmic ointments, 91, 91f
Opiate agonists
 abuse, 317–318
 dependence, naltrexone for, 319
 for pain management, 301, 310–315, 312t–314t
Opiate antagonists, for pain management, 301, 318–320
Opiate partial agonists
 abuse, 315
 for pain management, 301, 310, 315–318, 317t
Opiate receptors, 301–302
Opicapone, 220
Opioid antagonists, as laxatives, 555
Opioids
 abuse/addiction, 24, 303, 819–821
 intoxication, 820
 relapse prevention in, 818–819
 overdose with, 820
 for pain management, 301
 withdrawal, 820
 treatment for, 820–821
Oral cavity
 anatomy of, 507, 508f
 assessment of, 511
Oral contraceptives, 649–653
 biphasic, 650t
 monophasic, 649t
 quadriphasic, 651t
 triphasic, 650t
Oral disorders, 507–515
Oral drug administration, 103–106
 absorption rate in, 76–77
 in children, 29–30, 30b
 in geriatric patients, 25
 in infants, 25
 inhaled, 96–98
 liquid-form, 108–110
 with nasogastric tube, 110–112, 111f
 single-dose packaging for, 105
 solid-form, 106–107
 unit-dose packaging for, 105, 105f
Oral hypoglycemic agents
 drug interactions of, 720
 herbal interactions of, 803b
 meglitinide, 565, 582–583, 583t, 583b
Oral hypoglycemic agents (*Continued*)
 NSAIDs and, 327
 salicylates and, 322
 sulfonylurea, 565, 580–582, 581t, 581b
 thiazolidinedione, 565, 583–585, 584t
Oral medicines, powder form of, 30
Oral syringe, 106, 106f
 measuring with, 109–110, 109f
Orally disintegrating tablet, 104–105
Orbactiv (oritavancin), 735t
Order section, 62
Orders
 computerized provider order entry (CPOE) systems, 72
 for controlled substances, 6
 for drugs
 for intravenous drug administration, 150–151
 for prescription drugs, 2
 transcription of, 74
Orexin receptor inhibitors, 199t–200t
oritavancin (Orbactiv), 735t
Orphan drugs, 8–9
Orphenadrine citrate, 715t
Ortho Evra, 89
Ortho Tri-Cyclen (norgestimate-ethinyl estradiol), 650t
Ortho-Cyclen (norgestimate-ethinyl estradiol), 649t
oseltamivir (Tamiflu), as antiviral agent, 766
Osmolality, 156
 of intravenous solutions, 157t
Osmolex. *See* amantadine (Osmolex)
Osmosis, 156
Osmotic pressure, 156
Osteoporosis, 657–658
 drug therapy for, 658–659
Otic medications, administration of, 92
Ototoxicity, of antimicrobial agents, 729
Outcome statements, in nursing process, 42–44
Ovaries, 615
Overactive bladder (OAB) syndrome, 675
 beta-3 adrenergic agent for, 677
Over-the-counter (OTC) drugs, 2
Over-the-needle catheters, for intravenous therapy, 158, 165
Overflow incontinence, 675–676
oxacillin, 741t
oxaprozin (Daypro), 323t–325t
Oxaydo (oxycodone), 312t–314t
oxazepam
 as alcohol withdrawal treatment, 818
 for anxiety disorders, 232, 233t
Oxazolidinones, 738–740
oxcarbazepine (Trileptal), as antiepileptic drug, 279, 290
Oxeze (formoterol), 184t–185t
oxiconazole nitrate (Oxistat), 757t–758t
Oxistat (oxiconazole nitrate), 757t–758t
oxybutynin (Ditropan), as urinary anticholinergic agent, 678t
oxycodone (Roxicodone; OxyContin; Xtampza ER; Oxaydo), 312t–314t
 abuse of, 819–820
 with acetaminophen, 312t–314t
 with aspirin, 312t–314t
OxyContin (oxycodone), 312t–314t
Oxygen saturation (SaO₂), 484
oxymetazoline (Afrin; Dristan Spray), 471, 474t
oxymorphone (Opana; Opana ER), 312t–314t
oxytocin (Pitocin), 636
 administration of, 637b, 639
 overdosage of, 637b
Ozempic (semaglutide), 590t
- P**
Pacerone (amiodarone hydrochloride), as antidysrhythmic agents, 390–394, 390b
Package inserts, 3
Pain, 300–301
 acute, 300–301
 assessment, graphic record of, 62
 cancer and, 706
 chronic, 301
 control, 309
 experience of, 300
 idiopathic, 301
 management, 301–310
 actions of, 322
 analgesics in, 301
 assessment for, 305–308
 drugs used for, 300–329
 implementation of, 308–309
 inadequate, 303
 nonpharmacologic approaches for, 308
 nonsteroidal antiinflammatory drugs for, 322, 323t–325t, 326b
 nursing implications for, 304b, 305–308
 opiate agonists for, 310–315, 312t–314t, 315b
 opiate antagonists for, 318–320
 opiate partial agonists for, 315–318, 317t
 patient education in, 309–310
 prostaglandin inhibitors for, 320–322
 range orders in, 308–309
 rating scales, 304, 307f
 uses of, 325–326
 World Health Organization's Pain Relief Ladder for, 302–303, 303f
 management of
 placebo use in, 23–24
 medication, addiction to, 24
 neuropathic, 301
 nociceptive, 301, 302f
 in older adult patient, life span considerations for, 308b
 perception, 300
 relief, 308
 somatic, 301
 threshold, 300
 tolerance, 300
 visceral, 301
Pain Care Bill of Rights, 303, 304b
palifermin (Kepivance), for mucositis, 510

- paliperidone (Invega), for psychoses, 263–264, 265t–267t
- palonosetron (Aloxi), as antiemetic agent, 538, 540t–545t
- Palpitations, in cardiovascular disease, 385
- Pancreatitis
DPP-4 inhibitor-related, 589
glucagon-like peptide-1 agonists causing, 592
- Panic disorders, 228–229
- pantoprazole (Protonix; Pantoloc), 524t
- Pantothenic acid (vitamin B₅), 779t
- Parallel tracking, of new drugs, 7–8
- Parasympathetic nervous system, 181, 187
- Parenteral administration, 119–136
absorption rate in, 14–15
blunt access devices in, 126
definition of, 14, 119
dose forms in, 126–128
equipment used for, 120–125
preparation for, 128–134, 129f
- Parenteral medicines, powder form of, 30
- Parenteral nutrition, 788–789
administration of, 781
central, 781, 784b
peripheral, 781
total (TPN), 781, 781b
- Paresthesias, peripheral vascular disease-related, 409
- Parietal cells, 516
- Parkinson's disease, 204–206
additional symptoms, 208t
antacid toxicity in, 521
drug therapy for, 206–222
actions of, 225
amantadine, 45–46
anticholinergic agent in, 221–222, 222t
assessment of, 206–207
catechol-O-methyltransferase inhibitors in, 220–221
dopamine agonists in, 211–219
implementation of, 207–208
monoamine oxidase type B inhibitors in, 209–211, 210t
nursing implications for, 206–209
patient education in, 209
uses of, 207f, 225
life span considerations for, 205b
stages of, 205, 205f
symptoms of, 204
types of, 204–205
- Parnate (tranylcypromine), for depressive disorders, 245, 246t–247t
- paroxetine (Paxil)
antipsychotic medications, 274
for depressive disorder, 246t–247t, 249
- Paroxysmal supraventricular tachycardia (PSVT), 382–383
- Partial agonists, 13, 14f
- Partial seizures, 277
- Passive diffusion, drug absorption in, 25
- Patanase (olopatadine), 476t
- Patch testing, for allergens, 85–87, 87f
- Patient
expectations of, 57
involvement in goal setting, 43
positive identification of, 76
refusal of medication by, 77
- Patient charts, 61–66
- Patient-controlled analgesia (PCA), in pain management, 309
- Patient education, 50–59
in Alzheimer's disease, 223–224
in antiepileptic therapy, 280–281
in antipsychotic agent, 271–272
in anxiety disorders, 54, 231–232
for compliance, 56
cultural and ethnic diversity and, 55
in depressive and bipolar disorders, 244–245
determination of readiness to learn in, 52–54, 54b
on diabetes mellitus, 53b, 54f, 568–575
discharge planning and teaching, 58, 78
in diuretic therapy, 457
in drug monitoring, 28–29
in eyedrops and ointment administration, 92
focused approach in, 51
on goals and expectations, 57–58
for health professionals, on substance abuse, 815
in heart failure, 444–446
in herbal medicine use, 794
in hypertension, 356
in inhaled medications, 96
about Internet use, 55–56, 56t
in intravenous administration, 165
learning domains of, 50–51
learning styles in, 51
literacy considerations in, 55
in lower respiratory disease, 491–493
motivation for learning in, 52
in nitroglycerin ointment, 86–87
in nose drop administration, 94
objectives in, 51–52
organization of teaching sessions and materials for, 51–52
in pain management, 309–310
in Parkinson's disease, 208–209
in patch testing for allergens, 85
in peripheral vascular disease, 412–413
principles of teaching and learning in, 51–55, 51b
record of, 64
relevant content in, 57
repetition in, 54–55
spacing of content in, 54
strategies for, 55–58
in substance abuse, 826
teach back method in, 52
in topical powders administration, 89–90
in transdermal drug delivery systems, 88
in vaginal douche administration, 99–100
in vaginal medication administration, 99
- Patient profile, 66
- Peak action, 17
- Peak flowmeter (PEF), 491
- Peak levels, of drugs, 27–28
- Pediapred (prednisolone), 611t
- Peganone (ethotoin), as antiepileptic drug, 282t, 283
- pegfilgrastim (Neulasta), as bone marrow stimulant, 704t
- penbutolol, as beta-adrenergic blocking agent, 186t
- penicillin, 740–742, 741t
development of, 724
drug interactions of, 720
- penicillin G (Bicillin L-A; Pfizerpen-G), 646t, 741t
- penicillin V potassium, 741t
- Penicillium notatum*, 724
- Penile erection, from apomorphine, 215–216
- pentazocine (Talwin), 315–316, 317t
- pentoxifylline, for peripheral vascular disease, 410–413
drug interactions of, 410–413
- Pepcid (famotidine), 522t
- Peptic ulcer disease (PUD), 517
corticosteroid-related, 607
drugs used to treat, 516–529
- Pepto-Bismol (bismuth subsalicylate), 558t
- perampanel (Fycompa), as antiepileptic drug, 297t–298t
- Percutaneous administration, 83–102
definition of, 83
health promotion and, 98b
- Percutaneous route
absorption rate in, 15
definition of, 14
- Perforomist (formoterol), 184t–185t, 496t
- Perfusion, 482–483
- Peri-Colace (sennosides A and B + docusate), 554t
- perindopril, as antihypertension agent, 365t
- Peripheral arterial disease, 330
- Peripheral devices, 153
- Peripheral intravenous therapy catheters for, 153
over-the-needle, 158, 165
- Peripheral nervous system, 180
- Peripheral opioid antagonists, 555
- Peripheral parenteral nutrition, 781
- Peripheral perfusion, angina pectoris and, 399
- Peripheral pulse, assessment of, 411, 412f
- Peripheral vascular disease, 330, 409–416
arterial, 409
cause of, 409
definition of, 409–410
diabetes mellitus and, 573
drug therapy for, 410–413
pathophysiology of, 409
treatment of, 410
venous, 409
- Peripheral vasoconstriction, beta-adrenergic blocking agent-related, 187
- Peripheral-acting adrenergic antagonists, for hypertension, 357f
- Peripherally inserted central venous catheter (PICCs), 154, 707

- perphenazine, for psychoses, 265t–267t
Pfizerpen-G (penicillin G), 741t
pH
gastric, 25
enteric-coated tablets and, 104
tube placement and, 111
respiratory, 484, 484t
Pharmacist, responsibilities of, 47
Pharmacodynamics, definition of, 13
Pharmacogenetics, definition of, 35
Pharmacokinetics
definition of, 14
gender differences in, 23
Pharmacology, definition of, 1
phenazopyridine hydrochloride
(Pyridium), for urinary tract
infection, 679
phencyclidine (PCP), 823
phenelzine (Nardil), for depressive
disorders, 245, 246t–247t
Phenergan (promethazine), as antiemetic
agent, 476t, 540t–545t
phenobarbital, 372
abuse, 294
as antiepileptic drug, 291
enzyme interactions of, 19
Phenothiazines
anticholinergic agent-related, 189
as antiemetic agents, 534, 537,
540t–545t
for psychoses, 265t–267t
phenylephrine
as adrenergic agents (Altafrin),
184t–185t, 689t
as nasal decongestant (Neo-
Synephrine), 474t
phenytoin (Dilantin)
absorption rate of, 25
antipsychotic medications, 274
as antiepileptic drug, 278, 282t, 283,
285b
drug interactions of, 187, 653, 828
enzyme interactions of, 19
statins, 344
Phexxi, 657
Phillip's Milk of Magnesia (magnesia
hydroxide), 521t, 554t
Phlebitis, intravenous therapy-related,
174–175, 174t
Phlegm, 483
Phobias, 229
Phosphodiesterase inhibitors
for erectile dysfunction, 665–667, 666t
for heart failure, 450–451
Phosphodiesterase-4 inhibitor, 502–503
Photosensitivity
from antimicrobial agents, 761
from antipsychotic agent, 273
Physical activity, 780–781
Physical data, for pain management, 308
Physical examination, in nursing
assessment, 40
Physiotherapy, definition of, 1
physostigmine, 188t
Phytomedicine, 794
phytonadione (vitamin K), 641b, 779t
Phytotherapy, 794
PICC line, 154, 707
Pillbox, 31
Pills, 104
pilocarpine (Isopto Carpine),
pimavanserin (Nuplazid), for
psychoses, 188t, 263–264, 265t–267t
pindolol (Visken), as beta-adrenergic
agent, 186t
pioglitazone (Actos), 584t
piperacillin, with tazobactam (Zosyn), 741t
piroxicam (Feldene; Teva-Pirocam),
323t–325t
Piroxicam, lithium and, 259
pitavastatin (Livalo), for hyperlipidemia,
343t
Placebo effect, 23–24
Plaque, dental, 508
drug therapy for, 512
nursing implications in, 510
Platelet aggregation inhibitor, for
peripheral vascular disease, 409,
413–414, 413b
Platelet inhibitors, 421–424
for thromboembolism, 418
Plavix (clopidogrel), for
thromboembolism prevention, 422
Pleuromutilin, 742
Plunger, of syringes, 120
PMS-Bisoprolol (bisoprolol), 186t
PMS-Promethazine (promethazine), as
antiemetic agent, 540t–545t
Policosanol, 805
Polyadenosine diphosphate ribose
polymerase inhibitors, 702
polycarbophil (FiberCon), 554t
Polycin (polymyxin B-bacitracin), 695t
polyethylene glycol (MiraLAX), 554t
Polyethylene glycol (PEG) 3350, 553
polyethylene glycol-electrolyte solution
(CoLyte; GoLYTELY; MoviPrep),
553, 554t
Polymorphisms, 35
polymyxin B-bacitracin (Polycin), 695t
Polypharmacy, 31b
Polysaccharides, 777
Postherpetic neuralgia, in pregabalin, 293
Postictal behavior, 277, 279
Postoperative nausea and vomiting
(PONV), 531–533
risk factors for, 531t
Postpartum care, 633–634
atony and hemorrhage, 636
Potassium, 780t
Powders
sterile, reconstitution of, 130–131
topical, administration of, 84–85
Pradaxa (dabigatran), for
thromboembolism, 433, 434b
pramipexole (Mirapex; Mirapex ER), for
Parkinson's disease, 216
Prandin (repaglinide), 583t
prasugrel (Effient), for
thromboembolism, 422
Pravachol (pravastatin), for
hyperlipidemia, 343t
pravastatin (Pravachol), for
hyperlipidemia, 343t
prazosin (Minipress), as antihypertension
agent, 373–376, 376t
Preclinical research and development
phase, of new drug development, 6
Precose (acarbose), 585, 586t
Prediabetes, 563, 565
prednicarbate (Dermatop), topical
preparations, 611t
prednisolone
dosage forms (Veripred 20; Pediapred),
611t
metabolism of, gender differences in,
27
ophthalmic suspension (Omnipred),
695t
Prednisone (Deltasone; Rayos), 611t
Preeclampsia, 630
pregabalin (Lyrica)
abuse, 292
as antiepileptic drug, 278, 291b, 293
Pregnancy
benzodiazepine precautions in, 198
complications of, 629, 635
discomfort of, 635
drug therapy in, 635–638
eclampsia in, 630
estrogen use in, 617b
gestational diabetes mellitus in, 563,
626, 630
history of, 626–627
hypertension disorders, 626, 630
misoprostol contraindication in, 523
monitoring parameters in, 31–34, 33t
nausea and vomiting in, 532
nutrition in, 776
patient education for, 634–635
progesterin therapy in, 619b
substance abuse during, 825
termination of, 630–632
uterine relaxants for, 638–640
uterine stimulants in, 635–638
Premature infants
gastric emptying time in, 25
gastric pH in, 25
intestinal transit in, 25
Premature rupture of membranes, 626,
630
Premedication assessments, 47, 84
Prepidil (dinoprostone), 631t
Prescribing errors, 72b
Prescription drugs
controlled substances, 6
orders for, 2, 71–72, 71f
Prescription medicines, 5–6
Prescriptions, expired, 31
Pressure ulcers, dressings for, 84
Preterm labor, 627f, 639
Priapism, from apomorphine, 215–216
Primary source, of information, 45
Primaxin (imipenem-cilastatin), 732t
primidone (Mysoline), as antiepileptic
drug, 297t–298t
Prinivil (lisinopril), as antihypertension
agent, 365t
Priority setting, in nursing process, 42,
43b
PRN (pro re nata) medications
administration of, 75
medication record of, 64
order, 72
ProAir HFA (albuterol), 184t–185t
ProAir RespiClick (albuterol), 184t–185t
probenecid, 720, 720b

- Procainamide, 387
 Procardia (nifedipine), 374t–375t, 405t
 Procedure protocol, in drug administration, 84
 for solid-form oral medication, 106–107
 prochlorperazine (Compro; PMS-Prochlorperazine)
 as antiemetic agent, 534, 540t–545t
 for psychoses, 265t–267t
 Procrit (epoetin alfa), as bone marrow stimulant, 704t
 Profuse diarrhea, from lithium, 259
 Progesterone, 620t
 functions of, 615
 Progesterin, 617–620, 620t
 in oral contraceptives, 649, 651t
 in pregnancy, safety precautions in, 619b
 smoking and, 616
 Progesterin-only pills, 651, 651t
 Programmable infusion pumps, 151–152
 Progress notes, 62
 Progressive fatigue, from lithium, 259
 Prokinetic agents, 526–527
 Prolia (denosumab), 660
 promethazine (Phenergan; Promethgan; PMS-Promethazine), as antiemetic agent, 476t, 538, 540t–545t
 Promethgan (promethazine), as antiemetic agent, 540t–545t
 propafenone (Rythmol), as antidysrhythmic agents, 389, 389b
 Propecia (finasteride), for benign prostatic hyperplasia, 664
 Proper name, of drug, 9
 propranolol (Inderal; Inderal LA; Teva-Propranolol), 186t
 Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, 347–348
 propylthiouracil, 602
 Proscar (finasteride), for benign prostatic hyperplasia, 664
 Prostaglandin agonists, for glaucoma, 691, 691b
 Prostaglandin inhibitors, for pain management, 301, 320–322
 Prostaglandins, 684–685
 gastrointestinal, 516, 523
 in obstetrics, 631t
 Prostate specific antigen (PSA) levels, 621
 Protease inhibitors, amiodarone hydrochloride and, 391
 Proteasome inhibitors, 702
 Protein binding, of drugs, 26
 Protein, dietary, 771, 777
 Proton pump inhibitors, for gastroesophageal reflux and peptic ulcer disease, 523–525, 524t
 Protozoa, sexually transmitted, 645b
 protriptyline (Vivactil), for depressive disorders, 246t–247t, 251
 Proventil HFA (albuterol), 184t–185t, 496t
 Provera (medroxyprogesterone), 620t
 pseudoephedrine (Sudafed)
 as methamphetamine component, 821
 as nasal decongestant, 474t, 821
 Pseudoparkinsonian symptoms, from antipsychotic agent, 268, 273
 Psychogenic vomiting, 532, 534
 Psychological therapy, definition of, 1
 Psychology, drug therapy and, 23–24
 Psychomotor domains, of learning, 51, 51f
 Psychoses, 262–263
 dementia-related, elderly patients with, increased mortality in, 264b
 drugs used for, 262–275
 actions of, 264b, 272–274
 uses of, 264b, 272
 treatment of, 263
 psyllium hydrophilic mucilloid (Metamucil), 554t, 556
 Pulmicort (budesonide phosphate), 500t, 611t
 Pulmonary edema, 176
 Pulmonary embolism, intravenous therapy-related, 176
 Pulmonary function tests, 484
 Pulse pressure, 353
 in substance abuse, 824
 Pumps, in intravenous therapy, 152
 Pyelonephritis, 670
 pyrazinamide (Tebrazid), as antitubercular agent, 750, 750b
 Pyridium (phenazopyridine hydrochloride), for urinary tract infection, 679
 pyridostigmine (Mestinon; Mestinon-SR), 188t
 pyridoxine (vitamin B₆), 779t
 as antiemetic agent, 534
 drug interactions with, 213
 Pyxis system, 68, 68f
- Q**
 QT interval prolongation, 384, 385t
 Quasense (levonorgestrel-ethinyl estradiol), 649t
 quazepam (Doral), for sedation and hypnosis, 197t
 Quelicin (succinylcholine), as neuromuscular blocking agent, 718t
 Questran (cholestyramine), 345–346
 quetiapine (Seroquel; Seroquel XR)
 as antipsychotic agent, 263–264, 265t–267t, 269
 for sleep disorder, 194
 quinapril (Accupril), as antihypertension agent, 365t
 quinidine, 386–387
 excretion of, 19
 Quinolone antibiotics, 742–745, 744t
 quinupristin-dalfopristin (Synercid), 745
 Qvar Redihaler (beclomethasone dipropionate), 500t
- R**
 rabeprazole (Aciphex; Aciphex Sprinkle; Pariet), 524t
 Radiation therapy
 inducing nausea and vomiting, 533
 mucositis caused by, 507
 raloxifene (Evista), administration errors with, 73
 ramelteon (Rozerem), as antidepressant, 199t–200t, 200
 ramipril (Altace), as antihypertension agent, 365t
 Ranexa (ranolazine), for angina pectoris, 406
 Range orders, in pain management, 308–309
 ranitidine (Zantac), 522t, 533
 ranolazine (Ranexa), for angina pectoris, 406
 Rapaflo (silodosin), for benign prostatic hyperplasia, 663t
 Rapid eye movement sleep (REM) sleep, 192
 Rare diseases, orphan drug development for, 8–9
 rasagiline (Azilect), for Parkinson's disease, 206, 209, 210t
 Rational therapy, 792–794
 Raynaud's disease, 409
 drug therapy for, 410–413
 vasospastic attack prevention in, 410
 Recarbrio, 730
 Rebound sleep, 193–194
 Receptors, 13, 14f, 180–181
 Reclast (zoledronic acid), 660t
 Recommended Dietary Allowances (RDAs), 776
 Reconstitution, of medications, of sterile powders, 130–131
 Recreational drugs, definition of, 2
 Rectal drug administration
 absorption rate in, 103
 advantages of, 76–77, 103
 disadvantages of, 76–77
 Rectal suppositories, 114–115, 114f
 Rectus femoris muscle, as intramuscular injection site, 142, 142f
 Recurrent aphthous stomatitis, 507–508
 Reentrant dysrhythmia, 382
 Refractory seizures, nonpharmacologic treatment of, 278–279
 Regurgitation, 530–531
 Rehabilitation
 realistic goals for, 42–43
 in substance abuse, 825
 Relebactam, 730
 Relenza (zanamivir), as antiviral agent, 767
 Relistor (methylnaltrexone), 554t
 Renal capacity, age and, 27
 Renal disease, diabetes mellitus and, 573–574
 Renal failure
 dosage adjustment for, 24t
 drug excretion in, 15, 23
 Renal function
 abnormal, 75–76
 age and, 27
 effect of drug half-life, 16–17
 effect on drug excretion, 15
 Renin inhibitors, for hypertension, 356, 357f, 369–371
 ReoPro (abciximab), 424
 repaglinide (Prandin), 583t
 Requip (ropinirole), for Parkinson's disease, 217
 reslizumab (Cinqair), as immunomodulator, 503, 503t

- Restoril (temazepam), for sedation and hypnosis, 197t
- Restrictive airway diseases, 483–484
- Retavase (reteplase), for thromboembolism, 435
- Retching, 530. *See also* Nausea and vomiting.
- reteplase (rtPA; Retavase), for thromboembolism, 435
- Retinol (vitamin A), 779t, 781
- Revia (naltrexone), 319
- Reye's syndrome, 30
- Rheumatoid arthritis, glucocorticoid therapy for, 610
- Rhinitis, 470
- Rhinitis medicamentosa, 472
- Rhinocort (budesonide), 478t
- Rhinoviruses, 470
- Rho(D) immune globulin (human)
 - adverse effects of, 632t
 - dosage and administration of, 632t
- Rho kinase inhibitor, 691–692
- Riboflavin (Vitamin B₂), 779t
- rifampin (Rifadin)
 - antipsychotic medications, 274
 - as antitubercular agent, 751, 751b
 - direct renin inhibitor, 372
 - drug interactions of, 198, 201, 667, 720
 - enzyme interactions of, 19
 - statins, 344
- risedronate (Actonel), 660t
- Risk factors, identification of, 39
- Risperdal (risperidone), as antipsychotic agent, 263–264, 265t–267t, 269
- risperidone (Risperdal), as antipsychotic agent, 263–264, 265t–267t, 269, 272
- rivaroxaban (Xarelto), for thromboembolism, 424–433, 425t
- Riva-Sotalol (sotalol), as beta-adrenergic blocking agent, 186t
- rivastigmine (Exelon), for Alzheimer's disease, 224
- Rivotril (clonazepam), as antiepileptic drug, 281, 282t
- Robaxin (methocarbamol), 715t
- Robinul (glycopyrrolate), 189t
- Robitussin (guaifenesin), as expectorant, 493
- Rocking movements, from pramipexole, 215
- roflumilast (Daliresp), 502
- Roloids, 521t
- rolapitant (Varubi), as antiemetic agent, 540t–545t
- ropinirole (Requip; Requip XL), for Parkinson's disease, 217
- rosiglitazone (Avandia), 584t
- rosuvastatin (Crestor), for hyperlipidemia, 343t
- rotigotine (Neupro), for Parkinson's disease, 218–219, 219b
- Roxicodone (oxycodone), 312t–314t
- Rozerem (ramelteon), as antidepressant, 199t–200t
- rufinamide (Banzel), as antiepileptic drug, 297t–298t
- Rythmol (propafenone), as antidysrhythmic agents, 389, 389b
- S**
- S-adenosylmethionine (SAM-e), 807, 807b
 - Safety and self-care, 208t
- Safety, of drug therapy
 - in enteral nutrition, 786b
 - hands-free device, 128f
 - MedWatch program, 8, 8b
 - in parenteral administration, 119–120, 127f
 - in substance abuse treatment, 825
 - in sulfonamide therapy, 746b
 - with syringes, 127f
- safinamide (Xadago), for Parkinson's disease, 210t
- St. John's wort, 255b, 274, 800, 801b
 - drug interactions of, 372–373, 653, 653b
- St. Joseph (aspirin), 323t–325t
 - NSAIDs and, 327
- salicylates
 - drug interactions of, 720
 - for pain management, 301, 321, 323t–325t
 - and Reye syndrome in children, 30
- Salicylism, 322
- Saline lock, 153, 166f
- Saline nose drops, 494
- Saline solutions
 - for lower respiratory disease, 494
 - normal/physiologic, 156
- Saliva
 - artificial, 510
 - flow, 509b
 - for therapeutic drug monitoring, 27
- Salivary glands, anatomy of, 507
- Salivation, 208t
- salmeterol (Serevent Diskus), 184t–185t, 496t, 497
- Salsalate, 323t–325t
- Sancuso (granisetron), as antiemetic agent, 540t–545t
- Saphris (asenapine), as antipsychotic agent, 263–264, 265t–267t, 269–270
- sargramostim (Leukine), as bone marrow stimulant, 704t
- SASH guideline, 160
- saxagliptin (Onglyza), 591t
- Schedules, of controlled substance
 - in Canada, 10
 - in United States, 4–5, 5b
- Schizophrenia, 262
- Sclera, 682
- scopolamine
 - as antiemetic agent, 538
 - transdermal (Transderm-Scoop), 89, 540t–545t
- Secondary generalization, 276
- Secondary source, of information, 45
- Second-generation antipsychotic agents, for psychoses, 263–264
- Secondary generalization, 276
- Sectral (acebutolol), as beta-adrenergic blocking agent, 186t
- Sedative-hypnotics, 193–196
 - benzodiazepines and, 234
 - hydroxyzine and, 236
 - interaction with alcohol, 19
- Sedative-hypnotics (*Continued*)
 - nonbenzodiazepine, 198–201, 199t–200t
 - adverse effects of, 198
 - drug interactions of, 201
- Sedentary lifestyle, in metabolic syndrome, 331–332
- segesterone-ethinyl estradiol vaginal ring (Annovera), 656
- Seizure disorders, 276
 - from antipsychotic agent, 269, 273
 - atonic or akinetic, 277
 - complex, 277
 - descriptions of, 277
 - drugs used for, 276–299
 - focal (localized), 277
 - generalized
 - convulsive, 277
 - nonconvulsive, 277
 - myoclonic, 277
 - simple motor, 277
 - tonic-clonic, 277
- Seizure threshold, 278
- Selective serotonin reuptake inhibitors (SSRIs), 246t–247t, 249–250, 259
 - for anxiety disorders, 235
 - drug interactions of, 801b
- selegiline
 - for depressive disorders (Emsam), 245, 246t–247t
 - for Parkinson's disease (Eldepryl; Zelapar), 206, 209, 210t
- Selenium, actions and sources of, 780t
- semaglutide (Ozempic), 590t
- sennosides A and B (Ex-Lax; Black Draught; Senokot), 554t
- Senokot (sennosides A and B), 554t
- Septicemia, intravenous therapy-related, 175
- Serevent Diskus (salmeterol), 184t–185t, 496t
- Seroquel (quetiapine), as antipsychotic agent, 263–264, 265t–267t, 269
- Serotonin antagonists, as antiemetic agents, 538, 540t–545t
- Serotonin-norepinephrine reuptake inhibitors, for depressive disorder, 246t–247t, 250–251
- Serotonin syndrome, 249b, 257
- sertaconazole (Ertaczo), as antifungal agent, 757t–758t
- sertraline (Zoloft), for depressive disorder, 246t–247t, 250
- Severe adverse effects, of drugs, 17
- Sexually transmitted infections, 644, 645b
 - substance abuse and, 825
- Sharps container, 122, 128f
- Sharps Disposal by Mail system, 126
- Shigellosis, 644
- Short-acting beta agonists, 496–497
- sildenafil (Viagra), for erectile dysfunction, 666t
- Silenor (doxepin), as antidepressant, 199t–200t
- Silicon, actions and sources of, 780t
- silodosin (Rapaflo), for benign prostatic hyperplasia, 663t
- Silver nitrate, contraindication for canker sore treatment, 509

- Simethicone, 519–520, 521t
 Simple motor seizures, 277
 Simple partial seizures, 276
 Simple phobia, 229
 Simply Sleep (diphenhydramine), as antidepressant, 199t–200t
 simvastatin (Zocor)
 calcium channel blockers, 373
 for hyperlipidemia, 343t
 simvastatin-ezetimibe (Vytorin), for hyperlipidemia, 344t
 Single medication order, 72
 Sinuses, paranasal, 469–470
 Sinusitis, bacterial, 471
 sitagliptin (Januvia), 591t
 Skelaxin (metaxalone), as muscle relaxant, 715t
 Skeletal muscle relaxants
 centrally acting, 714–716
 direct-acting, 716–717
 Skin tests, for allergens, 85–87, 87f
 skin prick method, 139
 Sleep
 definition of, 192
 drugs used for, 192–203
 non-rapid eye movement sleep (NREM), 192
 rapid eye movement sleep (REM), 192
 and sleep pattern disturbance, 192–193
 Sleep cycle, 193f
 Sleep disorders, 192
 nonbenzodiazepine sedative-hypnotic therapy for, 198–201, 199t–200t
 sedative-hypnotic therapy for, 193–196, 197t
 valerian treatment for, 199t–200t
 Slow conduction fibers, 383
 “Smoker’s breath”, 508–509
 Smoking, 274, 706
 cessation, 616
 diabetes mellitus and, 569
 drug interactions of, 198
 effect on drug metabolism, 23
 halitosis and, 508–509
 hypertension and, 361
 in metabolic syndrome, 332
 peripheral vascular disease and, 411
 during pregnancy, 34
 selective serotonin reuptake inhibitors and, 253
 tricyclic antidepressants and, 250
 Sneezing, 470
 Social phobia, 229
 Sodium bicarbonate, 520, 521t
 sodium phosphate (Osmo-Prep), 554t
 Sodium, actions and sources of, 780t
 Sodium-glucose cotransporter 2 (SGLT 2) inhibitors, 335, 565, 586–588, 588t
 solifenacin (VESIcare), for overactive bladder, 678t
 Soliqua (glargine and lixisenatide), 590t
 Solu-Medrol (methylprednisolone), 611t
 Soma (carisoprodol), as muscle relaxant, 715t
 Somatic pain, 301
 Sonata (zaleplon), as antidepressant, 199t–200t
 Sorine (sotalol), as beta-adrenergic blocking agent, 186t
 sotalol (Betapace; Sorine; Riva-Sotalol), as beta-adrenergic blocking agent, 186t
 Soufflé cup, 105
 Sound-alike medications, 73–74
 Sour stomach, 516
 Spasticity, 711, 714
 Spectracef (cefditoren), 733t
 “Speed shock”, 176–177
 Sphincter muscle, of eyes, 682
 Spinal cord injury-associated neuropathic pain, 293
 Spiriva HandiHaler (tiotropium), 498t
 Spiriva Respimat (tiotropium), 498t
 Spirometry, 484–485, 485t
 spironolactone (Aldactone), 464
 with hydrochlorothiazide (Aldactazide), 466t
 Sporanox. *See* itraconazole (Sporanox)
 Sputum, 483
 Stalevo (entacapone/levodopa/carbidopa), for Parkinson’s disease, 220
 Standards of care, 61
 Standing medication order, 72
Staphylococcus aureus, methicillin-resistant (MRSA), 725
 Starlix (nateglinide), 583t
 Stat order, 72
 Statin therapy, for hyperlipidemia, 340–341, 343t
 benefit groups and recommended treatment, 340t
 combination products, 344t
 dosage recommendations, 340t
 Status epilepticus, 277
 in antiepileptic therapy, 292
 Staxyn (vardenafil), for erectile dysfunction, 666t
 Stendra (avanafil), for erectile dysfunction, 666t
 Sterile surgical field, drugs used in, 133–134
 Stevens-Johnson syndrome, 35
 Stiolto Respimat (tiotropium/olodaterol), 496t
 Stomach. *See also* Gastroesophageal reflux disease (GERD); Peptic ulcer disease (PUD).
 disorders
 common, 516–517
 drug therapy, 518–519
 goals of treatment, 517–518
 physiology of, 516
 Stomatitis, 507–508, 706–707
 Stool softeners, 555
 Streptogramins, 745–746
 streptomycin, 730t
 Stress, 208t
 in Alzheimer’s disease, 223
 management of, in Parkinson’s disease, 208
 Stress incontinence, 675–676
 Stress management
 in corticosteroid therapy, 609
 in hypertension, 361–362
 in sleep disorders, 195
 in substance abuse, 826
 Striverdi Respimat (olodaterol), 496t
 Stroke syndrome, 711
 Stroke, definition of, 330
 Subcutaneous drug administration, 139–141, 140f
 absorption rate in, 76–77
 sites of, 140f, 142–143
 technique of, 143–145
 Subjective data, of information, 45
 Sublingual drug administration, 14, 90f, 401
 Sublingual film, 104–105, 215
 Sublingual tablets, 90–91, 104–105
 Suboxone (buprenorphine/naloxone), 104–105, 317t
 Substance abuse, 809–830
 adverse effects from medications and, 810b
 classification of, 809
 epidemiology of, 810
 health professionals and, 813–815
 educating, 815
 legal considerations in, 815
 implementation in, 825–826
 measures of, 810t
 nursing implications
 assessment, 823–825
 patient education, 826
 principles of treatment for, 815–826
 screening for, 810–813, 816t
 signs of impairment in, 810, 810t
 substances in, 810b, 812t–813t
 Substance P, 180–181
 Subsys (fentanyl), 309, 312t–314t
 Succinimides, for seizure disorders, 282t, 285
 succinylcholine (Anectine; Quelicin), as neuromuscular blocking agent, 718t
 sucralfate (Carafate), 525
 Sufenta (sufentanil), 312t–314t
 sufentanil (Sufenta), 312t–314t
 Suicidal ideation, 240
 bupropion-related, 252
 in depressive and bipolar disorders, 256–257
 selective serotonin reuptake inhibitor-related, 250
 serotonin-norepinephrine reuptake inhibitor-related, 243
 tricyclic antidepressant-related, 251
 vilazodone-related, 254
 Sular (nisoldipine), as antihypertension agent, 374t–375t
 sulconazole (Exelderm), as antifungal agent, 757t–758t
 sulfacetamide (Bleph-10), 695t
 sulfasalazine (Azulfidine), 746t
 Sulfonamides, 746–747, 746t, 746b
 drug interactions of, 720
 Sulfonylurea oral hypoglycemic agents, 565, 580–582, 581t, 581b
 Sulfur, actions and sources of, 780t
 sulindac (Apo-Sulin), 323t–325t
 Summary section, 61–62
 Suppository, 114
 Supraventricular dysrhythmia, 382–383
 Suprax (cefixime), 733t
 Surgical bypass, causing diarrhea, 551
 Suspensions, 105

Sustained-release tablet administration, 401

Sustol (granisetron), as antiemetic agent, 540t–545t

suvorexant (Belsomra), as antidepressant, 199t–200t

Symbicort (budesonide/formoterol), 500t

Sympathomimetic agents, for glaucoma, 689

Sympathomimetic amines, drug interactions of, 211

Synalar (fluocinolone), 611t

Synapse, 180–181

Syncope
 angina pectoris and, 399
 in cardiovascular disease, 385

Syndrome X, 330–331

Syndros (dronabinol), as antiemetic agent, 540t–545t

Synercid (quinupristin-dalfopristin), 745

Synergistic effect, of drugs, 19t

Synthroid (levothyroxine), 600, 601t

Syphilis, 644, 646t

Syringes, 120–122
 calibration of, 120–122, 120f
 components of, 121f
 disposal of, 125–126
 for insulin therapy, 121–122
 calibration of, 122f
 delivery aids for, 121–122
 prefilled, 122, 123f
 Luer system of, 120, 121f
 millimeter scale of, 120
 oral, measuring with, 106, 106f
 packaging of, 124–125
 parts of, 120f
 prefilled, 122
 preparing two medications in, 131–133, 132f
 pumps, in intravenous therapy, 152–153
 safety devices for, 126
 selection criteria of, 124t
 size
 for intramuscular drug administration, 140
 for subcutaneous drug administration, 141

tuberculin, 120–121, 121f
 calibration of, 121f
 size, 137

Syrups, 105

Systolic dysfunction, 438

T

Tablets, 104–105
 buccal, 90–91
 chewable, 25
 crushing, 25, 29–30, 105b, 108f
 enteric-coated, 25, 104, 104f, 105b
 for children, 29–30
 layered, 104f
 orally disintegrating, 104–105
 scored, 104, 104f
 sublingual, 90–91
 sublingual film, 104–105
 timed-release, 25

tadalafil (Cialis), for erectile dysfunction, 666t

tafluprost (Zioptan), 691t

Tagamet HB. *See* cimetidine (Tagamet HB; Apo-Cimetidine)

Talwin (pentazocine), 315–316, 317t

Tamiflu (oseltamivir), as antiviral agent, 766

tamsulosin (Flomax), for benign prostatic hyperplasia, 663t

Tandem setup, 157

tapentadol (Nucynta; Nucynta ER), 311, 312t–314t

Tardive dyskinesia, from antipsychotic agent, 268, 273

Target symptoms, in psychoses, 263

Targeted anticancer agents, 703

Tartar, dental, 508

tasimelteon (Hetlioz), as antidepressant, 198, 199t–200t

Tavist (clemastine fumarate), 476t

Tazicef (ceftazidime), 733t

tazobactam, with piperacillin (Zosyn), 741t

Teach back method, 52

Teaspoons, for drug measurement, 106, 106f, 106t

Tebrazid (pyrazinamide), as antitubercular agent, 750, 750b

Teflaro (ceftaroline), 733t

Tegretol (carbamazepine), as antiepileptic drug, 278, 286

Tekturna (aliskiren), as antihypertension agent, 369–371

telavancin (Vibativ), 735t

telmisartan (Micardis), as antihypertension agent, 368t

temazepam (Restoril; Novo-Temazepam), for sedation and hypnosis, 197t

tenecteplase (rtPA; TNKase), for thromboembolism, 435

Tenormin (atenolol), as beta-adrenergic blocking, 186t

Teratogens, 31, 33t
 progestins as, 619b

terazosin (Hytrin), 373–376, 376t, 663t

terbinafine
 oral (Lamisil), 762
 topical (Lamisil AT), 757t–758t

terbutaline, 184t–185t
 adverse effects of, 181–182
 herbal interactions of, 801b

Tertiary source, of information, 45

Testim (testosterone gel), 621t

Testopel (testosterone pellets), 621t

Testosterone, 615
 functions of, 615
 gel (AndroGel; Testim), 621t
 oral products, 621t
 pellets (Testopel), 621t
 safety precautions in, 621b
 short- and long-acting, 621t
 USP in gel base (Androderm), 621t

testosterone cypionate, 621t

testosterone enanthate, 621t

tetracyclines, 9f, 526, 747–748, 748t

tetrahydrozoline hydrochloride (Visine; Opti-Clear), as alpha-adrenergic agents, 689t

Teva-Chlorpromazine (chlorpromazine), for psychoses, 263–264, 265t–267t

Teva-Diclofenac (diclofenac), 323t–325t

Teva-Famotidine (famotidine), 521, 522t

Teva-Indomethacin (indomethacin), 323t–325t

Teva-Pirocam (piroxicam), 323t–325t

Teva-Propranolol (propranolol), 186t

theophylline derivatives, drug interactions of, 722

Therapeutic drug monitoring, 27–28

Therapeutic intent, 46

Therapeutic methods, 1

Therapeutic outcomes, 44

Therapeutic range, definition of, 17

Therapeutic response, criteria for, 47

Thiamine (Vitamin B₁), 779t

Thiazolidinedione oral hypoglycemic agents, 565, 583–585, 584t, 584b

thimerosal, drug interactions of, 691

thioridazine, as antipsychotic agent, 263–264, 265t–267t, 269–270

Thioxanthenes, for psychoses, 265t–267t

Thrombin inhibitors, for
 thromboembolism, 418, 433–434

Thrombocytopenia, cancer and, 708

Thromboembolic disorders, 417–437
 causes of, 417
 drug therapy for, 418–421
 anticoagulants, 424–433
 factor Xa inhibitors, 424–433, 425t, 426b
 fibrinolytic agents, 418, 434–435
 glycoprotein IIb/IIIa inhibitors, 418, 424
 platelet inhibitors, 421–424
 thrombin inhibitors, 418, 433–434
 nonpharmacologic prevention and treatment of, 418

Thrombophlebitis, intravenous therapy-related, 174–175

Thrombosis, definition of, 417

Thrombus, 417

Thrush, oral, 508

Thyroid gland
 anatomy and physiology of, 596, 597f
 diseases, 596–597. *See also*
 Hyperthyroidism;
 Hypothyroidism.
 drug therapy for, 597–603
 nursing implications for, 598–599
 treatment of, 597, 597b

Thyroid replacement hormones, 600–601, 600b, 601t

thyroid USP (Armour Thyroid), 600, 601t

Thyroid-stimulating hormone (TSH), 596

Thyrolar (liotrix), 600, 601t

Thyrotoxicosis, 597

Thyroxine (T₄), 596

tiagabine (Gabitril), as antiepileptic drug, 278–279, 297t–298t

ticagrelor (Brilinta), for
 thromboembolism, 423, 424b

Tigan (trimethobenzamide), as antiemetic agent, 540t–545t

tigecycline (Tygacil), 736

Tikosyn (dofetilide), as antidysrhythmic agents, 392–393, 393b

- Time-response curves, of drug actions, 17f
- timolol maleate (Timoptic), for glaucoma, 690t
- timolol, as beta-adrenergic blocking agent, 186t
- Timoptic (timolol maleate), for glaucoma, 690t
- Tinactin (tolnaftate), as antifungal agent, 757t–758t
- Tin, actions and sources of, 780t
- Tindamax (tinidazole), for bacterial vaginosis, 755
- tinidazole (Tindamax), for bacterial vaginosis, 755
- Tinnitus, diuretic therapy-related, 460
- tiotropium (Spiriva HandiHaler; Spiriva Respimat), 498t
- Tip, of syringes, 120
- tirofiban (Aggrastat), 424
- Tissue perfusion, in peripheral vascular disease, 412
- tizanidine (Zanaflex), 297t–298t
- as muscle relaxant, 715t
- TNKase (tenecteplase), for thromboembolism, 435
- tobramycin, 730t
- eye drops (Tobrex ophthalmic), 695t
- Toilet bowl cleaners, dopamine agonists and, 213
- tolazamide, 581t
- tolbutamide, 581t
- Tolerable Upper Intake Level (UL), 776
- Tolerance, of drugs, 24, 196, 809–810
- of amphetamines, 822
- tolmetin, 323t–325t
- tolnaftate (Tinactin), as antifungal agent, 757t–758t
- tolterodine (Detrol), as overactive bladder syndrome, 678t
- Tonic-clonic seizures, 277
- Topamax (topiramate), as antiepileptic drug, 278, 294
- Topical drugs, 14
- absorption rate in, 15, 25
- dose forms in, 96–97
- in infants, 25
- ointment, 402–403
- ophthalmic, 683–684
- oral analgesics, 509
- of powders, 84
- to skin, 83–84
- Topicort (desoximetasone), 611t
- topiramate (Topamax)
- as antiepileptic drug, 278, 294
- for sleep disorder, 194
- Topoisomerase inhibitors, 701
- Toprol-XL (metoprolol), as beta-adrenergic blocking agent, 186t
- Torsades de pointes, 384
- torsemide (Demadex), 458, 458t
- Total parenteral nutrition (TPN), 781, 781b
- Toviaz (fesoterodine), for overactive bladder syndrome, 678t
- Toxic epidermal necrolysis, 35
- Toxicity, of drugs
- cumulative effect in, 24
- therapeutic drug monitoring for, 27
- Toxnet website, 33–34
- Trachea, anatomy and physiology of, 482, 483f
- Trademark, 2
- Tradjenta (linagliptin), 591t
- tramadol (Ultram; Conzip), 311, 312t–314t
- Trandate (labetalol), as beta-adrenergic agent, 186t
- trandolapril, as antihypertension agent, 365t
- Tranquilizers
- definition of, 229–230
- drug interactions of, 198, 201
- Transcription, of medication order, 74
- Transdermal contraceptives, 653–655
- Transdermal drug administration
- absorption rate in, 25
- administration of, 89–90
- in geriatric patients, 25
- for nitroglycerin, 88f, 89
- Transdermal opioid analgesia, in pain management, 309
- Transdermal patch, 89, 654, 654b
- administration of, 403
- Transderm-Scoop (scopolamine), 540t–545t
- Transient ischemic attacks, aspirin therapy for, 421
- Translingual spray administration, 401
- Tranxene-T (clorazepate), as antiepileptic drug, 281, 282t
- tranylcypromine (Parnate), for depressive disorders, 245, 246t–247t
- Travatan Z (travoprost), 691t
- Traveler's diarrhea, 551
- travoprost (Travatan Z), 691t
- Trazodone
- for depressive disorders, 255
- for sleep disorder, 194
- Treatment resistant, 278
- Treatment responsive, 278
- Trelegy Ellipta (fluticasone/vilanterol/umeclidinium), 500t
- Tremors
- adrenergic agent-related, 182
- in Parkinson's disease, 207
- tricyclic antidepressant-related, 252
- triamcinolone
- dosage forms (Kenalog; Nasacort; Triesence; Triderm), 611t
- for eye disorders (Triesence), 695t
- as intranasal corticosteroid (Nasacort), 478t
- triamterene (Dyrenium), 465
- with hydrochlorothiazide (Dyazide; Maxzide), 466t
- triazolam (Halcion), for sedation and hypnosis, 196, 197t
- Tricyclic antidepressants, 199t–200t
- anticholinergic adverse effect, 189, 222
- for depressive disorder, 246t–247t, 251–253
- drug interactions of, 690
- Triderm (triamcinolone), 611t
- Triesence (triamcinolone), 695t
- trifluoperazine, for psychoses, 263–264, 265t–267t
- trifluridine (Viroptic), 694t
- Triglycerides, 338
- trihexyphenidyl hydrochloride, for Parkinson's disease, 222t
- Triiodothyronine (T₃), 596
- trimethobenzamide (Tigan), as antiemetic agent, 215, 537, 540t–545t
- trimethoprim-polymyxin B (Polytrim ophthalmic), 695t
- trimipramine (Surmontil), for depressive disorders, 246t–247t, 251
- Trintellix (vortioxetine), for depressive disorders, 257
- trospium, as urinary anticholinergic agent, 678t
- Trough levels, for drugs, 27–28
- Trulicity (dulaglutide), 590t
- Trusopt (dorzolamide), as carbonic anhydrase inhibitor, 688t
- Tryptophan, drug interactions of, 250, 253
- Tube feeding
- continuous, 113–114
- intermittent, 113
- Tuberculin syringe, 105–106, 120–121, 121f
- Tuberculosis, antitubercular agents for, 748–751
- Tudorza Pressair (aclidinium), 498t
- Tums, in antacid, 521t
- Tunneled central venous catheters, 154
- Tygacil (tigecycline), 736
- Tylenol. *See* acetaminophen (Tylenol), for pain management
- Type 2 diabetes mellitus, in metabolic syndrome, 331, 335
- Tyrosine kinase inhibitors, 701
- ## U
- Ulcers
- peptic. *See* Peptic ulcer disease (PUD)
- peripheral vascular disease-related, 410
- Uloric (febuxostat), as gout agents, 721, 721t
- Ultram (tramadol), 311, 312t–314t
- Ultravate (halobetasol), as corticosteroid, 611t
- umeclidinium (Incruse Ellipta), 498t
- Unbound drug, 18
- Underuse, of drug therapy, in geriatric patients, 31
- Underweight patients, drug dosage and, 22–23
- Unified Parkinson's Disease Rating Scale (UPDRS), 206
- Unipolar disorders, 239
- Unit-dose drug distribution system, 67–68, 67f, 105
- for liquid-form oral medications, 107
- for solid-form oral medications, 108–110
- United States Adopted Names Council, 2
- United States Pharmacopeia (USP)/National Formulary (NF)*, 2–3
- United States Pharmacopeial Convention, 2–3
- Unstable angina, 397
- Upper respiratory tract
- anatomy and physiology of, 469–470, 470f

- Upper respiratory tract (*Continued*)
 disease, 469–481
 common, 470–471
 drug therapy for, 472–473
 nursing implications for, 473
 treatment of, 471–472
- Urethritis, 670
- Urge incontinence, 675–676
- Urgency, 675–676
- Urinalysis, 671, 672t
- Urinary antimicrobial agents, 673–674
- Urinary antispasmodic agents, 676
- Urinary system
 anatomy of, 671f
 disease
 nursing implications for, 670–673
 overactive bladder (OAB)
 syndrome, 675
- Urinary tract infections, 670–673
 drug therapy for, 673–674
 history of, 670–671
- Uroxatral (alfuzosin), for benign prostatic hyperplasia, 663t
- Urticaria, 18
 US legislation pertaining to safety of medicines, 5t
- US Preventive Services Task Force, 810–813
- Uterine relaxants, 638–640
- Uterine stimulants, 635–638
- Utibron Neohaler (glycopyrrolate/indacaterol), 496t
- V**
- Vaccines, anticancer, 703
- Vaginal discharge, causes of, 645b
- Vaginal douche, administration of, 99–100
- Vaginal medications, administration of, 98–99, 99f
- Vaginitis, 644
- valacyclovir (Valtrex), as antiviral agent, 766
- valbenazine (Ingrezza), as antipsychotic agents, 269
- Valerian, as antidepressant, 199t–200t, 200, 801
- Valium. *See* diazepam (Valium; Apo-Diazepam)
- Valproate, as antiepileptic drug, 279
- valproic acid (Depakene), as antiepileptic drug, 295–296
- valsartan (Diovan), 368t
- valsartan-sacubitril (Entresto), for heart failure, 446–448, 447b
- Valtrex (valacyclovir), as antiviral agent, 766
- Vanadium, actions and sources of, 780t
- Vancocin (vancomycin), 735t
 bacterial resistance to, 725
- vancomycin (Vancocin), 735t
 bacterial resistance to, 725
- Vanos (fluocinonide), topical preparations of, 611t
- Vantin (cefepodoxime), 733t
- varденаfil (Levitra; Staxyn), for erectile dysfunction, 666t
- Variant angina, 397
- Varubi (rolapitant), as antiemetic agent, 540t–545t
- Vascepa, 351
- Vascular endothelial growth factor antagonist, 697
- Vasodilators
 for heart failure, 441
 for hypertension, 356, 357f, 378–379
 for Raynaud's disease, 409
- Vasospasm, causing Raynaud's disease, 409–410
- Vasotec (enalapril), as antihypertension agent, 365t
- Vasotec IV (enalaprilat), as antihypertension agent, 365t
- Vastus lateralis muscle, as intramuscular injection site, 142, 142f, 142b
- Vaughan Williams classification system, of antidysrhythmic agents, 383, 384t
- vecuronium bromide, as neuromuscular blocking agents, 718t
- Venipuncture, 162–165
 in-the-needle catheters, 153, 154f
- venlafaxine (Effexor), for depressive disorders, 246t–247t, 250
- Venous thromboembolism, androgens, 621
- Ventilation, definition of, 482
- Ventolin HFA (albuterol), as adrenergic agent, 184t–185t, 496t
- Ventricular dysrhythmias, 382–383
- Ventrogluteal area, as intramuscular injection site, 142–143, 142b, 143f
- verapamil (Calan)
 for angina pectoris, 405t
 as antihypertension agent, 374t–375t
 enzyme interactions of, 18–19
 metabolism of, gender differences in, 27
- Verbal medication orders, 72
- Verdeso (desonide), 611t
- Veripred 20 (prednisolone), 611t
- Very-low-density lipoproteins (VLDLs), 339f
- VESIcare (solifenacin), for overactive bladder syndrome, 678t
- Viagra (Sildenafil), for erectile dysfunction, 666t
- Vials, 126–128, 128f
 preparation of medication from, 130–131, 130f
 removal of liquid from, 130f
- Vibativ (telavancin), 735t
- Vibramycin (doxycycline), 748t
- Victoza (liraglutide), 590t
- Video recordings, for patient education, 51
 Vigabatin, 297t–298t
- Vigamox (moxifloxacin), 695t
- vilazodone (Viibryd), for depressive disorders, 256
- Vimpat (lacosamide), as antiepileptic drug, 297t–298t
- Viral infections
 sexually transmitted, 644, 645b
 upper respiratory, 470
- Viroptic (trifluridine), 694t
- Visceral pain, 301
- Visual acuity, 687
 diminished, 686b
- Vital signs
 in dysrhythmias, 385
 record, 63f
 in sleep disorders, 195
 in substance abuse, 824
- Vitamin A (retinol), 773, 779t
 effect on wound healing, 84b
- Vitamin B₁ (thiamine), 779t
- Vitamin B₂ (riboflavin), 779t
- Vitamin B₃ (niacin)
 actions and sources of, 779t
 for hyperlipidemia, 340–341, 348–350
- Vitamin B₅ (pantothenic acid), 779t
- Vitamin B₆ (pyridoxine), 779t
 as antiemetic agent, 534
 drug interactions with, 213
- Vitamin B₁₂ (cyanocobalamin), 779t
- Vitamin B₁₂ deficiency
 biguanide oral antidiabetic agent, 580
 proton pump inhibitors causing, 522
- Vitamin C (ascorbic acid), 773, 779t
 effect on wound healing, 84b
- Vitamin D (ergocalciferol), 773, 779t
- Vitamin D₂ (cholecalciferol), 779t
- Vitamin E (alpha-tocopherol), 773, 779t
- Vitamin K (phytonadione), 779t
 deficiency, hyperlipidemia therapy-related, 342
- Vitamins, 771
 actions and sources of, 779t
 deficiencies of, 789
 fat-soluble, 779t
 water-soluble, 779t
- Vivactil (protriptyline), for depressive disorders, 246t–247t, 251
- Vivelle (estradiol), 618t–619t
- Vivelle-Dot (estradiol), 618t–619t
- Vivitrol (naltrexone), 319
- Voltaren (diclofenac), 323t–325t
- Volume-control chambers, for intravenous drug administration, 150
- Volutrol, 157
- Vomiting. *See* Nausea and vomiting
- vortioxetine (Trintellix), for depressive disorders, 257
- Vraylar (cariprazine), for psychoses, 263–264, 265t–267t
- Vulvovaginitis, 646t
- Vytorin (simvastatin-ezetimibe), for hyperlipidemia, 344t
- W**
- warfarin (Coumadin), 345
 drug interactions of, 18, 433, 547, 653, 788b, 828
 herbal interactions of, 800b, 803b
 for thromboembolism, 432
- Water
 distribution in body, 150, 150f
 as nutrient, 778–780
- Water-soluble drugs, distribution in the body, 26
- Water-soluble vitamins, 779t
- Weight
 caloric intake and, 774–775, 775b
 diabetes mellitus and, 569, 585
 drug therapy and, 22–23
 in hypertension, 355–356, 356t

- Weight (*Continued*)
 metabolic syndrome and, 332
 nutrition and, 775b
- Welchol (colesevelam), for
 hyperlipidemia, 345–346
- Wellbutrin. *See* bupropion (Wellbutrin;
 Zyban)
- Wetting agents, 554–555
- White House Office of National Drug
 Control Policy, 71
- Winged (butterfly or scalp) needles, 153,
 153f
- Withdrawal, 809–810
 alcohol, 822
 symptoms of, 817, 818f
 treatment, 822
 cocaine, 823
 in drug-dependent patients, 24
 methamphetamine, 822
 opioids, 820
 in substance abuse, 826
- Wong-Baker FACES pain rating scale,
 304, 305f
- World Health Organization (WHO)
 adverse drug reaction definition
 of, 17
 Oral Mucositis Scale, 509t
 Pain Relief Ladder, 302–303, 303f
- Wound care products, 84
- Wound healing, 84b
- X**
- Xadago (safinamide), for Parkinson's
 disease, 210t
- Xalatan (latanoprost), 691t
- Xanthine oxidase inhibitors, 720–722, 721t
- Xarelto (rivaroxaban), for
 thromboembolism, 424–433, 425t
- Xerostomia, 509
 drug therapy for, 512
 nursing implications in, 510
- Xolair (omalizumab), as
 immunomodulator, 503, 503t
- Xopenex (levolbuterol), 496t
- Xtampza ER (oxycodone), 312t–314t
- Xulane (norelgestromin-ethinyl estradiol
 transdermal system), 653–654
- Xultophy (degludec and liraglutide), 590t
- Xylac (loxapine), for psychoses, 263–264,
 265t–267t
- Xylocaine. *See* lidocaine (Xylocaine)
- xylometazoline, 471
- Xyzal Allergy 24 (levocetirizine), 476t
- Y**
- Yaz (drospirenone-ethinyl estradiol), 649t
- Z**
- Z-track method, of intramuscular
 injections, 145, 146f
- Zaditor (ketotifen), as ophthalmic
 antihistamine, 696t
- zaleplon (Sonata), as antidepressant,
 199t–200t
- Zanaflex (tizanidine), as muscle relaxant,
 715t
- zanamivir (Relenza), as antiviral agent,
 767
- Zantac (ranitidine), 521, 522t, 533
- Zarontin (ethosuximide), as antiepileptic
 drug, 282t, 285
- Zaroxolyn (metolazone), 462t
- Zelapar (selegiline), for Parkinson's
 disease, 210t
- Zerbaxa (ceftolozane/tazobactam), 733t
- Zerviate. *See* cetirizine (Zerviate; Zyrtec)
- Zestril (lisinopril), as antihypertension
 agent, 365t
- Zetia (ezetimibe), for hyperlipidemia, 346
- Zetonna (ciclesonide), 478t
- Zinc
 actions and sources of, 780t
 effect on wound healing, 84b
- Zinecard (dexrazoxane), as
 chemoprotective agent, 704t
- Zioptan (tafluprost), 691t
- ziprasidone (Geodon), as antipsychotic
 agent, 263–264, 265t–267t, 269
- Zirgan (ganciclovir), 694t
- Zithromax (azithromycin), 738t
- Zocor (simvastatin), 343t
- Zofran (ondansetron), as antiemetic
 agent, 540t–545t
- Zohydro ER (hydrocodone), 312t–314t
- zoledronic acid (Reclast; Aclasta), 660t
- zolpidem (Ambien), as antidepressant,
 199t–200t
- Zonegran (zonisamide), as antiepileptic
 drug, 278, 296–297
- zonisamide (Zonegran), as antiepileptic
 drug, 278, 296–297
- Zonular fibers, 682
- Zosyn (piperacillin with tazobactam), 741t
- Zovirax. *See* acyclovir (Zovirax)
- Zubsolv (buprenorphine/naloxone), 317t
- Zyban. *See* bupropion (Wellbutrin;
 Zyban)
- Zyloprim (allopurinol), as gout agents,
 721, 721t
- Zymaxid (gatifloxacin), 695t
- Zyprexa (olanzapine), as antipsychotic
 agent, 263–264, 265t–267t, 269
- Zyrtec (cetirizine), 476t
- Zyvox (linezolid), 738